HIV Plus Magazine #95

THE 2013 COMPLETE HIV TREATMENT GUIDE

’80s LADIES

TROUBLE PAYING FOR MEDS? OUR STATE-BY-STATE LOOK AT DRUG ASSISTANCE PROGRAMS CAN HELP

Pop icons Cyndi Lauper, Debbie Gibson, & Paula Poundstone on why they’re still committed to the fight against AIDS

CRAMER CAMERA VS.

SMART, SEXY, FUNNY, AND HIVPOSITIVE PHOTOGRAPHER DUANE CRAMER TELLS US ABOUT HIS BATTLE TO COME OUT, FIGHTING STIGMA, AND LOSING HIS FATHER TO AIDS

JULY/AUGUST 2013

www.hivplusmag.com

What is STRIBILD? STRIBILD is a prescription medicine used to treat HIV-1 in adults who have never taken HIV-1 medicines before. It combines 4 medicines into 1 pill to be taken once a day with food. STRIBILD is a complete single-tablet regimen and should not be used with other HIV-1 medicines.

STRIBILD does not cure HIV-1 infection or AIDS. To control HIV-1 infection and decrease HIV-related illnesses you must keep taking STRIBILD. Ask your healthcare provider if you have questions about how to reduce the risk of passing HIV-1 to others. Always practice safer sex and use condoms to lower the chance of sexual contact with body fluids. Never reuse or share needles or other items that have body fluids on them.

IMPORTANT SAFETY INFORMATION What is the most important information I should know about STRIBILD? STRIBILD can cause serious side effects: t Build-up of an acid in your blood (lactic acidosis), which is a serious medical emergency.

Symptoms of lactic acidosis include feeling very weak or tired, unusual (not normal) muscle pain, trouble breathing, stomach pain with nausea or vomiting, feeling cold especially in your arms and legs, feeling dizzy or lightheaded, and/or a fast or irregular heartbeat. t Serious liver problems. The liver may become large (hepatomegaly) and fatty (steatosis). Symptoms of liver problems include your skin or the white part of your eyes turns yellow (jaundice), dark “tea-colored” urine, light-colored bowel movements (stools), loss of appetite for several days or longer, nausea, and/or stomach pain. t You may be more likely to get lactic acidosis or serious liver problems if you are female, very overweight (obese), or have been taking STRIBILD for a long time. In some cases, these serious conditions have led to death. Call your healthcare provider right away if you have any symptoms of these conditions.

t Worsening of hepatitis B (HBV) infection. If you also have HBV and stop taking STRIBILD, your hepatitis may suddenly get worse.

Do not stop taking STRIBILD without first talking to your healthcare provider, as they will need to monitor your health.

STRIBILD is not approved for the treatment of HBV. Who should not take STRIBILD? Do not take STRIBILD if you: t Take a medicine that contains: alfuzosin, dihydroergotamine, ergotamine, methylergonovine, cisapride, lovastatin, simvastatin, pimozide, sildenafil when used for lung problems (Revatio®), triazolam, oral midazolam, rifampin or the herb St. John’s wort. t For a list of brand names for these medicines, please see the Brief Summary on the following pages. t Take any other medicines to treat HIV-1 infection, or the medicine adefovir (Hepsera®).

What are the other possible side effects of STRIBILD? Serious side effects of STRIBILD may also include: t New or worse kidney problems, including kidney failure. Your healthcare provider should do regular blood and urine tests to check your kidneys before and during treatment with STRIBILD. If you develop kidney problems, your healthcare provider may tell you to stop taking STRIBILD. t Bone problems, including bone pain or bones getting soft or thin, which may lead to fractures. Your healthcare provider may do tests to check your bones. t Changes in body fat can happen in people taking HIV-1 medicines. t Changes in your immune system.

Your immune system may get stronger and begin to fight infections. Tell your healthcare provider if you have any new symptoms after you start taking STRIBILD. The most common side effects of STRIBILD include nausea and diarrhea. Tell your healthcare provider if you have any side effects that bother you or don’t go away.

What should I tell my healthcare provider before taking STRIBILD? t All your health problems. Be sure to tell your healthcare provider if you have or had any kidney, bone, or liver problems, including hepatitis virus infection. t All the medicines you take, including prescription and nonprescription medicines, vitamins, and herbal supplements. STRIBILD may affect the way other medicines work, and other medicines may affect how STRIBILD works. Keep a list of all your medicines and show it to your healthcare provider and pharmacist. Do not start any new medicines while taking STRIBILD without first talking with your healthcare provider. t If you take hormone-based birth control (pills, patches, rings, shots, etc). t If you take antacids. Take antacids at least 2 hours before or after you take STRIBILD. t If you are pregnant or plan to become pregnant. It is not known if STRIBILD can harm your unborn baby. Tell your healthcare provider if you become pregnant while taking STRIBILD. t If you are breastfeeding (nursing) or plan to breastfeed.

Do not breastfeed. HIV-1 can be passed to the baby in breast milk. Also, some medicines in STRIBILD can pass into breast milk, and it is not known if this can harm the baby.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Please see Brief Summary of full Prescribing Information with important warnings on the following pages.

STRIBILD is a prescription medicine used as a complete single-tablet regimen to treat HIV-1 in adults who have never taken HIV-1 medicines before. STRIBILD does not cure HIV-1 or AIDS.

I started my personal revolution Talk to your healthcare provider about starting treatment.

STRIBILD is a complete HIV-1 treatment in 1 pill, once a day.

Ask if it’s right for you.

Patient Information STRIBILDTM (STRY-bild) (elvitegravir 150 mg/cobicistat 150 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg) tablets #SJFG TVNNBSZ PG GVMM 1SFTDSJCJOH *OGPSNBUJPO 'PS NPSF JOGPSNBUJPO QMFBTF TFF UIF GVMM 1SFTDSJCJOH *OGPSNBUJPO JODMVEJOH 1BUJFOU *OGPSNBUJPO What is STRIBILD? t STRIBILD is a prescription medicine used to treat HIV-1 in adults who have never taken HIV-1 medicines before. 453*#*-% JT B DPNQMFUF SFHJNFO BOE TIPVME OPU CF VTFE XJUI PUIFS )*7 NFEJDJOFT t STRIBILD does not cure HIV-1 or AIDS. :PV NVTU TUBZ PO DPOUJOVPVT )*7 UIFSBQZ UP DPOUSPM )*7 JOGFDUJPO BOE EFDSFBTF )*7 SFMBUFE JMMOFTTFT t Ask your healthcare provider about how to prevent passing HIV-1 to others. %P OPU TIBSF PS SFVTF OFFEMFT JOKFDUJPO FRVJQNFOU PS QFSTPOBM JUFNT UIBU DBO IBWF CMPPE PS CPEZ þ VJET PO UIFN %P OPU IBWF TFY XJUIPVU QSPUFDUJPO "MXBZT QSBDUJDF TBGFS TFY CZ VTJOH B MBUFY PS QPMZVSFUIBOF DPOEPN UP MPXFS UIF DIBODF PG TFYVBM DPOUBDU XJUI TFNFO WBHJOBM TFDSFUJPOT PS CMPPE

t %P OPU TUPQ UBLJOH 453*#*-% XJUIPVU ý STU UBMLJOH UP ZPVS IFBMUIDBSF QSPWJEFS t *G ZPV TUPQ UBLJOH 453*#*-% ZPVS IFBMUIDBSF QSPWJEFS XJMM OFFE UP DIFDL ZPVS IFBMUI PGUFO BOE EP CMPPE UFTUT SFHVMBSMZ GPS TFWFSBM NPOUIT UP DIFDL ZPVS )#7 JOGFDUJPO 5FMM ZPVS IFBMUIDBSF QSPWJEFS BCPVU BOZ OFX PS VOVTVBM TZNQUPNT ZPV NBZ IBWF BGUFS ZPV TUPQ UBLJOH 453*#*-% Who should not take STRIBILD? Do not take STRIBILD if you also take a medicine that contains: t BEFGPWJS )FQTFSB®

t BMGV[PTJO IZESPDIMPSJEF 6SPYBUSBM®

t DJTBQSJEF 1SPQVMTJE® 1SPQVMTJE 2VJDLTPMW®

t FSHPU DPOUBJOJOH NFEJDJOFT JODMVEJOH EJIZESPFSHPUBNJOF NFTZMBUF % ) & ® .JHSBOBM® FSHPUBNJOF UBSUSBUF $BGFSHPU® .JHFSHPU® &SHPTUBU® .FEJIBMFS &SHPUBNJOF® 8JHSBJOF® 8JHSFUUFT® BOE NFUIZMFSHPOPWJOF NBMFBUF &SHPUSBUF® .FUIFSHJOF®

t MPWBTUBUJO "EWJDPS® "MUPQSFW® .FWBDPS®

t PSBM NJEB[PMBN

What is the most important information I should know about STRIBILD?

t QJNP[JEF 0SBQ®

STRIBILD can cause serious side effects, including: 1. Build-up of lactic acid in your blood (lactic acidosis). -BDUJD BDJEPTJT DBO IBQQFO JO TPNF QFPQMF XIP UBLF 453*#*-% PS TJNJMBS OVDMFPTJEF BOBMPHT NFEJDJOFT -BDUJD BDJEPTJT JT B TFSJPVT NFEJDBM FNFSHFODZ UIBU DBO MFBE UP EFBUI -BDUJD BDJEPTJT DBO CF IBSE UP JEFOUJGZ FBSMZ CFDBVTF UIF TZNQUPNT DPVME TFFN MJLF TZNQUPNT PG PUIFS IFBMUI QSPCMFNT Call your healthcare provider right away if you get any of the following symptoms which could be signs of lactic acidosis: t GFFM WFSZ XFBL PS UJSFE t IBWF VOVTVBM OPU OPSNBM NVTDMF QBJO t IBWF USPVCMF CSFBUIJOH t IBWF TUPNBDI QBJO XJUI OBVTFB PS WPNJUJOH t GFFM DPME FTQFDJBMMZ JO ZPVS BSNT BOE MFHT t GFFM EJ[[Z PS MJHIUIFBEFE t IBWF B GBTU PS JSSFHVMBS IFBSUCFBU 2. Severe liver problems. 4FWFSF MJWFS QSPCMFNT DBO IBQQFO JO QFPQMF XIP UBLF 453*#*-% *O TPNF DBTFT UIFTF MJWFS QSPCMFNT DBO MFBE UP EFBUI :PVS MJWFS NBZ CFDPNF MBSHF IFQBUPNFHBMZ BOE ZPV NBZ EFWFMPQ GBU JO ZPVS MJWFS TUFBUPTJT Call your healthcare provider right away if you get any of the following symptoms of liver problems: t ZPVS TLJO PS UIF XIJUF QBSU PG ZPVS FZFT UVSOT ZFMMPX KBVOEJDF

t EBSL iUFB DPMPSFEw VSJOF t MJHIU DPMPSFE CPXFM NPWFNFOUT TUPPMT

t MPTT PG BQQFUJUF GPS TFWFSBM EBZT PS MPOHFS t OBVTFB t TUPNBDI QBJO You may be more likely to get lactic acidosis or severe liver problems if you are female, very overweight (obese), or have been taking STRIBILD for a long time.

3. Worsening of Hepatitis B infection. *G ZPV IBWF IFQBUJUJT # WJSVT )#7 JOGFDUJPO BOE UBLF 453*#*-% ZPVS )#7 NBZ HFU XPSTF þ BSF VQ JG ZPV TUPQ UBLJOH 453*#*-% " iþ BSF VQw JT XIFO ZPVS )#7 JOGFDUJPO TVEEFOMZ SFUVSOT JO B XPSTF XBZ UIBO CFGPSF t %P OPU SVO PVU PG 453*#*-% 3Fý MM ZPVS QSFTDSJQUJPO PS UBML UP ZPVS IFBMUIDBSF QSPWJEFS CFGPSF ZPVS 453*#*-% JT BMM HPOF

t TJMEFOBý M 3FWBUJP® XIFO VTFE GPS USFBUJOH MVOH QSPCMFNT

t SJGBNQJO 3JGBEJO® 3JGBNBUF® 3JGBUFS® 3JNBDUBOF®

t TJNWBTUBUJO 4JNDPS® 7ZUPSJO® ;PDPS®

t USJB[PMBN )BMDJPO®

t UIF IFSC 4U +PIO T XPSU Do not take STRIBILD if you also take any other HIV-1 medicines, including: t 0UIFS NFEJDJOFT UIBU DPOUBJO UFOPGPWJS "USJQMB® $PNQMFSB® 7JSFBE® 5SVWBEB®

t 0UIFS NFEJDJOFT UIBU DPOUBJO FNUSJDJUBCJOF MBNJWVEJOF PS SJUPOBWJS $PNCJWJS® &NUSJWB® &QJWJS® PS &QJWJS )#7® &Q[JDPN® ,BMFUSB® /PSWJS® 5SJ[JWJS®

STRIBILD is not for use in people who are less than 18 years old.

What are the possible side effects of STRIBILD? STRIBILD may cause the following serious side effects: t 4FF i8IBU JT UIF NPTU JNQPSUBOU JOGPSNBUJPO * TIPVME LOPX about STRIBILD?” t /FX PS XPSTF LJEOFZ QSPCMFNT JODMVEJOH LJEOFZ GBJMVSF :PVS IFBMUIDBSF QSPWJEFS TIPVME EP CMPPE BOE VSJOF UFTUT UP DIFDL ZPVS LJEOFZT CFGPSF ZPV TUBSU BOE XIJMF ZPV BSF UBLJOH 453*#*-% :PVS IFBMUIDBSF QSPWJEFS NBZ UFMM ZPV UP TUPQ UBLJOH 453*#*-% JG ZPV EFWFMPQ OFX PS XPSTF LJEOFZ QSPCMFNT t #POF QSPCMFNT DBO IBQQFO JO TPNF QFPQMF XIP UBLF 453*#*-% #POF QSPCMFNT JODMVEF CPOF QBJO TPGUFOJOH PS UIJOOJOH XIJDI NBZ MFBE UP GSBDUVSFT :PVS IFBMUIDBSF QSPWJEFS NBZ OFFE UP EP UFTUT UP DIFDL ZPVS CPOFT t Changes in body fat DBO IBQQFO JO QFPQMF XIP UBLF )*7 NFEJDJOF 5IFTF DIBOHFT NBZ JODMVEF JODSFBTFE BNPVOU PG GBU JO UIF VQQFS CBDL BOE OFDL iCVGGBMP IVNQw CSFBTU BOE BSPVOE UIF NJEEMF PG ZPVS CPEZ USVOL -PTT PG GBU GSPN UIF MFHT BSNT BOE GBDF NBZ BMTP IBQQFO 5IF FYBDU DBVTF BOE MPOH UFSN IFBMUI FGGFDUT PG UIFTF DPOEJUJPOT BSF OPU LOPXO t Changes in your immune system *NNVOF 3FDPOTUJUVUJPO 4ZOESPNF DBO IBQQFO XIFO ZPV TUBSU UBLJOH )*7 NFEJDJOFT :PVS JNNVOF TZTUFN NBZ HFU TUSPOHFS BOE CFHJO UP ý HIU JOGFDUJPOT UIBU IBWF CFFO IJEEFO JO ZPVS CPEZ GPS B MPOH UJNF 5FMM ZPVS IFBMUIDBSF QSPWJEFS SJHIU BXBZ JG ZPV TUBSU IBWJOH BOZ OFX TZNQUPNT BGUFS TUBSUJOH ZPVS )*7 NFEJDJOF

EJHPYJO -BOPYJO®

EJTPQZSBNJEF /PSQBDF®

FTUB[PMBN FUIPTVYJNJEF ;BSPOUJO®

þ FDBJOJEF 5BNCPDPS®

þ VSB[FQBN þ VUJDBTPOF 'MPWFOU® 'MPOBTF® 'MPWFOU® %JTLVT 'MPWFOU® )'" 7FSBNZTU®

JUSBDPOB[PMF 4QPSBOPY®

What should I tell my healthcare provider before taking STRIBILD? LFUPDPOB[PMF /J[PSBM®

MJEPDBJOF 9ZMPDBJOF®

Tell your healthcare provider about all your medical conditions, including: NFYJMFUJOF t *G ZPV IBWF PS IBE BOZ LJEOFZ CPOF PS MJWFS QSPCMFNT JODMVEJOH PYDBSCB[FQJOF 5SJMFQUBM®

IFQBUJUJT # JOGFDUJPO QFSQIFOB[JOF t *G ZPV BSF QSFHOBOU PS QMBO UP CFDPNF QSFHOBOU *U JT OPU LOPXO JG ® 453*#*-% DBO IBSN ZPVS VOCPSO CBCZ 5FMM ZPVS IFBMUIDBSF QSPWJEFS QIFOPCBSCJUBM -VNJOBM

JG ZPV CFDPNF QSFHOBOU XIJMF UBLJOH 453*#*-% QIFOZUPJO %JMBOUJO® 1IFOZUFL®

o 5IFSF JT B QSFHOBODZ SFHJTUSZ GPS XPNFO XIP UBLF BOUJWJSBM QSPQBGFOPOF 3ZUINPM®

NFEJDJOFT EVSJOH QSFHOBODZ 5IF QVSQPTF PG UIJT SFHJTUSZ JT UP RVJOJEJOF /FVEFYUB®

DPMMFDU JOGPSNBUJPO BCPVU UIF IFBMUI PG ZPV BOE ZPVS CBCZ 5BML SJGBCVUJO .ZDPCVUJO®

XJUI ZPVS IFBMUIDBSF QSPWJEFS BCPVU IPX ZPV DBO UBLF QBSU JO UIJT SFHJTUSZ SJGBQFOUJOF 1SJGUJO®

t *G ZPV BSF CSFBTUGFFEJOH OVSTJOH PS QMBO UP CSFBTUGFFE %P OPU SJTQFSJEPOF 3JTQFSEBM® 3JTQFSEBM $POTUB®

CSFBTUGFFE JG ZPV UBLF 453*#*-% TBMNFUFSPM 4FSFWFOU® PS TBMNFUFSPM XIFO UBLFO JO DPNCJOBUJPO :PV TIPVME OPU CSFBTUGFFE JG ZPV IBWF )*7 CFDBVTF PG UIF SJTL PG XJUI þ VUJDBTPOF "EWBJS %JTLVT® "EWBJS )'"®

QBTTJOH )*7 UP ZPVS CBCZ TJMEFOBý M 7JBHSB® UBEBMBý M $JBMJT® PS WBSEFOBý M -FWJUSB® 5XP PG UIF NFEJDJOFT JO 453*#*-% DBO QBTT UP ZPVS CBCZ JO ZPVS 4UBYZO® GPS UIF USFBUNFOU PG FSFDUJMF EZTGVODUJPO &% *G ZPV HFU CSFBTU NJML *U JT OPU LOPXO JG UIF PUIFS NFEJDJOFT JO 453*#*-% DBO EJ[[Z PS GBJOU MPX CMPPE QSFTTVSF IBWF WJTJPO DIBOHFT PS IBWF QBTT JOUP ZPVS CSFBTU NJML BO FSFDUJPO UIBU MBTU MPOHFS UIBO IPVST DBMM ZPVS IFBMUIDBSF 5BML XJUI ZPVS IFBMUIDBSF QSPWJEFS BCPVU UIF CFTU XBZ UP GFFE QSPWJEFS PS HFU NFEJDBM IFMQ SJHIU BXBZ ZPVS CBCZ UBEBMBý M "EDJSDB® GPS UIF USFBUNFOU PG QVMNPOBSZ BSUFSJBM Tell your healthcare provider about all the medicines you take, IZQFSUFOTJPO including prescription and nonprescription medicines, vitamins, UFMJUISPNZDJO ,FUFL®

and herbal supplements: UIJPSJEB[JOF t 453*#*-% NBZ BGGFDU UIF XBZ PUIFS NFEJDJOFT XPSL BOE PUIFS WPSJDPOB[PMF 7GFOE®

NFEJDJOFT NBZ BGGFDU IPX 453*#*-% XPSLT XBSGBSJO $PVNBEJO® +BOUPWFO®

t #F TVSF UP UFMM ZPVS IFBMUIDBSF QSPWJEFS JG ZPV UBLF BOZ PG UIF GPMMPXJOH NFEJDJOFT [PMQJEFN "NCJFO® &EMVMBS® *OUFSNF[[P® ;PMQJNJTU®

)PSNPOF CBTFE CJSUI DPOUSPM QJMMT QBUDIFT SJOHT TIPUT FUD

Know the medicines you take. ,FFQ B MJTU PG BMM ZPVS NFEJDJOFT BOE TIPX JU UP ZPVS IFBMUIDBSF QSPWJEFS BOE QIBSNBDJTU XIFO ZPV HFU B "OUBDJE NFEJDJOFT UIBU DPOUBJOT BMVNJOVN NBHOFTJVN OFX NFEJDJOF %P OPU TUBSU BOZ OFX NFEJDJOFT XIJMF ZPV BSF UBLJOH IZESPYJEF PS DBMDJVN DBSCPOBUF 5BLF BOUBDJET BU MFBTU IPVST 453*#*-% XJUIPVU ý STU UBMLJOH XJUI ZPVS IFBMUIDBSF QSPWJEFS CFGPSF PS BGUFS ZPV UBLF 453*#*-% .FEJDJOFT UP USFBU EFQSFTTJPO PSHBO USBOTQMBOU SFKFDUJPO PS IJHI Keep STRIBILD and all medicines out of reach of children.

CMPPE QSFTTVSF 5IJT #SJFG 4VNNBSZ TVNNBSJ[FT UIF NPTU JNQPSUBOU JOGPSNBUJPO BNJPEBSPOF $PSEBSPOF® 1BDFSPOF®

BCPVU 453*#*-% *G ZPV XPVME MJLF NPSF JOGPSNBUJPO UBML XJUI ZPVS IFBMUIDBSF QSPWJEFS :PV DBO BMTP BTL ZPVS IFBMUIDBSF QSPWJEFS PS BUPSWBTUBUJO -JQJUPS® $BEVFU®

QIBSNBDJTU GPS JOGPSNBUJPO BCPVU 453*#*-% UIBU JT XSJUUFO GPS IFBMUI CFQSJEJM IZESPDIMPSJD 7BTDPS® #FQBEJO®

QSPGFTTJPOBMT PS DBMM PS HP UP XXX 453*#*-% DPN CPTFOUBO 5SBDMFFS®

*TTVFE "VHVTU CVTQJSPOF DBSCBNB[FQJOF $BSCBUSPM® &QJUPM® &RVFUSP® 5FHSFUP®

DMBSJUISPNZDJO #JBYJO® 1SFWQBD®

DMPOB[FQBN ,MPOPQJO®

DMPSB[FQBUF (FO YFOF® 5SBOYFOF®

$0.1-&3" &.53*7" (*-&"% UIF (*-&"% -PHP (4* )&14&3" 453*#*-% UIF 453*#*-% -PHP 5367"%" BOE 7*3&"% BSF USBEFNBSLT PG (JMFBE 4DJFODFT *OD PS JUT SFMBUFE DPNQBOJFT "53*1-" DPMDIJDJOF $PMDSZT®

JT B USBEFNBSL PG #SJTUPM .ZFST 4RVJCC (JMFBE 4DJFODFT --$ "MM PUIFS NBSLT SFGFSFODFE IFSFJO BSF UIF QSPQFSUZ PG UIFJS SFTQFDUJWF PXOFST NFEJDJOFT UIBU DPOUBJO EFYBNFUIBTPOF The most common side effects of STRIBILD include: t /BVTFB t %JBSSIFB Tell your healthcare provider if you have any side effect that bothers you or that does not go away. t 5IFTF BSF OPU BMM UIF QPTTJCMF TJEF FGGFDUT PG 453*#*-% 'PS NPSF JOGPSNBUJPO BTL ZPVS IFBMUIDBSF QSPWJEFS t $BMM ZPVS IFBMUIDBSF QSPWJEFS GPS NFEJDBM BEWJDF BCPVU TJEF FGGFDUT :PV NBZ SFQPSU TJEF FGGFDUT UP '%" BU '%"

EJB[FQBN 7BMJVN®

ª (JMFBE 4DJFODFT *OD "MM SJHIUT SFTFSWFE 2$

IN THIS ISSUE

JULY/AUGUST 2013

6

2013 TREATMENT GUIDE

12 MEDICATION BY THE NUMBERS 9^V_ _^ Q\\ _V dXU 641 Q``b_fUT TbeWc ecUT d_ dbUQd 89F _b 89F bU\QdUT S_]`\YSQdY_^c

37 INVESTIGATIONAL MEDICINE GXQdºc S_]Y^W e` Y^ " !$/

41 COMPLEMENTARY MEDICINE

44

6b_] ]QccQWU d_ `bQiUb¶gXYSX Q\dUb^QdYfU dbUQd]U^dc XU\`/

42 HOW TO PAY FOR YOUR MEDS 4beW QccYcdQ^SU Y^ i_eb cdQdU

11 WHY TREATMENT AS PREVENTION IS CRITICAL ?^U Reci 89F `_cYdYfU UhUSedYfU dU\\c ec gXi cdQiY^W _^ XYc bUWY]U^ Yc Y]`_bdQ^d ^_d _^\i d_ XYc XUQ\dX Red dXQd _V UfUbi_^U U\cU Y^ XYc \YVU

FEATURES

44

5ISPVHI %VBOF $SBNFS T -FOT

AUR SNZRQ 56C ]\`VaVcR ]U\a\T_N]UR_ UN` `U\a PRYRO_VaVR` QVT[VaN_VR` N[Q RcR_fQNf ]R\]YR ;\d UR³` ONPê dVaU N [Rd PNZ]NVT[ a\ PUN[TR U\d dR QRNY dVaU aUR PU_\[VP P\[QVaV\[ N[Q N O\\ê \S .S_VPN[ .ZR_VPN[ VZNTR` YVêR aUR \[R NO\cR S_\Z `YNcR_f a\ a\QNf

6

"OE UIF %JWBT 1MBZFE 0O

0f[QV 9Nb]R_ 1ROOVR 4VO`\[ N[Q =NbYN =\b[Q`a\[R NYY ORPNZR `aN_` V[ aUR &% `¯aUR URVTUa \S aUR .61@ R]VQRZVP ?RNQ dUf 56C V` N PNb`R aURf _RZNV[ ]N``V\[NaR NO\ba

?> D85 3?F5B* 1bN[R 0_NZR_ P\b_aR`f \S 1bN[R 0_NZR_ =U\a\T_N]Uf

FROM TOP: MIRANDA PENN TURIN; COURTESY SUBJEC T

DAILY DOSE

<b_ P\cR_ `bOWRPa³` T_N[QSNaUR_ 7\R 0_NZR_ @_ _VTUa N[Q N S_VR[Q PV_PN &

EDITOR'S LETTER

M

?>CNIL CH =BC?@

A

G

4YQ^U 1^TUbc_^ =Y^cXQ\\

A

Z

I

N

?PJ& ALIOJ JO<FCMB?L

E :_U FQ\U^dY^_

G;H;ACHA ?>CNIL >UQ\ 2b_fUb]Q^

CHN?L;=NCP? ;LN >CL?=NIL B_RUbd 8}RUbd CS_dd =S@XUbc_^ M?HCIL G;H;A?LM& CHN?AL ;N?> G;LE?NCHA >CACN;F ?>CNIL =YSXU\\U 7QbSYQ B_RRYU 9]Uc ;UfY^ CdUS ;MMI=C;N? ?>CNIL Ce^^YfYU 2biTe] G;H;A?L& CHN?AL ;N?> G;LE?NCHA CdUfU^ ?º2bYU^ =IJS ?>CNIL DbeTi BY^W ;MMI=C;N? ;LN >CL?=NIL 2__ :QbSX_g M?HCIL >CL?=NIL& =FC?HN M?LPC=?M CdUgQbd >QSXd ?>CNILC;F CHN?LH 4QfYT 1bdQfYQ =CL=OF;NCIH >CL?=NIL :Uç <UddYUbU F?;> Q?< ;L=BCN?=N >? P?FIJ?L @UdUb 4Y =Qc_ @OF@CFFG?HN G;H;A?L 1bWec 7Q\Y^T_

=L?;NC P? >CL?=NIL& >CACN;F G?>C; 4QfU :_X^c_^ JLI>O=NCIH >CL?=NIL :_X^ <UgYc >CL?=NIL& >CACN;F G?>C; CS_dd BQWQ^ M?HCIL IHFCH? JLI>O=?L 3XbYcd_`XUb 8QbbYdi ;>P?LNCMCHA JLI>O=NCIH G;H;A?L 8UYTY =UTY^Q =L?;NCP? >CL?=NIL

G;H;A?L& ;JJFC=;NCIH >? P?FIJG?HN 1\Uh <Y] Q?< JLI>O=NCIH =IIL>CH;NIL :_U ?[_^[g_

HERE MEDIA

CdU`XU^ @ :QbSX_g =?I @Qe\ 3_\YSX]Q^ =@I D_^i CXi^W\U ?PJ& AG& 2Ub^QbT B__[ ?PJ& JO<FCMBCHA :_U <Q^Tbi ?>CNILC;F >CL?=NIL <eSQc 7bY^T\Ui =B;CLG;H

?R?=ONCP? PC=? JL?MC>?HNM

:_U <Q^Tbi

2Ub^QbT B__[ 3XbYcdY^ 4U^^Yc :_X^ =_^WYQbT_ CdU`XU^ =ebbQi 1\Uh @Qe\ :_cX B_cU^jgUYW :_U FQ\U^dY^_ PC=? JL?MC>?HNM 7bUW 2b_ccYQ 5bYS 2eY CdUfU^ 3Q`_^U :ecdY^ 7QbbUdd M?HCIL PC=? JL?MC>?HNM

ADVERTISING & SUBSCRIPTIONS OFFICES 120 West 45th Street, 23rd ďŹ&#x201A;oor, New York, New York 10036-4041 Phone ",+,# ,.,'2+** Â&#x17E; ;^p_lncmcha @[r ",+,# ,.,'2--2 Mo\m]lcjncihm ",+,# ,.,'2+**& ?rn( +3 Â&#x17E; Mo\m]lcjncihm @[r ",+,# ,.,'+-..

EDITORIAL OFFICES +*33* Qcfmbcl_ <fp^(& J_hnbiom_ Mocn_& Fim ;ha_f_m& =[fc`ilhc[ 3**,.

Phone "-+*# 2*0'.,22 Â&#x17E; @[r "-+*# 2*0'.,02 Â&#x17E; ?g[cf g[cf:BCPJfomG[a(]ig

DISTRIBUTE HIV PLUS FOR FREE AT YOUR OFFICE OR FACILITY <=J#AIDS service organizations, community-based groups, pharmacies, physiciansâ&#x20AC;&#x2122; ofďŹ ces, and other qualifying agencies can request bulk copies for free distribution at your ofďŹ ce or facility. Log on to HIVPlusMag.com and select â&#x20AC;&#x153;organization copiesâ&#x20AC;? on the â&#x20AC;&#x153;subscribeâ&#x20AC;? link at the top of the page to download a copy request form. There is a 10-copy minimum.

FREE INDIVIDUAL SUBSCRIPTIONS HIV Plus magazine is now available FREE to individual subscribers. Subscribe and get a digital copy of each magazine delivered to the privacy of your computer six times per year. We require only your email address to initiate delivery. You may also share your copies with friends. To sign up, just log on to HIVPlusMag.com and select â&#x20AC;&#x153;individual subscriptionsâ&#x20AC;? on the â&#x20AC;&#x153;subscribeâ&#x20AC;? link at the top of the page.

NEED SUBSCRIPTION HELP? If you have any questions or problems with your bulk or individual magazine delivery, just email our circulation department at Jeff.Lettiere@HereMedia.com.

BRADFORD ROGNE

WHATâ&#x20AC;&#x2122;S YOUR STORY? We want to hear from you: Email us at editor@HIVPlusMag.com or write us at HIV Plus, 10990 Wilshire Blvd., Penthouse Suite, Los Angeles, CA 90024. Visit Twitter @HIVPlusMag. HIV Plus "CMMH +/,,'-*20# cm jo\fcmb_^ \cgihnbfs \s B_l_ Jo\fcmbcha Ch](& +*33* Qcfmbcl_ <fp^(& J_hnbiom_ Mocn_& Fim ;ha_f_m& =; 3**,.( HIV Plus cm [ l_acmn_l_^ nl[^_g[le i` B_l_ G_^c[ Ch]( ?hncl_ ]ihn_hnm ¢ ,*+- \s B_l_ Jo\fcmbcha Ch]( ;ff lcabnm l_m_lp_^( Jlchn_^ ch nb_ OM;( CORRECTION: In the March/April issue, a photo used to illustrate a story on Chicago's South Side Help Center depicted children served by the agency. The children are in a youth program of the agency and not one related to HIV services; they are not HIV-positive.

GOING MOBILE DON ' T HAVE HIV.

Mig_ncg_m j_ijf_ [mmog_ C ^i \_][om_ C loh [ g[a[tch_ `il [h^ [\ion jimcncp_ j_ijf_ [h^ C i`n_h ^ih!n \inb_l ni ]ill_]n nb_g( Qbs9 Cn Ă&#x2014;abnm mncag[ c` C ^ih!n i\d_]n& [h^ C ^i b[p_ [ ^cm[\cfcns4 C b[p_ Ă&#x2014;\ligs[fac[( C n[e_ +, ^c``_l_hn nsj_m i` g_^c][ncihm [h^ mojjf_g_hnm ^[cfs& [fq[sm nlscha ni Ă&#x2014;h^ mig_ _[ms miol]_ i` ch`i ih nb_ mc^_ _``_]nm [h^ qbc]b ih_m C ][h!n n[e_ nia_nb_l [h^Ă&#x160;\_][om_ `ilgof[lc_m ]b[ha_ `[l nii `l_ko_hnfsĂ&#x160;qb[n nb_ []no[f jcff cm mojjim_^ ni fiie fce_ "qb_h sio b[p_ `iol ^c``_l_hn qbcn_ jcffm ni n[e_ nb[n \_]ig_m ]lo]c[f#( Nb[n!m ih_ i` nb_ l_[mihm C fip_ iol nl_[ng_hn aoc^_4 q_ n_ff sio [ff i` nbim_ nbcham& [h^ gil_& [\ion _p_ls mchaf_ ^loa om_^ ni nl_[n BCP [h^ BCP'l_f[n_^ ]igjfc][ncihm( ;h^ nbcm mogg_l sio ][h [fmi a_n nbcm ch`i ch iol h_q HIV+ Treatment App& [ pcmo[f [h^ ch`ilg[ncp_ gi\cf_ [jj nb[n f_nm sio nio]b& m][h& m]liff& [h^ chn_l[]n qcnb [ff nb_ ch`ilg[ncih ch nbcm aoc^_( Sio ][h ]fc]e ih siol mn[n_!m ;>;J jlial[g& sio ][h pcmcn nb_ g[e_l i` siol ^loa& [h^& \_mn i` [ff& sio ][h Ă&#x2014;h^ [h BCP'mj_]c[fcmn jb[lg[]s h_[l sio "nb_l_ [l_ _p_h gil_ \_ffm [h^ qbcmnf_m ]igcha f[n_l nbcm s_[l(# F_n g_ ehiq qb[n sio nbche A_n nb_ `l__

I

[jj [n BCPJfomG[a(]ig)nl_[ng_hnaoc^_(

>c[h_ ;h^_lmih'Gchmb[ff EDITOR IN CHIEF

J U LY/A U G U S T 2 0 1 3 Â&#x17E; HIV plus

5

AND THE T DIVA V S PLAYED A ON 6_b dXbUU g_]U^ gX_ RUSQ]U cdQbc Y^ dXU !)( c dXU RQdd\U d_ U^T 194C Yc Q^ U^TebY^W SQecU

By JASE PEEPLES

XU !)( c ]Qi RU V_^T\i bU]U] RUbUT V_b RbY^WY^W RYW XQYb RQT VQcXY_^ dbU^Tc Q^T =DF d_ dXU V_bUVb_^d _V `_` Se\debU Red dXU TUSQTU gQc Q\c_ ]Qb[UT Ri _^U _V dXU RYWWUcd XUQ\dX U`YTU]YSc Y^ bUS_bTUT XYcd_bi 194C D_TQi ]ecYS \UWU^T 3i^TY <Qe`Ub S_]U TYQ^ @Qe\Q @_e^Tcd_^U Q^T `_` deb^UT 2b_QTgQi `bY^SUcc 4URRYU 7YRc_^¶dXbUU g_]U^ gX_ XYd cdQbT_] Qd dXU XUYWXd _V dXU 194C SbYcYc¶S_^dY^eU d_ bQYcU dXUYb f_YSUc Y^ dXU RQdd\U d_ cdQ]` _ed dXU TYcUQcU 9dºc Q ÂWXd dXUiºfU `b_eT\i V_eWXd V_b Q\]_cd # iUQbc Q^T _^U dXQdºc \UVd Ydc cXQbU _V cSQbc _^ dXUYb XUQbdc Qc gU\\ <Qe`Ub gX_ Yc SU\URbQdY^W dXU # dX Q^^Y fUbcQbi _V XUb TURed Q\Re] @UR³` @\ B[b`bNY gYdX Q ce]]Ub d_eb _V dXU E C bUSQ\\c dXU UQb\i iUQbc gXU^ dXU TYcUQcU Âbcd ]QTU Q^ Y]`QSd _^ XUb \YVU ·C_ ]Q^i `U_`\U Y^ ]i \YVU Q^T Y^ dXU ]ecYS Y^Tecdbi gUbU TiY^W ¸ cXU cQic ·1^T ^_d ^UQb\i U^_eWX gQc RUY^W T_^U Ri _eb W_fUb^]U^d Qd dXU dY]U d_ XU\` ¸ DX_eWX 194C gQc c`bUQTY^W Qd Q^ Q\Qb] Y^W bQdU Y^ dXU UQb\i º( c UTeSQdY_^ QR_ed dXU TYcUQcU gQc `bQSdYSQ\\i ^_^UhYcdU^d Q^T @bUcYTU^d B_^Q\T BUQWQ^ g_e\T ^_d ]Q[U Q ]QZ_b `eR\YS cdQdU]U^d _^ Yd e^dY\ !)(' dXU iUQb QVdUb <Qe`Ub \_cd XUb Âbcd \_fUT _^U d_ dXU U`YTU]YS ·?^U _V ]i fUbi TUQb VbYU^Tc 7bUW_bi `QccUT QgQi Y^ !)(& Vb_] 194C ¸ cXU cQic ·8U \YfUT Y^ dXU Q`Qbd]U^d e`cdQYbc gYdX XYc `Qbd^Ub GU dbYUT d_ XU\` XY] dXb_eWX Yd Q\\ Qc RUcd gU S_e\T 9d gQc Q fUbi cSQbi dY]U ¸ 1c Y^VUSdY_^ bQdUc c_QbUT dXU `eR\YSºc \QS[ _V UTeSQdY_^ QR_ed dXU TYcUQcU _^\i Y^dU^cY ÂUT Ydc Y]`QSd ·DXU dXY^W QR_ed 194C Y^ dXU RUWY^^Y^W gQc dXQd Yd cSQbUT `U_`\U ¸ bUSQ\\c S_]UTYQ^ @Qe\Q @_e^Tcd_^U gX_ X_^UT XUb

J U LY/A U G U S T 2 0 1 3 HIV plus

7

SbQVd Y^ CQ^ 6bQ^SYcS_ºc S_]UTi S\eRc Q^T S_^dY^eUc U^dUbdQY^Y^W QeTYU^SUc QSb_cc dXU S_e^dbi ·9d Yc dXU _^\i TYcUQcU dXQd 9 SQ^ dXY^[ _V Y^ ]i \YVUdY]U gXUbU `U_`\U TYT^ºd [^_g gXUbU Yd gQc S_]Y^W Vb_] 194C b_TU Y^d_ d_g^ _^ Q ]_d_bSiS\U Q^T dXU QéYSdY_^ _V

VUQb cdYW]Q Q^T XicdUbYQ b_TU Y^ dXU cYTUSQb ¸ <Y[U dXU TYcUQcU dXU VUQb cebb_e^TY^W dXU U`YTU]YS QçUSdUT `U_`\U _V Q\\ QWUc¶Q VQSd @_e^Tcd_^U bU]U]RUbc _^\i d__ gU\\ ·9 f_\e^dUUbUT Qd Q Wb_e` X_]U¯dXQd gQc c`USYÂSQ\\i V_b SXY\TbU^ gYdX 194C ¸ cXU cQic

·GU gUbU d_\T dXQd dXUcU SXY\TbU^ gUbU \Q^ WeYcXY^W e^d_eSXQR\U Y^ X_c`YdQ\c gXUbU dXUi g_e\T TYU 9d gQc Q dUbbYR\U ci]`d_] _V XicdUbYQ C_ ]Q^i SXY\TbU^ gUbU e^^USUccQb Y\i Rb_eWXd d_ VQSY\YdYUc Q^T cU`QbQdUT Vb_] VQ]Y\i \YVU RUSQecU gU\\ Y^dU^TUT `U_`\U gUbU cSQbUT _V dXYc TYcUQcU DXQd gQc TURY\YdQdY^W ¸ DXU TYcUQcU S_^dY^eUT S\QY]Y^W \YfUc dXb_eWX_ed dXU º) c RUS_]Y^W Q^ e^V_bWUd dQR\U Qc`USd _V 4URRYU 7YRc_^ºc dbQ^cYdY_^ Vb_] `_` XYd]Q[Ub d_ 2b_QTgQi `UbV_b]Ub ·9d cUU]UT \Y[U gU gUbU Q\gQic \_cY^W c_]U R_Ti ¸ 7YRc_^ cQic ·=Q^i dY]Uc 9 g_e\T Â^YcX Q cX_g Q^T Â^T _ed dXQd Q V_b]Ub SQcd ]U]RUb `QccUT 9d gQc bUQ\\i XQbT 9 bU]U] RUb 9 gQc Y^ Q `b_TeSdY_^ _V 9R` :V`z_NOYR` gYdX Q^ QSd_b gX_ gQc 89F `_cYdYfU 8U gQc cdb_^W Qc Q^ _h XQT Q^ Q]QjY^W c`YbYd Q^T `\QiUT XYc `Qbd RUQedYVe\\i¶XU gQc Zecd UhdbQ_bTY^Qbi 1^T dXU ^Uhd dXY^W 9 [^Ug XU `QccUT Vb_] 89F 194C ¸ 1c TYèSe\d Qc dXUcU Uh`UbYU^SUc gUbU dXUi V_bWUT UQSX _V dXUcU g_]U^ Y^d_ QTf_SQdUc TUTYSQdUT d_ U^TY^W dXU TYcUQcU ?fUb dXU iUQbc UQSX _V dXU] XQc Q\YW^UT gYdX Q^T `UbV_b]UT V_b ^e]Ub_ec 89F 194C SXQbY dYUc SQecUc UQSX _V dXUcU TYfQc S_^dY^eU d_ SXQ]`Y_^ =_cd bUSU^d\i 7YRc_^ d__[ Q RbUQ[ Vb_] gbYdY^W ]ecYS V_b XUb e`S_]Y^W Q\Re] d_ Q``UQb Qd CQ^ 6bQ^ SYcS_ºc <[R ;VTUa <[Yf SQRQbUd `UbV_b]Q^SU Q S_^SUbd RU^UÂd Y^W R_dX dXU BYSX]_^T 5b]Ud 194C 6_e^TQdY_^ Q^T 2b_QTgQi 3QbUc 5aeYdi 6YWXdc 194C

OPPOSITE PAGE: TROY SMITH; THIS PAGE: MICHAEL SCHWARTZ

“IT IS THE ONLY DISEASE THAT I CAN THINK OF, IN MY LIFETIME, WHERE PEOPLE DIDN’T KNOW WHERE IT WAS COMING FROM. AIDS RODE INTO TOWN ON A MOTORCYCLE, AND THE AFFLICTION OF FEAR, STIGMA, AND HYSTERIA RODE IN THE SIDECAR,” REMEMBERS PAULA POUNDSTONE. ?^U _V @_e^Tcd_^Uºc \QdUcd WYWc gQc U]SUUY^W dXU c`bY^W RU^UÂd V_b dXU 194C 6_e^TQdY_^ _V 3XYSQW_ dXU =YTgUcdºc RYW WUcd `bYfQdU c_ebSU _V `XY\Q^dXb_`YS ce``_bd V_b 89F cUbfYSUc 1^T gXY\U dXU S_]UTYQ^ Yc^ºd ceb`bYcUT gUºbU cdY\\ RQdd\Y^W 89F cXUºc dXQ^[Ve\ V_b dXU `b_WbUcc dXQdºc RUU^ ]QTU ·9d SQ]U _^ c_ RYW Q^T RQT X_g S_e\T gU XQfU Uh`USdUT d_ gY^ dXQd RQdd\U Q^i UQb\YUb/¸ cXU cQic ·9 X_`U dXU bUcUQbSX Q^T `bUfU^dY_^ Uç_bdc S_^dY^eU Qc VQcd Qc dXUi SQ^¯gXU^ `U_`\U TYU Vb_] 194C Yd SQ^ ^UfUb cUU] VQcd U^_eWX Red bU]U]RUb gXUbU gU gUbU 9^ dUb]c _V dXU g_b\Tºc `bY_bYdYUc 9 SQ^ dU\\ i_e dXQd dXU ]_^Ui c`U^d _^ bUcUQbSX Q^T `bUfU^ dY_^ Yc Q W__T Y^fUcd]U^d ¸ 1TTYdY_^Q\\i <Qe`Ub XQc ^_d _^\i RUU^ Q V_bSU _V ^QdebU Y^ dXU ÂWXd d_ U^T 89F cXU XQc Q\c_ RUU^ Q^ e^gQfUbY^W QSdYfYcd V_b <72D UaeQ\Ydi cY^SU dXU RUWY^^Y^W _V XUb SQbUUb CXU S_V_e^TUT dXU DbeU 3_\_bc 6e^T Y^ " ( Q^ _bWQ^YjQdY_^ dXQd QTf_SQdUc UaeQ\Ydi V_b Q\\ Q^T QY]c d_ bQYcU QgQbU^Ucc _V <72D i_edX X_]U\Ucc^Ucc Qc gU\\ Qc RbY^W Q^ U^T d_ Yd ·I_e ÂWXd VUQb Q^T YW^_bQ^SU dXb_eWX UTeSQdY_^ Q^T QgQbU^Ucc ¸ cXU cQic _V dXU ]_dYfQdY_^ RUXY^T XUb QTf_SQSi ·8QfY^W ^UfUb RUU^ Q `Ubc_^ gX_ gQc QVbQYT d_ c`UQ[ e` 9 [^Ug 9 XQT d_ XU\` ]Q[U c_]U ^_YcU Q^T T_ gXQdUfUb 9 S_e\T d_ ]Q[U Q TYçUbU^SU ¸ DXQd TYçUbU^SU XQc Y^S\eTUT Q \_^W \Ycd _V 89F SXQbYdYUc Q^T _bWQ^YjQdY_^c gYdX gXYSX dXU cY^WUb XQc g_b[UT _fUb dXU iUQbc Y^S\eT Y^W $&&&$ dXU >U\c_^ =Q^TU\QµRQS[UT SQ] `QYW^ d_ XU\` bQYcU W\_RQ\ QgQbU^Ucc _V 89F Q^T 194C Q^T 2b_QTgQi 3QbUc 5aeYdi 6YWXdc 194C 9^ " ! <Qe`Ub Q^T <QTi 7QWQ RUSQ]U dXU VQSUc _V =13 3_c]UdYScº XYWX\i `eR\YSYjUT FYfQ 7\Q] SQ]`QYW^ RU^UÂdY^W dXU =13 194C 6e^T

2ed gXY\U SXQbYdYUc ceSX Qc dXUcU XU\`UT Ve^T dXU ]UTYSQ\ RbUQ[dXb_eWXc dXQd ]QTU 89F Q ]_bU ]Q^QWUQR\U TYcUQcU <Qe`Ub g_b bYUc dXUbU XQc RUU^ Q TQ^WUb_ec cXYVd Y^ dXU WU^UbQ\ `eR\YSºc QddYdeTU ·DXU RYWWUcd SXQ\\U^WU d_TQi Yc dXQd `U_`\U ^_ \_^WUb dXY^[ _V 89F 194C Qc Q^ YcceU ¸ cXU

cQic ·2ed gXY\U dXU TbeW dXUbQ`YUc XQfU T_^U Q^ Y^SbUTYR\U Z_R _V [UU`Y^W `U_`\U gYdX 89F Q\YfU Yd Yc Q^ QbTe_ec Z_eb^Ui V_b `U_`\U dQ[ Y^W dXU TbeWc DXU cYTU UçUSdc QbU cYW^YÂSQ^d GU ^UUT d_ S_^dY^eU d_ bUY^fUcd Y^ `bUfU^dY_^ Uç_bdc Q^T d_ `ed Q\\ dXU bUc_ebSUc gU SQ^ Y^d_ U^TY^W dXU U`YTU]YS ¸ ✜

DA ILY DO SE

WHY TREATMENT AS PREVENTION IS CRITICAL ?^U Reci 89F `_cYdYfU UhUSedYfU dU\\c ec gXi cdQiY^W _^ XYc bUWY]U^ Yc Y]`_bdQ^d ^_d _^\i d_ XYc XUQ\dX Red dXQd _V UfUbi_^U U\cU Y^ XYc \YVU 2i Di\Ub 8U\]c c c_]U_^U gX_ Yc 89F `_c YdYfU cYdc _^ dXU R_QbT _V dXU ^_^`b_VYd 7Qi =U^ยบc 8UQ\dX 3bYcYc Q^T VbQ^[\i SQbUc QR_ed Xe]Q^Ydi 9 VY^T ]icU\V Qc[Y^W dXU cQ]U aeUcdY_^ _fUb Q^T _fUb* GXQd U\cU SQ^ RU T_^U d_ `bUfU^d ^Ug 89F Y^VUSdY_^c/ DXU Q^cgUb d_ `bUfU^dY_^ XQc \_^W RUU^ Wb_e^TUT Y^ dXU cY]`\UยถQ\RUYd ^_d Q\gQic V_\\_gUTยถcQVU cUh ]Q^dbQ 2ed gUยบbU [YT TY^W _ebcU\fUc YV gU T_^ยบd QS[^_g\UTWU dXQd cQVU cUh Yc ]eSX UQcYUb cQYT dXQ^ T_^U 3_^T_]c ]Qi RU Y^Uh`U^cYfU _b VbUU `U_`\U ]Qi [^_g dXU bYc[ Q^T cSYU^SU ]Qi RQS[ dXU bQdY_^Q\U Red gXU^ Yd S_]Uc d_ cUh bQdY_^Q\ dXY^[Y^W _VdU^ \_cUc _ed =_bU _VdU^ dXQ^ ^_d 9 `bQSdYSUT cQVU cUh 2ed Q\\ Yd d__[ gQc _^U ]_]U^d Y^ " ' gXU^ Q\\ ]i dXU_bi be\Uc Q^T SQedY_^ gUbU _fUbbYTTU^ Ri dXQd YbbQdY_^Q\ iUd Xe]Q^ ^UUT d_ RU Y^dY]QdU Q^T cXQbU Q `XicYSQ\ S_^^USdY_^ gYdX c_]U_^U 9 SQbUT V_b CY^SU ]i TYQW^_cYc Y^ " ' 9 S_^dY^eU d_ XUQb S\QY]c QR_ed dXU bUTeSUT bYc[ _V dbQ^c]YccY_^ V_b `U_`\U gYdX fYbQ\ \_QTc \_g U^_eWX d_ RU TUU]UT ยทe^TUdUSdQR\U ยธ 2UV_bU 9 cdQbdUT ]UTYSQdY_^ 9 TYc]YccUT dXQd Qc ^_dXY^W ]_bU dXQ^ Q `\UQ d_ `_dU^dYQ\ Y^dY]QdU `Qbd^Ubc 1 gQi d_ cQi ยท9dยบc ?; d_ XQfU cUh gYdX ]Uยถ9ยบ] e^TUdUSdQR\U ยธ

PHOTOS.COM

A

Deb^c _ed 9 gQc gb_^W D_TQi Qc 9 fU^debU RQS[ Y^d_ dXU TQdY^W g_b\T `U_`\U _VdU^ Qc[ ยท1bU i_e _^ ]UTY SQdY_^/ 1bU i_e XUQ\dXi/ยธ DXUbU Yc Q]`\U UfYTU^SU dXQd dXUcU aeUcdY_^cยถQ^T dXUYb Q^cgUbcยถ]YWXd RU ]_bU dXQ^ Zecd bXUd_bYS 1 bUSU^d cdeTi Vb_] Q Wb_e` _V 3Q^QTYQ^ bUcUQbSXUbc Y^TYSQdUc dXQd Q^ e^TUdUSd QR\U fYbQ\ \_QT ]QY^dQY^UT Ri ]UTYSQdY_^ UccU^dYQ\\i U\Y]Y^QdUc dbQ^c]YccY_^ bYc[ Y^ cdbQYWXd S_e`\Uc CdeTYUc XQfU Q\c_ ceWWUcdUT dXQd QTXUbU^SU d_ Q^dYbUdb_fYbQ\ dXUbQ`i S_e\T bUTeSU dXU `_ccYRY\Ydi _V dbQ^c]YccY_^ Q]_^W WQi ]U^ DXYc Yc XeWU 1c Q^i W__T T_Sd_b gY\\ dU\\ i_e dXUbU Yc Q\gQic bYc[ Y^f_\fUT gYdX Q^i cUheQ\ QSdYf Ydi 9 Q] ^_d QbWeY^W dXQd gU cX_e\T QRQ^T_^ dXU cQVU cUh S_^fUbcQdY_^ 1c c_]U_^U gX_ Yc d_TQi e^TUdUSdQR\U 9 cdY\\ ecU `b_dUSdY_^ Q^T TU]Q^T dXU cQ]U Vb_] Q `Qbd^Ub 2ed YV dXUbU Yc cSYU^dYVYS UfYTU^SU dXQd UQb\i dbUQd ]U^d SQ^ g_b[ Qc Q^_dXUb \QiUb _V `bUfU^ dY_^ Yd g_e\T RU YbbUc`_^cYR\U d_ YW^_bU dXU SbYdYSQ\ ^UUT V_b UfUbi_^U d_ [^_g dXUYb cdQ dec Q^T RUWY^ dbUQd]U^d c__^Ub dXQ^ \QdUb D_ ]Q[U cebU dbUQd]U^d Qc `bUfU^dY_^ Yc Qc ceSSUccVe\ Qc `_ccYR\U gU ]ecd S_^dY^eU d_ VYWXd dXU cdYW]Q _V RUY^W `_cYdYfU ]Y^Y ]YjU dXU VUQb _V WUddY^W dUcdUT Q^T SQ\\ _^ ]UTYSQ\ Q^T `XQb]QSUedYSQ\ `b_fYTUbc d_

]Q[U ]UTYSQdY_^ QfQY\QR\U d_ UfUbi_^U gX_ ^UUTc Yd 2Ui_^T dXUcU cicdU]YS SXQ\\U^WUc dXUbU QbU dXU UfU^ ]_bU `bUccY^W `Ubc_^Q\ S_^ cYTUbQdY_^c gXU^ RUWY^^Y^W Q^dYbUdb_fYbQ\ dbUQd]U^d 6_b ]U Yd gQc^ยบd Q^ UQci TUSY cY_^+ dXU VUQb _V cYTU UVVUSdc dXU `_ccYRY\ Ydi _V TbeW bUcYcdQ^SU Q^T dXU dX_eWXd _V RUY^W _^ ]UTYSQdY_^ V_b dXU bUcd _V ]i \YVU ]QTU V_b Q d_eWX SQ\\ E\dY]QdU\i dX_eWX 9 ]QTU dXU TUSYcY_^ d_ cdQbd Q bUWY]U^ gYdX dXU XU\` _V ]i `bY]Qbi SQbU `XicYSYQ^ 4Uc`YdU dXU SXQ\\U^WUc dbUQd]U^d Qc `bUfU^dY_^ Yc Q Wb_gY^W bUQ\Ydi dXQd gU ]ecd `ebceU 9d bUaeYbUc ec Q\\ d_ U^S_eb QWU Q^T Uh`USd _eb WYb\VbYU^T R_i VbYU^T XecRQ^T gYVU d_ [^_g dXUYb cdQdec Q^T cUU[ `b_`Ub dbUQd]U^d DXUbU Yc^ยบd Q ]_]U^d d_ gQYdยถ_eb \_fUT _^Uc cX_e\T \UQb^ dXUYb cdQdec ^_g 2USQecU YV gU UfUb X_`U d_ bUQ\\i Q^cgUb dXU `bUfU^dY_^ aeUc dY_^ gU XQfU d_ bYW_b_ec\i Uh`\_bU UfUbi `_ccYRY\Ydi Q^T Ydยบc S\UQb dXQd UQb\i dbUQd ]U^d Yc Q `b_]YcY^W `b_c`USd

AfYR_ 5RYZ` V` cVPR ]_R`VQR[a \S 1Rba`PU 6[P `Va` \[ aUR O\N_Q \S QV_RPa\_` S\_ aUR 4Nf :R[ยณ` 5RNYaU 0_V`V` N[Q V` S\b[QR_ \S aUR ;RRQYR =_VPX =_\WRPa โ J U LY/A U G U S T 2 0 1 3

ย

HIV plus

11

2013 HIV COMPLETE

TREATMENT

GUIDE

BUcUQbSXUT Q^T S_]`Y\UT Ri 4YQ^U 1^TUbc_^ =Y^cXQ\\ >UQ\ 2b_fUb]Q^ Ce^^YfYU 2biTe] =YSXU\\U 7QbSYQ Q^T DbeTi BY^W

12

HIV plus

J U LY/A U G U S T 2 0 1 3

Everyone needs to know about the meds we take, so HIV Plus offers our most comprehensive look ever at the medications approved by the Food and Drug Administration for the treatment of HIV and opportunistic infections, as well as a state-by-state map of drug assistance programs, complementary therapies, and drug trials. Remember, before you take anything you should talk with your doctor about what meds youâ&#x20AC;&#x2122;re on, any drug allergies, whether you smoke, drink, or take other supplements or recreational drugs, if you breast-feed, or are pregnant or want to be. This info was culled from the National Institutes of Healthâ&#x20AC;&#x2122;s drug database, the FDA, and the individual pharmaceutical companies.

THE 2013 COMPLETE HIV TREATMENT GUIDE

JLIN?;M? CHBC<CNILM B?FJ JL?P?HN L?JFC=;NCIH I@ BCP MEDICATION 4R[R_VP ;NZR =Q[Ub

PREZISTA QN_b[NcV_ :Q^ccU^

REYATAZ NaNgN[NcV_ 2bYcd_\ =iUbc CaeYRR

APTIVUS aV]_N[NcV_ 2_UXbY^WUb 9^WU\XUY]

CRIXIVAN V[QV[NcV_ =UbS[

14

HIV plus

TRADITIONAL DOSAGE

DRUG INTERACTIONS, PRECAUTIONS, & RECOMMENDATIONS

Two 400-mg capsules or one 800-mg tablet with one 100-mg Norvir capsule, once daily, with food

4beWc Y^ dXYc S\Qcc QddQS[ `b_dUQcU gXYSX 89F ^UUTc d_ bU`b_TeSU 4_ ^_d dQ[U @bUjYcdQ gYdX Eb_HQdbQ\ FYSdbU\Yc 4 8 5 $% 5]R_\Uh =YWbQ^Q\ 3QVUbW_d 5bW_]Qb ]UdXi \UbW_^_fY^U @b_`e\cYT ?bQ` _bQ\ ]YTQj_\Q] 8Q\SY_^ CQY^d :_X^ºc g_bd =UfQS_b 1\d_`bUf 1TfYS_b J_S_b CY] S_b Fid_bY^ BYVQTY^ BYVQdUb BYVQ]QdU BY]QSdQ^U BUfQ dY_ gXU^ ecUT d_ dbUQd `e\]_^Qbi QbdUbYQ\ Xi`UbdU^cY_^ 3bYhYfQ^ ;Q\UdbQ 9^fYbQcU _b 9^SYfU[ EcU gYdX SQedY_^ YV dQ[Y^W FYQWbQ BUfQdY_ <UfYdbQ CdQhi^ 3YQ\Yc 1TSYbSQ <Y`Yd_b 3bUcd_b @bQfQSX_\ 3_\Sbic _b 3_\ @b_RU^USYT 3_QbdU] _b BYQ]Ud =Qi bUTeSU RYbdX S_^db_\ `Y\\cº Uè SQSi+ dQ[U _dXUb `bUSQedY_^c

=_cd cUbY_ec* cUfUbU \YfUb TYcUQcU cUfUbU bQcX XYWX R\__T ceWQb _b TYQRUdUc SXQ^WUc Y^ R_Ti VQd _b Y]]e^U cicdU] ?dXUb* TYQbbXUQ ^QecUQ ]Y\T bQcX XUQTQSXU cd_] QSX `QY^ f_]YdY^W

300 mg, in capsule form, taken with 100 mg of Norvir, once daily, with food. For adults unable to tolerate Norvir, 400 mg of Reyataz with food is recommended.

Take at the same time every day

4_ ^_d dQ[U gYdX FUbcUT 8Q\SY_^ 3QVUbW_d =YWbQ^Q\ 4 8 5 $% =UdXUbWY^U _dXUb UbW_d ]UTYSY^Uc _b ?bQ` 3Q]`d_cQb 3bYhYfQ^ =UfQS_b J_S_b Eb_HQdbQ\ BUfQdY_ BY]QSdQ^U BYVQTY^ BYVQdUb BYVQ]QdU CQY^d :_X^ºc g_bd FYbQ]e^U 4Yc[ec _b 1TfQYb 4_ ^_d dQ[U FVU^T _b FYSdbU \Yc YV i_e QbU dQ[Y^W BUiQdQj Q^T >_bfYb Q^T T_ ^_d dQ[U DUWbUd_\ gYdX BUiQdQj Q\_^U 9V i_e QbU dQ[Y^W FYTUh FYTUh 53 _b Q^dQSYTc dQ[U BUiQdQj dg_ X_ebc RUV_bU _b _^U X_eb QVdUb dX_cU ]UTYSY^Uc EcU gYdX SQedY_^ YV dQ[Y^W TbeWc V_b Y^TYWUcdY_^ XUQbdReb^ _b e\SUbc

=_cd cUbY_ec* cUfUbU bQcX iU\\_g Y^W _V c[Y^ _b UiUc XUQbd bXidX] SXQ^WU TYQRUdUc [YT^Ui cd_^Uc SXQ^WUc Y^ R_Ti VQd SXQ^WUc Y^ Y]]e^U cicdU] g_bcU^Y^W \YfUb TYcUQcU Y^SbUQcUT R\UUTY^W `b_R \U]c WQ\\R\QTTUb TYc_bTUbc ?dXUb* ^QecUQ XUQTQSXU cd_]QSX `QY^ f_]YdY^W TYQbbXUQ TU`bUccY_^ VUfUb TYjjY^Ucc db_eR\U c\UU`Y^W ]ecS\U `QY^ ^e]R^Ucc dY^W\Y^W _b Reb^Y^W _V XQ^Tc _b VUUd

500 mg (two 250mg capsules or 5 milliliters of oral solution) with 200 mg (two 100-mg capsules/tablets or 2.5 milliliters of solution) of Norvir, twice daily. Capsules or solution may be taken with or without meals; tablets must be taken with meals

6_b dbUQd]U^d Uh`UbYU^SUT `QdYU^dc _^\i DQ[U gYdX Qd \UQcd dg_ _dXUb Q^dY 89F TbeWc Red T_ ^_d ecU gYdX _dXUb `b_ dUQcU Y^XYRYd_bc EcU gYdX SQedY_^ YV dQ[Y^W SUbdQY^ Q^dYcUY jebU ]UTYSQdY_^c EcU gYdX SQedY_^ YV i_e XQfU XU]_`XY\YQ _b _dXUb S_^TYdY_^c dXQd Y^SbUQcU dXU SXQ^SU _V R\UUTY^W _b \YfUb TYc_bTUbc

=_cd cUbY_ec* cUfUbU _b VQdQ\ \YfUb TYcUQcU cUfUbU R\UUTY^W Y^ dXU RbQY^ ^Ug _b g_bcU^UT TYQRUdUc ?dXUb* TYQbbXUQ ^QecUQ VUfUb f_]YdY^W dYbUT^Ucc XUQTQSXU Q^T cd_]QSX `QY^

800 mg, taken every eight hours, with water or another beverage, without food (one hour before or two hours after a meal) or with a light meal

4_ ^_d dQ[U gYdX _bQ\ FUbcUT @b_`e\cYT J_S_b =UfQ S_b ?bQ` 3_bTQb_^U 8Yc]Q^Q\ 8Q\SY_^ HQ^Qh BUfQdY_ Eb_HQdbQ\ BYVQTY^ BY]QSdQ^U BYVQ]QdU BYVQdUb CQY^d :_X^ºc g_bd GYWbQY^U 3QVUbW_d 4 8 5 $% =YWbQ^Q\ 5bW_dbQdU =UdXUbWY^U _b BUiQdQj EcU gYdX SQedY_^ gYdX FYQWbQ 3YQ\Yc <UfYdbQ <Y`Yd_b Q^T 3bUcd_b 4bY^[ `\U^di _V ÃeYTc Q^T T_ ^_d dQ[U dXU TbeW gYdX ]UQ\c dXQd QbU XYWX Y^ SQ\_bYUc VQd Q^T `b_dUY^

=_cd cUbY_ec* <YfUb VQY\ebU [YT^Ui cd_^Uc SXQ^WUc Y^ R_Ti VQd TYQ RUdUc Q^U]YQ cUfUbU `QY^ ]ecS\U gUQ[^Ucc ?dXUb* QRT_]Y^Q\ `QY^ VQdYWeU _b gUQ[^Ucc \_g bUT R\__T SU\\ S_e^d ÃQ^[ `QY^ `QY^Ve\ ebY ^QdY_^ VUU\Y^W e^gU\\ ^QecUQ e`cUd cd_]QSX TYQbbXUQ f_]Yd Y^W QSYT bUWebWYdQdY_^ Y^SbUQcUT _b TUSbUQcUT Q``UdYdU RQS[ `QY^ XUQTQSXU TYjjY^Ucc dQcdU SXQ^WUc bQcX YdSXi c[Y^ iU\\_gY^W _V dXU c[Y^ Q^T _b UiUc e``Ub bUc`YbQd_bi Y^VUSdY_^ Tbi c[Y^ c_bU dXb_Qd

J U LY/A U G U S T 2 0 1 3

SIDE EFFECTS

JLIN?;M? CHBC<CNILM B?FJ JL?P?HN L?JFC=;NCIH I@ BCP MEDICATION MEDICATION 4R[R_VP ;NZR 4R[R_VP ;NZR =Q[Ub =Q[Ub

INVIRASE `N^bV[NcV_ ZR`fYNaR 8_ç]Q^^ <Q B_SXU

KALETRA Y\]V[NcV_ N[Q _Va\[NcV_ 1RR_dd <QR_bQd_bYUc

LEXIVA S\`NZ]_R[NcV_ FYYF 8UQ\dXSQbU

TRADITIONAL DOSAGE

DRUG INTERACTIONS, PRECAUTIONS, & RECOMMENDATIONS

1,000 mg (five 200-mg capsules or two 500mg tablets), in combination with 100 mg of Norvir, twice daily, at least two hours after a meal

4_ ^_d ecU gYdX Eb_HQdbQ\ 3_bTQb_^U FQcS_b DY[_ci^ DQ]R_S_b Y^dbQfU^_ec \YT_SQY^U BidX]_\ AeY^YTY^U @b_`e\cYT UbW_d ]UTYSQdY_^c ceSX Qc @Qb\_TU\ =YWbQ^Q\ 5bW_^_fY^U 2U\\Q]Y^U 3QVUbW_d 5bW_]Qb =UdXUbWY^U _b @Ub]Qh _bQ\ FUbcUT ?bQ` BYVQTY^ BUfQdY_ gXU^ ecUT d_ dbUQd `e\]_^Qbi Xi`UbdU^cY_^ =UfQS_b 1TfYS_b J_S_b :efYci^S CY]S_b Fid_bY^ 4UcibU\ ?\U`db_ _b 8Q\SY_^ EcU gYdX SQedY_^ gYdX BUiQdQj 3bYhYfQ^ ;Q\UdbQ FYbQSU`d 1`dYfec BUcSbY`d_b FYbQ]e^U <Y`Yd_b 3bUcd_b FYQWbQ <UfYdbQ 3YQ\Yc 1TSYbSQ CQY^d :_X^ºc g_bd WQb\YS SQ`ce\Uc X_b]_^Q\ S_^dbQSU`dYfUc SUbdQY^ SQ\SYe] SXQ^^U\ R\_S[ Ubc SUbdQY^ Q^dYRY_dYSc Q^T Q^dYVe^WQ\ ]UTYSY^Uc c_]U Q^dY`ciSX_dYSc _b Q^dYTU`bUccQ^dc Q^T `b_d_^ `e]` Y^XYR Yd_bc 4_ ^_d ecU YV i_e XQfU cUfUbU \YfUb `b_R\U]c \_g `_dQccYe] _b \_g ]QW^UcYe] Y^ i_eb R\__T 3_^WU^YdQ\ <_^W AD Ci^Tb_]U _b S_]`\UdU QdbY_fU^dbYSe\Qb R\_S[ EcU gYdX SQedY_^ YV i_e XQfU _dXUb XUQbd _b \YfUb `b_R\U]c XU]_`XY\YQ _b TYQRUdUc

=_cd cUbY_ec* g_bcU^Y^W _V \YfUb `b_R\U]c Y^SbUQcUT R\UUT Y^W gYdX XU]_`XY\YQ TYQRUdUc _b XYWX R\__T ceWQb U\UfQdUT SX_ \UcdUb_\ _b dbYW\iSUbYTUc SXQ^WUc Y^ R_Ti VQd Y]]e^U cicdU] _b XUQbd bXidX] ?dXUb* >QecUQ f_]YdY^W TYQbbXUQ VQdYWeU QRT_]Y^Q\ `QY^

800 mg, typically four tablets, once daily, or 400 mg, typically two tablets, twice daily. Swallow tablets whole; do not chew, break, or crush.

An oral solution is available but should be taken with food

4_ ^_d dQ[U gYdX 8Q\SY_^ ]YTQj_\Q] _bQ\ cibe` SUbdQY^ cdUb_YTc 9^SYfU[ ?bQ` =UfQS_b J_S_b BY]QSdQ^U BYVQ TY^ BYVQdUb BYVQ]QdU BUfQdY_ gXU^ ecUT d_ dbUQd `e\]_ ^Qbi QbdUbYQ\ Xi`UbdU^cY_^ CdU^TbQ Eb_HQdbQ\ FYSdbU\Yc HQbU\d_ CQY^d :_X^ºc g_bd UbW_d S_^dQY^Y^W ]UTYSY^Uc Y^S\eTY^W UbW_dQ]Y^U 3QVUbW_d Q^T _dXUbc TYXiTb_Ub W_dQ]Y^U 4 8 5 $% Q^T _dXUbc UbW_^_fY^U 5bW_dbQdU Q^T ]UdXi\UbW_^_fY^U =UdXUbWY^U EcU gYdX SQedY_^ gYdX FYQWbQ 3YQ\Yc <UfYdbQ 1TSYbSQ RYbdX S_^db_\ `Y\\c _b S_^dbQSU`dYfU `QdSXUc S_^dQY^Y^W Ucdb_WU^ DQcYW^Q C`biSU\ <Y`Yd_b 3bUcd_b 1dbY`\Q CecdYfQ FYbQ]e^U 1WU^ UbQcU <UhYfQ FYbQSU`d 4Y\Q^dY^ DUWbUd_\ =iS_RedY^ 6\_^QcU CUbUfU^d 1TfQYb 3_\Sbic DbQS\UUb 4ebQWUcYS 9_^cic 6U^d_bQ Q^T ]UdXQT_^U

=_cd cUbY_ec* SXQ^WUc Y^ XUQbd bXidX] cUfUbU \YfUb `b_R\U]c `Q^SbUQdYdYc SXQ^WUc Y^ Y]]e^U cicdU] SXQ^WUc Y^ R_Ti VQd ^Ug _b g_bcU^UT TYQRUdUc U\UfQdUT dbYW\iSUbYTU _b SX_\UcdUb_\ \UfU\c ?dXUb* TYQbbXUQ ^QecUQ cd_] QSX `QY^ f_]YdY^W gUQ[^Ucc XUQTQSXU

For those used to protease inhibitors, 700 mg plus a 100-mg capsule of Norvir, twice daily. For those new to therapy, 1,400 mg of Lexiva twice daily, sometimes paired with Norvir, depending on the patient. Lexiva is available in tablets or oral solution; tablets can be taken with or without food, oral solution without food.

Reduced dosage recommended for patients with liver impairment

4_ ^_d dQ[U g YdX BUcSbY`d_b Eb_HQdbQ\ B YVQTY^ B Y]QSdQ^U CQY^d :_X^ºc g_bd SUbdQY^ QbbidX]YQ ]UTYSQdY_^c UbW_d RQcUT ]UTYSQdY_^c @b_`e\cYT J_S_b =UfQS_b ?bQ` BUfQ dY_ gXU^ ecUT d_ dbUQd `e\]_^Qbi QbdUbYQ\ Xi`UbdU^cY_^ FUbcUT _b 8Q\SY_^ 9V i_e dQ[U _bQ\ S_^dbQSU`dYfUc S_^ cYTUb Q\dUb^QdYfU RYbdX S_^db_\ ]UdX_Tc 4_ ^_d dQ[U gYdX FYbQ]e^U e^\Ucc Q\c_ dQ[Y^W >_bfYb EcU gYdX SQedY_^ gYdX 8" R\_S[Ubc Q^T SQ\SYe] SXQ^^U\ R\_S[Ubc 4_ ^_d ecU YV i_e XQfU CdUfU^c :_X^c_^ ci^Tb_]U _b YV i_e dQ[U TbeWc dXQd ecU dXU U^ji]U 3I@#1$ d_ ]UdQR_\YjU

=_cd cUbY_ec* cUfUbU c[Y^ bUQSdY_^c Y^S\eTY^W CdUfU^c :_X^c_^ ci^Tb_]U ^Ug _b g_bcU^UT TYQRUdUc bUTYcdbYRe dY_^ _V R_Ti VQd U\UfQdUT SX_ \UcdUb_\ Q^U]YQ c`_^dQ^U_ec R\UUTY^W [YT^Ui cd_^Uc ?dXUb* TYQbbXUQ bQcX ^QecUQ f_]Yd Y^W XUQTQSXU

SIDE SIDE EFFECTS EFFECTS

J U LY/A U G U S T 2 0 1 3 HIV plus

15

The

one

for me

Patient model. Pill shown is not actual size.

What is COMPLERA? ®

COMPLERA is a prescription HIV medicine that is used as a complete regimen to treat HIV-1 in adults who have never taken HIV medicines before and who have an amount of HIV in their blood (this is called “viral load”) that is no more than 100,000 copies/mL. COMPLERA contains 3 medicines – rilpivirine, emtricitabine and tenofovir disoproxil fumarate. It is not known if COMPLERA is safe and effective in children under the age of 18 years.

COMPLERA® does not cure HIV-1 infection or AIDS. To control HIV-1 infection and decrease HIV-related illnesses you must keep taking COMPLERA. Avoid doing things that can spread HIV-1 to others: always practice safer sex and use condoms to lower the chance of sexual contact with body fluids; never reuse or share needles or other items that have body fluids on them, do not share personal items that may contain bodily fluids. Ask your healthcare provider if you have questions about how to reduce the risk of passing HIV-1 to others.

IMPORTANT SAFETY INFORMATION What is the most important information you should know about COMPLERA? COMPLERA® can cause serious side effects: t Build-up of an acid in your blood (lactic acidosis), which is a serious medical emergency. Symptoms of lactic acidosis include feeling very weak or tired, unusual (not normal) muscle pain, trouble breathing, stomach pain with nausea or vomiting, feeling cold, especially in your arms and legs, feeling dizzy or lightheaded, and/or a fast or irregular heartbeat. t Serious liver problems. The liver may become large (hepatomegaly) and fatty (steatosis). Symptoms of liver problems include your skin or the white part of your eyes turns yellow (jaundice), dark “tea-colored” urine, light-colored bowel movements (stools), loss of appetite for several days or longer, nausea, and/or stomach pain. t You may be more likely to get lactic acidosis or serious liver problems if you are female, very overweight (obese), or have been taking COMPLERA for a long time.

In some cases, these serious conditions have led to death. Call your healthcare provider right away if you have any symptoms of these conditions. t Worsening of hepatitis B (HBV) infection. If you also have HBV and stop taking COMPLERA, your hepatitis may suddenly get worse. Do not stop taking COMPLERA without first talking to your healthcare provider, as they will need to monitor your health. COMPLERA is not approved for the treatment of HBV.

Who should not take COMPLERA? Do not take COMPLERA if you have ever taken other anti-HIV medicines.

COMPLERA may change the effect of other medicines and may cause serious side effects. Your healthcare provider may change your other medicines or change their doses.

Do not take COMPLERA if you also take these medicines: t anti-seizure medicines: carbamazepine (Carbatrol, Equetro, Tegretol, Tegretol-XR, Teril, Epitol); oxcarbazepine (Trileptal), phenobarbital (Luminal), phenytoin (Dilantin, Dilantin-125, Phenytek) t anti-tuberculosis medicines: rifabutin (Mycobutin), rifampin (Rifater, Rifamate, Rimactane, Rifadin) and rifapentine (Priftin) t proton pump inhibitors for stomach or intestinal problems: esomeprazole (Nexium, Vimovo), lansoprazole (Prevacid), dexlansoprazole (Dexilant), omeprazole (Prilosec), pantoprazole sodium (Protonix), rabeprazole (Aciphex) t more than 1 dose of the steroid medicine dexamethasone or dexamethasone sodium phosphate t St. John’s wort (Hypericum perforatum) If you are taking COMPLERA you should not take other HIV medicines or other medicines containing tenofovir (Viread, Truvada, Stribild or Atripla); other medicines containing emtricitabine or lamivudine (Emtriva, Combivir, Epivir, Epivir-HBV, Epzicom, Trizivir, Atripla, Stribild or Truvada); rilpivirine (Edurant) or adefovir (Hepsera).

In addition, tell your healthcare provider if you are taking the following medications because they may interfere with how COMPLERA works and may cause side effects: t certain antacid medicines containing aluminum, magnesium hydroxide, or calcium carbonate (examples: Rolaids, TUMS). These medicines must be taken at least 2 hours before or 4 hours after COMPLERA. t medicines to block stomach acid including cimetidine (Tagamet), famotidine (Pepcid), nizatidine (Axid), or ranitidine HCL (Zantac). These medicines must be taken at least 12 hours before or 4 hours after COMPLERA. t any of these medicines: clarithromycin (Biaxin); erythromycin (E-Mycin, Eryc, Ery-Tab, PCE, Pediazole, Ilosone), fluconazole (Diflucan), itraconazole (Sporanox), ketoconazole (Nizoral) methadone (Dolophine); posaconazole (Noxifil), telithromycin (Ketek) or voriconazole (Vfend). t medicines that are eliminated by the kidneys like acyclovir (Zovirax), cidofovir (Vistide), ganciclovir (Cytovene IV, Vitrasert), valacyclovir (Valtrex) and valganciclovir (Valcyte).

COMPLERA.

A complete HIV treatment in only 1 pill a day.

COMPLERA is for adults who have never taken HIV-1 medicines before and have no more than 100,000 copies/mL of virus in their blood.

Ask your healthcare provider if itâ&#x20AC;&#x2122;s the one for you.

These are not all the medicines that may cause problems if you take COMPLERA. Tell your healthcare provider about all prescription and nonprescription medicines, vitamins, or herbal supplements you are taking or plan to take.

The most common side effects reported with COMPLERA are trouble sleeping (insomnia), abnormal dreams, headache, dizziness, diarrhea, nausea, rash, tiredness, and depression. Some side effects also reported include vomiting, stomach pain or discomfort, skin discoloration (small spots or freckles) and pain.

Before taking COMPLERA, tell your healthcare provider if you: liver problems, including hepatitis B or C virus infection, or have abnormal liver tests t Have kidney problems t Have ever had a mental health problem t Have bone problems t Are pregnant or planning to become pregnant. It is not known if COMPLERA can harm your unborn child t Are breastfeeding: Women with HIV should not breastfeed because they can pass HIV through their milk to the baby. Also, COMPLERA may pass through breast milk and could cause harm to the baby

This is not a complete list of side effects. Tell your healthcare provider or pharmacist if you notice any side effects while taking COMPLERA, and call your healthcare provider for medical advice about side effects.

t Have

COMPLERA can cause additional serious side effects: t New or worsening kidney problems, including kidney failure. If you have had kidney problems, or take other medicines that may cause kidney problems, your healthcare provider may need to do regular blood tests. t Depression or mood changes. Tell your healthcare provider right away if you have any of the following symptoms: feeling sad or hopeless, feeling anxious or restless, have thoughts of hurting yourself (suicide) or have tried to hurt yourself. t Changes in liver enzymes: People who have had hepatitis B or C, or who have had changes in their liver function tests in the past may have an increased risk for liver problems while taking COMPLERA. Some people without prior liver disease may also be at risk. Your healthcare provider may need to check your liver enzymes before and during treatment with COMPLERA. t Bone problems can happen in some people who take COMPLERA. Bone problems include bone pain, softening or thinning (which may lead to fractures). Your healthcare provider may need to do additional tests to check your bones. t Changes in body fat can happen in people taking HIV medicine. t Changes in your immune system. Your immune system may get stronger and begin to fight infections that have been hidden in your body for a long time. Tell your healthcare provider if you start having new symptoms after starting COMPLERA.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit http://www.fda.gov/medwatch or call 1-800-FDA-1088.

Additional Information about taking COMPLERA: t Always take COMPLERA exactly as your healthcare provider tells you to take it. t Take COMPLERA with a meal. Taking COMPLERA with a meal is important to help

get the right amount of medicine in your body. (A protein drink does not replace a meal).

Stay under the care of your healthcare provider during treatment with COMPLERA and see your healthcare provider regularly.

Please see Brief Summary of full Prescribing Information with important warnings on the following pages.

Learn more at www.COMPLERA.com

Brief Summary of full Prescribing Information

t

®

COMPLERA (kom-PLEH-rah) (emtricitabine, rilpivirine, tenofovir disoproxil fumarate) tablets Brief summary of full Prescribing Information. For more information, please see the full Prescribing Information including Patient Information.

What is COMPLERA? t

COMPLERA is a prescription HIV (Human Immunodeficiency Virus) medicine that is used to treat HIV-1 in adults – who have never taken HIV medicines before, and – who have an amount of HIV in their blood (this is called ‘viral load’) that is no more than 100,000 copies/mL. Your healthcare provider will measure your viral load.

(HIV is the virus that causes AIDS (Acquired Immunodeficiency Syndrome)). t

COMPLERA contains 3 medicines – rilpivirine, emtricitabine, tenofovir disoproxil fumarate – combined in one tablet. It is a complete regimen to treat HIV-1 infection and should not be used with other HIV medicines.

t

It is not known if COMPLERA is safe and effective in children under the age of 18 years old.

t

COMPLERA does not cure HIV infection or AIDS. You must stay on continuous therapy to control HIV infection and decrease HIV-related illnesses.

t

Ask your healthcare provider if you have any questions about how to prevent passing HIV to other people. Do not share or re-use needles or other injection equipment, and do not share personal items that can have blood or body fluids on them, like toothbrushes and razor blades. Always practice safer sex by using a latex or polyurethane condom to lower the chance of sexual contact with semen, vaginal fluids or blood.

Who should not take COMPLERA? Do not take COMPLERA if: t your HIV infection has been previously treated with HIV medicines. t

you are taking any of the following medicines: – anti-seizure medicines: carbamazepine (Carbatrol, Equetro, Tegretol, Tegretol-XR, Teril, Epitol); oxcarbazepine (Trileptal); phenobarbital (Luminal); phenytoin (Dilantin, Dilantin-125, Phenytek) – anti-tuberculosis (anti-TB) medicines: rifabutin (Mycobutin); rifampin (Rifater, Rifamate, Rimactane, Rifadin); rifapentine (Priftin) – proton pump inhibitor (PPI) medicine for certain stomach or intestinal problems: esomeprazole (Nexium, Vimovo); lansoprazole (Prevacid); dexlansoprazole (Dexilant); omeprazole (Prilosec, Zegerid); pantoprazole sodium (Protonix); rabeprazole (Aciphex) – more than 1 dose of the steroid medicine dexamethasone or dexamethasone sodium phosphate – St. John’s wort (Hypericum perforatum)

t

If you take COMPLERA, you should not take: – Other medicines that contain tenofovir (Atripla, Stribild, Truvada, Viread)

What is the most important information I should know about COMPLERA? COMPLERA can cause serious side effects, including: t Build-up of lactic acid in your blood (lactic acidosis). Lactic acidosis can happen in some people who take COMPLERA or similar (nucleoside analogs) medicines. Lactic acidosis is a serious medical emergency that can lead to death. Lactic acidosis can be hard to identify early, because the symptoms could seem like symptoms of other health problems. Call your healthcare provider right away if you get any of the following symptoms which could be signs of lactic acidosis: – feel very weak or tired – have unusual (not normal) muscle pain – have trouble breathing – have stomach pain with nausea (feeling sick to your stomach) or vomiting – feel cold, especially in your arms and legs

– Other medicines that contain emtricitabine or lamivudine (Combivir, Emtriva, Epivir or Epivir-HBV, Epzicom, Trizivir, Atripla, Truvada, Stribild) – rilpivirine (Edurant) – adefovir (Hepsera) What should I tell my healthcare provider before taking COMPLERA? Before you take COMPLERA, tell your healthcare provider if you: t have or had liver problems, including hepatitis B or C virus infection, kidney problems, mental health problem or bone problems t

– feel dizzy or lightheaded Severe liver problems. Severe liver problems can happen in people who take COMPLERA. In some cases, these liver problems can lead to death. Your liver may become large (hepatomegaly) and you may develop fat in your liver (steatosis). Call your healthcare provider right away if you get any of the following symptoms of liver problems:

t

– your skin or the white part of your eyes turns yellow (jaundice) – dark “tea-colored” urine – light-colored bowel movements (stools)

are breast-feeding or plan to breast-feed. You should not breastfeed if you have HIV because of the risk of passing HIV to your baby. Do not breastfeed if you are taking COMPLERA. At least two of the medicines contained in COMPLERA can be passed to your baby in your breast milk. We do not know whether this could harm your baby. Talk to your healthcare provider about the best way to feed your baby.

– loss of appetite for several days or longer

Tell your healthcare provider about all the medicines you take, including prescription and nonprescription medicines, vitamins, and herbal supplements.

– nausea

t

– stomach pain t

are pregnant or plan to become pregnant. It is not known if COMPLERA can harm your unborn child.

Pregnancy Registry. There is a pregnancy registry for women who take antiviral medicines during pregnancy. The purpose of this registry is to collect information about the health of you and your baby. Talk to your healthcare provider about how you can take part in this registry.

– have a fast or irregular heartbeat t

Worsening of Hepatitis B infection. If you have hepatitis B virus (HBV) infection and take COMPLERA, your HBV may get worse (flare-up) if you stop taking COMPLERA. A “flare-up” is when your HBV infection suddenly returns in a worse way than before. COMPLERA is not approved for the treatment of HBV, so you must discuss your HBV with your healthcare provider.

– Do not let your COMPLERA run out. Refill your prescription or talk to your healthcare provider before your COMPLERA is all gone.

– Do not stop taking COMPLERA without first talking to your healthcare provider.

– If you stop taking COMPLERA, your healthcare provider will need to check your health often and do blood tests regularly to check your HBV infection.

Tell your healthcare provider about any new or unusual symptoms you may have after you stop taking COMPLERA.

You may be more likely to get lactic acidosis or severe liver problems if you are female, very overweight (obese), or have been taking COMPLERA for a long time.

COMPLERA may affect the way other medicines work, and other medicines may affect how COMPLERA works, and may cause serious side effects. If you take certain medicines with COMPLERA, the amount of COMPLERA in your body may be too low and it may not work to help control your HIV infection.

The HIV virus in your body may become resistant to COMPLERA or other HIV medicines that are like it.

Especially tell your healthcare provider if you take: t an antacid medicine that contains aluminum, magnesium hydroxide, or calcium carbonate. If you take an antacid during treatment with COMPLERA, take the antacid at least 2 hours before or at least 4 hours after you take COMPLERA. t

t

a medicine to block the acid in your stomach, including cimetidine (Tagamet), famotidine (Pepcid), nizatidine (Axid), or ranitidine hydrochloride (Zantac). If you take one of these medicines during treatment with COMPLERA, take the acid blocker at least 12 hours before or at least 4 hours after you take COMPLERA. any of these medicines (if taken by mouth or injection): – clarithromycin (Biaxin) – erythromycin (E-Mycin, Eryc, Ery-Tab, PCE, Pediazole, Ilosone)

trouble sleeping (insomnia)

t

abnormal dreams

t

headache

t

dizziness

t

diarrhea

t

nausea

t

rash

t

tiredness

t

depression

Additional common side effects include:

– fluconazole (Diflucan)

t

vomiting

– itraconazole (Sporanox)

t

stomach pain or discomfort

– ketoconazole (Nizoral)

t

skin discoloration (small spots or freckles)

– methadone (Dolophine)

t

pain

– posaconazole (Noxafil) – telithromycin (Ketek) – voriconazole (Vfend) t

The most common side effects of COMPLERA include: t

medicines that are eliminated by the kidney, including acyclovir (Zovirax), cidofovir (Vistide), ganciclovir (Cytovene IV, Vitrasert), valacyclovir (Valtrex), and valganciclovir (Valcyte)

Tell your healthcare provider if you have any side effect that bothers you or that does not go away.

These are not all the possible side effects of COMPLERA. For more information, ask your healthcare provider or pharmacist.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088 (1-800-332-1088).

What are the possible side effects of COMPLERA?

How should I take COMPLERA?

COMPLERA can cause serious side effects, including: t See “What is the most important information I should know about COMPLERA?”

t

Stay under the care of your healthcare provider during treatment with COMPLERA.

t

Take COMPLERA exactly as your healthcare provider tells you to take it.

t

Always take COMPLERA with a meal. Taking COMPLERA with a meal is important to help get the right amount of medicine in your body. A protein drink does not replace a meal.

t

Do not change your dose or stop taking COMPLERA without first talking with your healthcare provider. See your healthcare provider regularly while taking COMPLERA.

t

If you miss a dose of COMPLERA within 12 hours of the time you usually take it, take your dose of COMPLERA with a meal as soon as possible. Then, take your next dose of COMPLERA at the regularly scheduled time. If you miss a dose of COMPLERA by more than 12 hours of the time you usually take it, wait and then take the next dose of COMPLERA at the regularly scheduled time.

t

Do not take more than your prescribed dose to make up for a missed dose.

t

t

New or worse kidney problems, including kidney failure, can happen in some people who take COMPLERA. Your healthcare provider should do blood tests to check your kidneys before starting treatment with COMPLERA. If you have had kidney problems in the past or need to take another medicine that can cause kidney problems, your healthcare provider may need to do blood tests to check your kidneys during your treatment with COMPLERA. Depression or mood changes. Tell your healthcare provider right away if you have any of the following symptoms: – feeling sad or hopeless – feeling anxious or restless – have thoughts of hurting yourself (suicide) or have tried to hurt yourself

t

Change in liver enzymes. People with a history of hepatitis B or C virus infection or who have certain liver enzyme changes may have an increased risk of developing new or worsening liver problems during treatment with COMPLERA. Liver problems can also happen during treatment with COMPLERA in people without a history of liver disease. Your healthcare provider may need to do tests to check your liver enzymes before and during treatment with COMPLERA.

t

Bone problems can happen in some people who take COMPLERA. Bone problems include bone pain, softening or thinning (which may lead to fractures). Your healthcare provider may need to do additional tests to check your bones.

t

Changes in body fat can happen in people taking HIV medicine. These changes may include increased amount of fat in the upper back and neck (“buffalo hump”), breast, and around the main part of your body (trunk).

Loss of fat from the legs, arms and face may also happen. The cause and long term health effect of these conditions are not known.

t

Changes in your immune system (Immune Reconstitution Syndrome) can happen when you start taking HIV medicines. Your immune system may get stronger and begin to fight infections that have been hidden in your body for a long time. Tell your healthcare provider if you start having new symptoms after starting your HIV medicine.

This Brief Summary summarizes the most important information about COMPLERA. If you would like more information, talk with your healthcare provider. You can also ask your healthcare provider or pharmacist for information about COMPLERA that is written for health professionals, or call 1-800-445-3235 or go to www.COMPLERA.com Issued: January 2013

COMPLERA, the COMPLERA Logo, EMTRIVA, GILEAD, the GILEAD Logo, GSI, HEPSERA, STRIBILD, TRUVADA, VIREAD, and VISTIDE are trademarks of Gilead Sciences, Inc., or its related companies.

ATRIPLA is a trademark of Bristol-Myers Squibb & Gilead Sciences, LLC. All other marks referenced herein are the property of their respective owners. ©2013 Gilead Sciences, Inc. All rights reserved. CPAC0023 03/13

THE 2013 COMPLETE HIV TREATMENT GUIDE

JLIN?;M? CHBC<CNILM B?FJ JL?P?HN L?JFC=;NCIH I@ BCP MEDICATION 4R[R_VP ;NZR =Q[Ub

NORVIR

_Va\[NcV_ 1RR_dd <QR_bQd_bYUc

VIRACEPT

[RYº[NcV_

FYYF 8UQ\dXSQbU

TRADITIONAL DOSAGE

DRUG INTERACTIONS, PRECAUTIONS, & RECOMMENDATIONS

600 mg (six 100mg tablets), twice daily, with a meal.

Swallow tablets whole with water; do not chew, break, or crush.

Also available in capsules or oral solution.

Reduced dosage recommended for people taking other protease inhibitors

4_ ^_d dQ[U gYdX HQdbQ\ 3_bTQb_^U DQ]R_S_b FQcS_b BidX]_\ 6eSYTY^ 8Yc]Q^Q\ CU\TQ^U ?bQ` @b_`e\cYT 3QVUbW_d =YWbQ^Q\ 4 8 5 $% 5bW_dbQdU =Q\UQdU FVU^T =UfQS_b J_S_b 8Q\SY_^ FUbcUT 1TfQYb CUbUfU^d <UfYdbQ BUfQdY_ YV ecUT V_b `e\]_^Qbi QbdUbYQ\ Xi`UbdU^cY_^ CQY^d :_X^ºc g_bd 4_ ^_d dQ[U gYdX R_dX 9^fYbQcU Q^T Q^i fUb cY_^ _V bYVQ]`Y^ BY]QSdQ^U BYVQTY^ BYVQdUb _b BYVQ]QdU Q^T ecU gYdX SQedY_^ gYdX UYdXUb _V dX_cU TbeWc cU`QbQdU\i EcU gYdX SQedY_^ gYdX <Y`Yd_b 3bUcd_b FYQWbQ <UfYdbQ 3YQ\Yc 1TSYbSQ DbQS\UUb BQ`Q]e^U 6\_^QcU 1WU^UbQcU 3bYhYfQ^ FYbQSU`d FYTUh =iS_RedY^ 1`dYfec BUcSbY` d_b BUiQdQj 3U\cU^dbY^ DU\jYb @bUjYcdQ DYQjQS 1TQ\Qd 9c_`dY^ >Yj_bQ\ C`_bQ^_h 4U]Ub_\ DUWbUd_\ 4Y\Q^dY^ `XU^_RQbRYdQ\ =iS_RedY^ 2YQhY^ 4ebQWUcYS dXU_`Xi\ \Y^U 3_\Sbic ecUT V_b dbUQd]U^d _V W_ed SUbdQY^ Q^dYSQ^SUb ]UTYSQdY_^c SUbdQY^ Q^dYTU`bUccQ^dc EcU gYdX SQedY_^ YV i_e XQfU _dXUb \YfUb `b_R\U]c _b TYQRUdUc

=_cd cUbY_ec* g_bcU^Y^W _V \YfUb TYcUQcU `Q^SbUQdYdYc TYQRUdUc _b XYWX R\__T ceWQb U\UfQdUT SX_ \UcdUb_\ _b dbYW\iSUbYTUc SXQ^WUc Y^ R_Ti VQd Y^SbUQcUT R\UUTY^W Q]_^W XU]_`XY\YQSc cUfUbU c[Y^ bUQSdY_^c ?dXUb* bQcX QRT_]Y^Q\ `QY^ TYQbbXUQ VUU\Y^W gUQ[ _b dYbUT XUQTQSXU ^QecUQ f_]Yd Y^W SXQ^WUc Y^ dQcdU \_cc _V Q``U dYdU TYjjY^Ucc dY^W\Y^W VUU\Y^W _b ^e]R^Ucc Y^ XQ^Tc Y^ VUUd _b Qb_e^T dXU \Y`c

1,250 mg (five 250-mg tablets or two 625-mg tablets), twice daily, or 750 milligrams (three 250-mg tablets) three times daily.

Each dose should be taken with a meal. An oral powder is also available

4_ ^_d dQ[U gYdX 3_bTQb_^U ?bQ` AeY^YTY^U AeY^Q W\edU 3QbTY_aeY^ AeY^YTUh 4 8 5 $% 9^ZUSdY_^ 5bW_ ]Qb =YWbQ^Q\ GYWbQY^U 3QVUbW_d =UdXUbWY^U 8Q\SY_^ FUbcUT BUfQdY_ YV ecUT V_b `e\]_^Qbi QbdUbYQ\ Xi`UbdU^ cY_^ Eb_HQdbQ\ @bY\_cUS BY]QSdQ^U BYVQTY^ BYVQdUb BYVQ]QdU CQY^d :_X^ºc g_bd =UfQS_b J_S_b _b CUbUfU^d EcU gYdX SQedY_^ gYdX <Y`Yd_b 3bUcd_b @bQfQSX_\ <UcS_\ FYQWbQ <UfYdbQ 3YQ\Yc 1TSYbSQ _b DbQS\UUb 9V Q\c_ dQ[Y^W FYTUh dQ[U FYbQSU`d gYdX V__T _^U X_eb QVdUb _b ]_bU dXQ^ dg_ X_ebc RUV_bU i_e dQ[U FYTUh =Qi bUTeSU UçUSdYfU ^Ucc _V RYbdX S_^db_\ `Y\\c c_ ecU QTTYdY_^Q\ _b Q\dUb^QdYfU V_b] _V S_^dbQSU`dY_^ 4_cUc _V 3bYhYfQ^ >_bfYb 9^fYbQcU 6_bd_fQcU =iS_RedY^ _b 4Y\Q^dY^ ]Qi ^UUT d_ RU QTZecdUT BUcSbY`d_b ]Qi \_gUb dXU Q]_e^d _V FYbQSU`d Y^ dXU R\__T _b fYSU fUbcQ 4_ ^_d dQ[U YV i_e XQfU ]_TUbQdU d_ cUfUbU \YfUb Y]`QYb]U^d

=_cd cUbY_ec* TYQRUdUc Q^T XYWX R\__T ceWQb XYWX R\__T `bUccebU SXQ^WUc Y^ R_Ti VQd SXQ^WUc Y^ Y]]e^U cicdU] ?dXUb* TYQbbXUQ ^QecUQ bQcX

SIDE EFFECTS

?HNLS ;H> @OMCIH CHBC<CNILM B?FJ <FI=E BCP @LIG ?HN?LCHA N =?FFM MEDICATION 4R[R_VP ;NZR =Q[Ub

TRADITIONAL DOSAGE

SELZENTRY

300 mg twice daily, or 150 mg twice daily if given with potent CYP3A inhibitors, or 600 mg twice daily if given with potent CYP3A inducers

ZN_NcV_\P

FYYF 8UQ\dXSQbU

20

HIV plus

J U LY/A U G U S T 2 0 1 3

WHAT IT DOES

DXYc Yc iUd Q^_dXUb ]USXQ^Yc] _V Y^XYR YdY^W fYbQ\ bU`\YSQ dY_^ 1\gQic dQ[U^ gYdX _dXUb Q^dY 89F ]UTYSQdY_^c

DRUG INTERACTIONS, PRECAUTIONS, & RECOMMENDATIONS

4_ ^_d dQ[U CQY^d :_X^ºc g_bd Qc Yd SQ^ \_gUb dXU Q]_e^d _V CU\jU^ dbi Y^ dXU R\__T C_]U _dXUb ]UTY SQdY_^c ]Qi Q\c_ QçUSd dXU Q]_e^d _V CU\jU^dbi Y^ dXU R\__T DU\\ i_eb T_Sd_b YV i_e XQfU Q XYcd_bi _V XU`QdYdYc 2 _b 3 XQfU XUQbd _b [YT^Ui `b_R\U]c _V YV i_e XQfU \_g R\__T `bUccebU _b dQ[U ]UTYSQdY_^ d_ \_gUb Yd

SIDE EFFECTS

=_cd cUbY_ec* XUQbd _b \YfUb TYc_bTUbc \_gUbUT R\__T `bUc cebU gXU^ cdQ^TY^W e` `_c cYR\U Y^SbUQcUT bYc[ _V SQ^SUb Q^T _dXUb Y^VUSdY_^c SXQ^W Uc Y^ dXU Y]]e^U cicdU] cUfUbU bQcX _b Q\\UbWYS bUQS dY_^ \UQTY^W d_ XU`d_d_hYSYdi ?dXUb* S_eWX VUfUb TYjjY^Ucc XUQTQSXU \_gUbUT R\__T `bUc cebU ^QecUQ R\QTTUb YbbYdQdY_^ e``Ub bUc`YbQd_bi Y^VUSdY_^

?HNLS ;H> @OMCIH CHBC<CNILM B?FJ <FI=E BCP @LIG ?HN?LCHA N =?FFM MEDICATION 4R[R_VP ;NZR =Q[Ub

FUZEON

R[SbcV_aVQR B_SXU <QR_bQd_bYUc RbQ^T ^Q]U DbY]UbYc WU^UbYS

TRADITIONAL DOSAGE

Injection of 90 mg in the upper arm, upper leg, or stomach twice daily

WHAT IT DOES

DXYc Yc Q^_dXUb ]USXQ^Yc] _V Y^XYRYdY^W fYbQ\ bU`\YSQdY_^ 1\gQic dQ[U^ gYdX _dXUb Q^dY 89F ]UTYSQdY_^c

DRUG INTERACTIONS, PRECAUTIONS, & RECOMMENDATIONS

C_]U `U_`\U ecU dXU 2Y_ZUSd_b " Q ^UUT\U VbUU TUfYSU d_ QT]Y^Yc dUb 6ejU_^ Red Y^ c_]U Yd SQecUc ^UbfU `QY^ dY^ W\Y^W RbeYcY^W Q^T S_\ \USdY_^ _V R\__T e^TUb dXU c[Y^

SIDE EFFECTS

=_cd cUbY_ec* Y^ZUSdY_^ cYdU Y^VUSdY_^c _b bUQS dY_^c ceSX Qc YdSXY^W cgU\\Y^W bUT^Ucc `QY^ _b dU^TUb^Ucc XQbTU^UT c[Y^ Re]`c Qd dXU cYdU _V Y^ZUSdY_^+ Q\\UbWYS bUQSdY_^cยถQ\c_ `QdYU^dc dQ[Y^W 6ejU_^ ]Qi TUfU\_` RQSdUbYQ\ `^Ue]_^YQ ]_bU _VdU^ dXQ^ _dXUbc Q\dX_eWX Yd Yc e^S\UQb YV dXU TbeW Yc dXU SQecU ?dXUb* `QY^ Q^T ^e]R^Ucc Y^ VUUd _b \UWc \_cc _V c\UU` TU`bUccY_^ TUSbUQcUT Q``UdYdU cY^ec `b_R\U]c U^\QbWUT \i]`X ^_TUc gUYWXd TUSbUQcU gUQ[^Ucc _b \_cc _V cdbU^WdX ]ecS\U `QY^ S_^cdY`QdY_^ Q^T `Q^SbUQc `b_R\U]c

CHN?AL;M? CHBC<CNILM B?FJ <FI=E ;H BCP'?H;<FCHA ?HTSG? ISENTRESS _NYaRT_NcV_

One 400-mg tablet, twice daily

=UbS[

2\_S[c Y^dUWbQcU Q^ U^ji]U 89F ^UUTc d_ bU`b_TeSU YdcU\V 1\gQic dQ[U^ gYdX _dXUb Q^dY 89F ]UTYSQdY_^c

DU\\ i_eb T_Sd_b YV i_e dQ[U dXU deRUbSe\_cYc ]UTYSQdY_^ bYVQ]`Y^ _b YV i_e XQfU \YfUb `b_R\U]c _b `XU^i\[Ud_^ebYQ 9V i_e ]Ycc Q T_cU c[Y` dXU ]YccUT T_cU Q^T W_ RQS[ d_ i_eb bUWe\Qb cSXUTe\U 4_ ^_d T_eR\U i_eb ^Uhd T_cU

=_cd cUbY_ec* cUfUbU c[Y^ bUQSdY_^c Q^T Q\\UbWYS bUQSdY_^c \YfUb `b_R\U]c SXQ^WUc Y^ i_eb Y]]e^U cicdU] ?dXUb* XUQTQSXU db_eR\U c\UU`Y^W ^QecUQ dYbUT^Ucc+ \Ucc S_]]_^ cYTU UรงUSdc Y^S\eTU gUQ[^Ucc cd_]QSX `QY^ TYjjY^Ucc TU`bUccY_^ Q^T ceYSYTQ\ dX_eWXdc Q^T QSdY_^c

Getting HIV treatment information has never been easier.

% '! "' ( & "#* ) #" +#(% !# ) * ' ($ '# ' '% '! "' " #%! ' #" #") " "' $ %! + ," % " ' #" % &#(% &

Get instant access to the

Treatment Guide Mobile App Point your mobile browser to www.hivplusmag.com/treatmentguide iPHONE PHOTO COURTESY OF APPLE INC.

THE 2013 COMPLETE HIV TREATMENT GUIDE

HO=F?IMC>? L?P?LM? NL;HM=LCJN;M? CHBC<CNILM "HLNC# B?FJ JL?P?HN L?JFC=;NCIH I@ BCP MEDICATION 4R[R_VP ;NZR =Q[Ub

TRUVADA

RZa_VPVaNOV[R N[Q aR[\S\cV_ QV`\]_\eVY SbZN_NaR 7Y\UQT CSYU^SUc

COMBIVIR

YNZVcbQV[R N[Q gVQ\cbQV[R FYYF 8UQ\dXSQbU 2bQ^T ^Q]U DUfQ @XQb]QSUedYSQ\c 7U^UbYS

EMTRIVA

RZa_VPVaNOV[R

7Y\UQT CSYU^SUc

EPIVIR

YNZVcbQV[R \_ A0 FYYF 8UQ\dXSQbU

22

HIV plus

TRADITIONAL DOSAGE

DRUG INTERACTIONS, PRECAUTIONS, & RECOMMENDATIONS

One tablet, containing 200 mg of emtricitabine and 300 mg of tenofovir disoproxil fumarate, once daily

DbefQTQ S_^dQY^c dg_ >BD9c gXYSX QSd _^ bUfUbcU dbQ^ cSbY`dQcU Q ceRcdQ^SU 89F ^UUTc V_b bU`\YSQdY_^ 4_ ^_d dQ[U DbefQTQ YV i_e dQ[U 1dbY`\Q 3_]RYfYb 5]dbYfQ 5`YfYb _b 5`YfYb 82F 5`jYS_] DbYjYfYb _b FYbUQT gXYSX XQfU dXU cQ]U _b cY]Y\Qb QSdYfU Y^WbUTYU^dc I_e ]Qi ^UUT d_ QTZecd T_cQWU YV Q\c_ dQ[Y^W FYTUh BUiQdQj _b ;Q\UdbQ 4_ ^_d dQ[U gYdX 8U`cUbQ 9V i_e XQfU XQT [YT^Ui `b_R\U]c _b dQ[U _dXUb TbeWc dXQd SQ^ SQecU [YT^Ui `b_R\U]c i_eb T_Sd_b cX_e\T T_ bUWe\Qb R\__T dUcdc d_ SXUS[ i_eb [YT^Uic 9^ " !" dXU 641 Q``b_fUT DbefQTQ V_b ecU Y^ 89F `bUfU^ dY_^ Q]_^W 89F ^UWQdYfU `U_`\U gX_ QbU Qd XYWX bYc[ _V QSaeYbY^W dXU fYbec DXU 641ºc e`TQdUT \QRU\Y^W _^ dXU TbeW ^_dUc dXQd `Ubc_^c ecY^W dXU TbeW `bUfU^dQdYfU\i ^UUT d_ RU S_^Âb]UT Qc 89F ^UWQdYfU UfUbi dXbUU ]_^dXc Q^T ecU dXU TbeW Qc `bUcSbYRUT Y^ S_]RY^QdY_^ gYdX cQVUb cUh `bQSdYSUc Q^T S_e^cU\Y^W

=_cd cUbY_ec* ReY\Te` _V \QSdYS QSYT Y^ dXU R\__T cUbY_ec \YfUb `b_R\U]c ÃQbU e`c _V XU`QdYdYc 2 fYbec Y^VUS dY_^ [YT^Ui `b_R\U]c dXY^^Y^W R_^Uc SXQ^WUc Y^ R_Ti VQd ci]`d_]c _V Y^ÃQ]]QdY_^ Vb_] `bUfY_ec Y^VUS dY_^c ?dXUb* TYQbbXUQ TYjjY^Ucc ^QecUQ f_]YdY^W XUQTQSXU VQdYWeU QR^_b]Q\ TbUQ]c c\UU`Y^W `b_R\U]c bQcX TU`bUccY_^ cX_bd^Ucc _V RbUQdX `QY^ VQddi \YfUb cd_]QSX `QY^ gUQ[ ^Ucc Y^TYWUcdY_^ Y^dUcdY^Q\ WQc XYWX f_\e]U _V ebY^U UhSUccYfU dXYbcd c[Y^ TYcS_\_bQdY_^ 9^ `QdYU^dc ecY^W Dbe fQTQ V_b `bUfU^dY_^ dXU ]_cd S_] ]_^ cYTU UçUSdc XQfU RUU^ XUQTQSXU QRT_]Y^Q\ `QY^ Q^T gUYWXd \_cc

One tablet, containing 150 mg of lamivudine and 300 mg zidovudine (both NRTIs), twice daily

4_ ^_d dQ[U gYdX _dXUb ]UTYSY^Uc S_^dQY^Y^W \Q]YfeTY^U jYT_feTY^U _b U]dbYSYdQRY^U ceSX Qc 5`YfYb 5`YfYb 82F BUdb_fYb 5`jYS_] DbYjYfYb 1dbY`\Q 5]dbYfQ Q^T DbefQTQ EcU SQedY_^ gYdX YV dQ[Y^W Y^dUbVUb_^ Q\VQ bYRQfYbY^ T_h_be RYSY^ _b WQ^SYS\_fYb DU\\ i_eb T_Sd_b YV i_eºfU `bUfY_ec\i XQT Q^i [YT^Ui _b \YfUb `b_R\U]c ceSX Qc XU`QdYdYc _b SYbbX_cYc `Q^SbUQdYdYc _b \_g bUT gXYdU R\__T SU\\ S_e^dc

=_cd cUbY_ec* \_g gXYdU Q^T bUT R\__T SU\\ S_e^dc cUbY_ec Q\\UbWYS bUQSdY_^c ReY\Te` _V \QSdYS QSYT Y^ dXU R\__T \YfUb d_hYSYdi _b g_bcU^Y^W _V \YfUb TYcUQcU `Q^SbUQdYdYc ]ecS\U TYc_bTUbc Q^T Y^ÃQ]]QdY_^ SXQ^W Uc Y^ R_Ti VQd SXQ^WUc Y^ dXU Y]]e^U cicdU] ?dXUb* XUQTQSXU ^QecUQ VQdYWeU TYQbbXUQ S_eWX cdeçi ^_cU WU^UbQ\ VUU\Y^W _V TYcS_]V_bd

One 200-mg capsule or 240 mg of oral solution, once daily

4_ ^_d ecU gYdX _dXUb TbeWc S_^dQY^Y^W U]dbYSYdQRY^U ceSX Qc 1dbY`\Q 3_]`\UbQ DbefQTQ _b CdbYRY\T

=_cd cUbY_ec* ReY\Te` _V \QSdYS QSYT Y^ dXU R\__T \YfUb `b_R\U]c Y^S\eTY^W ÃQbU e` _V XU`QdYdYc 2 QVdUb TYcS_^ dY^eQdY_^ ?dXUb* XUQTQSXU TYQbbXUQ ^QecUQ VQdYWeU TYjjY^Ucc TU`bUc cY_^ Y^c_]^YQ QR^_b]Q\ TbUQ]c bQcX QRT_]Y^Q\ `QY^ QcdXU^YQ Y^SbUQcUT S_eWX bXY^YdYc

300 mg daily, in one or two doses, in tablets or oral solution

4_ ^_d dQ[U gYdX 5]dbYfQ 3_]RYfYb 5`jYS_] DbYjYfYb 1dbY`\Q DbefQTQ CdbYRY\T _b 3_]`\UbQ 5`YfYb Yc ^_d bUS_] ]U^TUT V_b ecU Y^ S_]RY^QdY_^ gYdX jQ\SYdQRY^U 9V i_e XQfU XU`QdYdYc 3 dXUbU Yc Q SXQ^SU _V cUfUbU \YfUb TUS_]`_cYdY_^ YV i_e QbU dQ[Y^W S_]RY^QdY_^ Q^dYbUdb_fYbQ\ dXUbQ`i Q^T Y^dUbVUb_^ Q\VQ TbeWc V_b XU` 3

=_cd cUbY_ec* ReY\Te` _V \QSdYS QSYT Y^ dXU R\__T cUfUbU \YfUb `b_R\U]c SXQ^WUc Y^ dXU Y]]e^U cicdU] SXQ^WUc Y^ R_Ti VQd ?dXUb* XUQTQSXU ^QecUQ ]Q\QYcU Q^T VQdYWeU ^QcQ\ `b_R\U]c TYQbbXUQ Q^T S_eWX

J U LY/A U G U S T 2 0 1 3

SIDE EFFECTS

HO=F?IMC>? L?P?LM? NL;HM=LCJN;M? CHBC<CNILM "HLNC# B?FJ JL?P?HN L?JFC=;NCIH I@ BCP MEDICATION 4R[R_VP ;NZR =Q[Ub

EPZICOM

NONPNcV_ `bYSNaR N[Q YNZVcbQV[R FYYF 8UQ\dXSQbU

RETROVIR

gVQ\cbQV[R \_ .GA

FYYF 8UQ\dXSQbU+ WU^UbYS fUbcY_^c Q\c_ QfQY\QR\U

TRIZIVIR

NONPNcV_ `bYSNaR YNZVcbQV[R N[Q gVQ\cbQV[R

TRADITIONAL DOSAGE

DRUG INTERACTIONS, PRECAUTIONS, & RECOMMENDATIONS

One tablet, containing 600 mg of abacavir sulfate and 300 mg of lamivudine (both NRTIs), once daily

4_ ^_d dQ[U YV i_e XQfU [YT^Ui `b_R\U]c _b QbU `b_^U d_ XUQbd TYcUQcU EcU gYdX SQedY_^ YV i_e Q\bUQTi dQ[U 1dbY`\Q 3_]RYfYb 5]dbYfQ 5`YfYb DbYjYfYb DbefQTQ JYQWU^ ]UdXQT_^U _b ]UTYSY^Uc ecUT d_ dbUQd XU`QdY dYc 9V i_e XQfU XU`QdYdYc 2 T_ ^_d be^ _ed _V 5`jYS_] _b cd_` dQ[Y^W Yd gYdX_ed dQ\[Y^W d_ i_eb XUQ\dX SQbU `b_ fYTUb I_eb `b_fYTUb cX_e\T ]_^Yd_b i_eb XUQ\dX Q^T T_ bUWe\Qb R\__T dUcdc d_ SXUS[ i_eb \YfUb YV i_e cd_` dQ[Y^W 5`jYS_] 4_ ^_d dQ[U YV i_e XQfU ]_TUbQdU d_ cUfUbU \YfUb `b_R\U]c

=_cd cUbY_ec* cUfUbU Q\\UbWYS bUQS dY_^c ReY\Te` _V QSYT Y^ dXU R\__T \YfUb `b_R\U]c ?dXUb* Y^c_]^YQ TU`bUccY_^ XUQTQSXU dYbUT^Ucc TYjjY^Ucc ^QecUQ TYQbbXUQ bQcX Q^T VUfUb

600 mg a day, taken in divided doses, in tablets, capsule, or syrup. Can also be given as an intravenous infusion, one mg per kilogram of body weight, over one hour, five or six times daily

4_ ^_d dQ[U gYdX _dXUb ]UTYSY^Uc dXQd S_^dQY^ dXU cQ]U QSdYfU Y^WbUTYU^dc Y^S\eTY^W 3_]RYfYb Q^T DbYjYfYb >_d bUS_]]U^TUT V_b ecU gYdX dXU Q^dYXU`QdYdYc TbeWc 3_`UWec BURUd_\ BYRQDQR _b BYRQc`XUbU EcU gYdX SQedY_^ YV dQ[Y^W WQ^SYS\_fYb _b Y^dUbVUb_^ Q\VQ 4_ ^_d ecU BUdb_fYb gYdX cdQfeTY^U _b T_h_beRYSY^ BUdb_fYb SQ^ Q\c_ RU ecUT d_ `bUfU^d dbQ^c]YccY_^ _V 89F Vb_] Q ]_dXUb d_ XUb e^R_b^ SXY\T

=_cd cUbY_ec* ^Uedb_`U^YQ Q^T Q^U]YQ \_g gXYdU Q^T bUT R\__T SU\\ S_e^dc ]i_`QdXi Q^T ]i_cYdYc ]ecS\U TYc_bTUbc Q^T Y^ÃQ]]Q dY_^ ReY\Te` _V \QSdYS QSYT Y^ dXU R\__T cUfUbU \YfUb `b_R\U]c SXQ^W Uc Y^ dXU Y]]e^U cicdU] SXQ^WUc Y^ R_Ti VQd ?dXUb* XUQTQSXU ]Q\QYcU ^QecUQ Q^_bUhYQ Q^T f_]YdY^W

One tablet (300 mg of abacavir sulfate, 150 mg of lamivudine, and 300 mg of zidovudine, all NRTIs), twice daily

4_ ^_d dQ[U YV i_e XQfU SUbdQY^ \YfUb `b_R\U]c _b gUYWX \Ucc dXQ^ ) `_e^Tc DQ[U gYdX SQedY_^ YV i_e XQfU Q `QbdYSe\Qb WU^U fQbYQdY_^ SQ\\UT 8<1 2 %' ! XU`QdYdYc 2 [YT^Ui _b XUQbd `b_R\U]c \_g R\__T SU\\ S_e^dc XYWX R\__T `bUccebU XYWX SX_\UcdUb_\ _b TYQRUdUc EcU gYdX SQedY_^ YV i_e dQ[U 2QSdbY] CU`dbQ 3id_fU^U 48@7 Y^dUbVUb_^ Q\VQ 1TbYQ]iSY^ 3_`UWic BURUd_\ FYbQ j_\U R_^U ]Qbb_g ce``bUccYfU ]UTYSY^Uc _b Sid_d_hYS ]UTYSY^Uc 1dbY`\Q 3_]RYfYb 3_]`\UbQ 5]dbYfQ 5`Y fYb _b 5`YfYb 82F 5`jYS_] BUdb_fYb DbefQTQ JUbYd _b JYQWU^

=_cd cUbY_ec* cUfUbU _b VQdQ\ Q\\Ub WYS bUQSdY_^c XUQbd QddQS[ ReY\Te` _V \QSdYS QSYT Y^ dXU R\__T \YfUb TYc_b TUbc R\__T `b_R\U]c ]ecS\U gUQ[ ^Ucc SXQ^WUc Y^ R_Ti VQd SXQ^WUc Y^ Y]]e^U cicdU] ?dXUb* ^QecUQ f_]YdY^W XUQTQSXU gUQ[^Ucc _b dYbUT^Ucc TYQbbXUQ VUfUb Q^T _b SXY\\c TU`bUccY_^ ]ecS\U Q^T Z_Y^d `QY^ c[Y^ bQcXUc S_\T ci]`d_]c ^Ubf_ec^Ucc Q^T UQb ^_cU Q^T dXb_Qd Y^VUSdY_^c

Depends on weight.

For individuals weighing 132 pounds or more, the recommended dose is 400 mg in enteric-coated capsules, once daily.

For adults weighing less than 132 pounds, the recommended dose is 250 mg, once daily. Take the drug on an empty stomach, and swallow the capsules whole; do not chew, break, crush, or dissolve. A powder form to be mixed with water is available for children

4_ ^_d dQ[U YV i_e dQ[U <_`ebY^ _b Ji\_`bY] gXYSX QbU ecUT d_ dbUQd W_ed Q^T [YT^Ui cd_^Uc _b dXU Q^dYXU`Q dYdYc TbeWc 3_`UWec BURUd_\ BYRQ DQR _b BYRQc`XUbU EcU gYdX SQedY_^ YV dQ[Y^W ]UdXQT_^U _b WQ^SYS\_fYb _b Q^i TbeWc dXQd ]Qi SQecU d_hYSYdi d_ dXU `Q^SbUQc _b ^Ubf_ec cicdU] 9V i_e QbU Q\c_ dQ[Y^W FYbUQT dXU T_cU _V FYTUh 53 cX_e\T RU bUTeSUT Q^T Yd cX_e\T RU dQ[U^ _^ Q^ U]`di cd_]QSX _b gYdX Q \YWXd ]UQ\

=_cd cUbY_ec* `Q^SbUQdYdYc ReY\Te` _V \QSdYS QSYT Y^ dXU R\__T \YfUb TYc _bTUbc fYcY_^ `b_R\U]c SXQ^WUc Y^ Y]]e^U cicdU] SXQ^WUc Y^ R_Ti VQd `UbY`XUbQ\ ^Ueb_`QdXi ?dXUb* TYQbbXUQ ^QecUQ f_]YdY^W XUQT QSXU cd_]QSX `QY^ c[Y^ bQcX

FYYF 8UQ\dXSQbU

VIDEX EC QVQN[\`V[R 2bYcd_\ =iUbc CaeYRR

SIDE EFFECTS

J U LY/A U G U S T 2 0 1 3 HIV plus

23

THE 2013 COMPLETE HIV TREATMENT GUIDE

HO=F?IMC>? L?P?LM? NL;HM=LCJN;M? CHBC<CNILM "HLNC# B?FJ JL?P?HN L?JFC=;NCIH I@ BCP MEDICATION 4R[R_VP ;NZR =Q[Ub

VIREAD

aR[\S\cV_ QV`\]_\eVY SbZN_NaR 7Y\UQT CSYU^SUc

ZERIT

`aNcbQV[R \_ Q!A

2bYcd_\ =iUbc CaeYRR

ZIAGEN

NONPNcV_

7\Qh_C]YdX;\Y^U

24

HIV plus

TRADITIONAL DOSAGE

DRUG INTERACTIONS, PRECAUTIONS, & RECOMMENDATIONS

One 300mg tablet, once daily.

Adults who are unable to swallow tablets whole may take 7 scoops of Viread oral powder.

Patients with kidney problems may be prescribed a lower dose

4_ ^_d dQ[U FYbUQT YV i_e QbU dQ[Y^W _dXUb ]UTYSY^Uc dXQd S_^dQY^ dU^_V_fYb 1dbY`\Q 3_]`\UbQ DbefQTQ _b CdbYRY\T _b QTUV_fYb 8U`cUbQ 4_cQWUc ]Qi ^UUT d_ RU SXQ^WUT YV i_e QbU dQ[Y^W FYTUh 53 BUiQdQj _b ;Q\UdbQ

For patients weighing 132 pounds or more, 40 mg, in capsules or oral solution, twice daily; for patients weighing less than 132 pounds, 30 mg twice daily

4_ ^_d dQ[U gYdX BUdb_fYb jYT_feTY^U _b Q^i jYT_feTY^U S_^dQY^Y^W `b_TeSdc ceSX Qc 3_]RYfYb _b DbYjYfYb 4_ ^_d dQ[U gYdX XiTb_hiebUQ gXYSX Yc ]Qb[UdUT e^TUb RbQ^T ^Q]Uc 4b_hYQ Q^T 8iTbUQ EcU gYdX SQedY_^ gYdX FYTUh 53 1TbYQ]iSY^ BeRUh 3_`UWec BURUd_\ BYRQc`XUbU FYbQj_\U B_VUb_^ 1 Q^T 9^db_^ 1 EcU gYdX SQedY_^ YV i_e XQfU \YfUb `Q^SbUQc _b [YT^Ui `b_R\U]c `UbY`XUbQ\ ^Ue b_`QdXi _b WQ\\cd_^Uc 6_b `QdYU^dc gYdX bU^Q\ Y]`QYb]U^d _b e^TUbW_Y^W XU]_TYQ\icYc T_cY^W QTZecd]U^dc ]Qi RU ^UUTUT 4_ ^_d TbY^[ Q\S_X_\ gXY\U _^ dXU TbeW

=_cd cUbY_ec* ReY\Te` _V Q^ QSYT Y^ dXU R\__T cUbY_ec \YfUb `b_R\U]c `Q^SbUQdYdYc SXQ^WUc Y^ R_Ti VQd SXQ^WUc Y^ Y]]e^U cicdU] `UbY`XUbQ\ ^Ueb_`QdXi ?dXUb* XUQTQSXU TYQbbXUQ bQcX ^QecUQ f_]YdY^W

600 mg in tablets daily, administered as either 300 mg twice daily or 600 mg once daily. Also available as an oral solution.

Patients with mild liver impairment should take 200 mg twice daily

4_ ^_d dQ[U YV i_e XQfU ]_TUbQdU d_ cUfUbU \YfUb Y]`QYb ]U^d 4_ ^_d RbUQcd VUUT gXY\U dQ[Y^W dXU TbeW 9V i_e XQfU Q cUfUbU Q\\UbWYS bUQSdY_^ T_ ^_d bUce]U dQ[Y^W JYQWU^ _b Q^i _dXUb QRQSQfYb S_^dQY^Y^W TbeW 5`jYS_] DbYjYfYb BYc[ _V Q\\UbWYS bUQSdY_^ Yc XYWXUb YV i_e XQfU Q WU^U fQbYQdY_^ SQ\\UT 8<1 2 %' !

=_cd cUbY_ec* cUfUbU Q\\UbWYS bUQSdY_^ ReY\Te` _V \QSdYS QSYT Y^ dXU R\__T gYdX \YfUb U^\QbWU]U^d SXQ^WUc Y^ R_Ti VQd SXQ^WUc Y^ Y]]e^U cicdU] Y^SbUQcUT bYc[ _V XUQbd QddQS[ Uc`USYQ\\i YV i_e XQfU _dXUb bYc[ VQSd_bc ceSX Qc c]_[Y^W XYcd_bi _V XUQbd db_eR\U TYQRUdUc XYWX R\__T `bUccebU _b XYWX SX_\UcdUb_\ ?dXUb* ^QecUQ f_]YdY^W dYbUT^Ucc XUQTQSXU TYQbbXUQ db_eR\U c\UU`Y^W VUfUb Q^T SXY\\c Q^T \_cc _V Q``UdYdU

Â&#x17E; J U LY/A U G U S T 2 0 1 3

FYbUQT Yc Q\c_ ecUT d_ dbUQd XU`QdYdYc 2

SIDE EFFECTS

=_cd cUbY_ec* ReY\Te` _V \QSdYS QSYT Y^ dXU R\__T cUfUbU \YfUb `b_R \U]c SXQ^WUc Y^ R_Ti VQd SXQ^WUc Y^ dXU Y]]e^U cicdU] R_^U `QY^ c_VdU^Y^W _b dXY^^Y^W ?dXUb* ^QecUQ bQcX TYQbbXUQ XUQTQSXU `QY^ TU`bUccY_^ gUQ[^Ucc

HIHHO=F?IMC>? L?P?LM? NL;HM=LCJN;M? CHBC<CNILM "HHLNC# B?FJ JL?P?HN L?JFC=;NCIH I@ BCP MEDICATION 4R[R_VP ;NZR =Q[Ub

EDURANT

_VY]VcV_V[R :Q^ccU^

INTELENCE Ra_NcV_V[R

:Q^ccU^

RESCRIPTOR

QRYNcV_QV[R

FYYF 8UQ\dXSQbU

SUSTIVA

RSNcV_R[g

2bYcd_\ =iUbc CaeYRR

VIRAMUNE [RcV_N]V[R

2_UXbY^WUb 9^WU\XUY]

TRADITIONAL DOSAGE

DRUG INTERACTIONS, PRECAUTIONS, & RECOMMENDATIONS

One 25-mg tablet, once daily, with a meal

>>BD9c QddQS[ dXU cQ]U U^ji]U >BD9c T_ Y^ Q TYçUbU^d gQi 4_ ^_d dQ[U 5TebQ^d gYdX Q^dYcUYjebU TbeWc \Y[U DUWbUd_\ DbY\U`dQ\ Q^T 4Y\Q^dY^+ Q^dYRQSdUbYQ\c =iS_RedY^ BYVQTY^ BY]QSdQ^U _b @bYVdY^+ `b_d_^ `e]` Y^XYRYd_bc ceSX Qc >UhYe] FY]_f_ @bUfQSYT @bY\_cUS @b_d_^Yh Q^T 1SY`XUh+ ]_bU dXQ^ _^U T_cU _V TUhQ]UdXQ c_^U+ _b CQY^d :_X^ºc g_bd EcU gYdX SQedY_^ gYdX Q^dYVe^WQ\c dQ[U^ _bQ\\i Q^dYRY_dYSc \Y[U 2YQhY^ Q^T UbidXb_]iSY^ Q^T ]UdXQT_^U DQ[U Q^dQSYTc _b 8" R\_S[Ubc Qd \UQcd !" X_ebc RUV_bU _b V_eb X_ebc QVdUb 5TebQ^d

=_cd cUbY_ec* TU`bUccY_^ _b ]__T SXQ^WUc Y^S\eTY^W ceY SYTQ\ dX_eWXdc+ SXQ^WUc Y^ R_Ti VQd+ SXQ^WUc Y^ Y]]e^U cicdU] ?dXUb* Y^c_]^YQ XUQTQSXU bQcX

200 mg (one 200-mg tablet or two 100-mg tablets), twice daily

4_ ^_d dQ[U gYdX dXU Q^dY 89F TbeWc 1SdYfec <UhYfQ BUiQdQj Ve\\ T_cU >_bfYb FYbQ]e^U CecdYfQ _b BUcSbY`d_b+ U`Y\U`ci Q^T cUYjebU ]UTYSY^Uc DUWbUd_\ 3QbRQdb_\ <e]Y^Q\ 4Y\Q^dY^ _b @XU^idU[+ XUbRQ\ `b_TeSdc S_^dQY^Y^W CQY^d :_X^ºc g_bd+ _b dXU Q^dYRQSdUbYQ\ TbeWc =iS_RedY^ BYVQTY^ BYVQdUb BYVQ]QdU _b @bYVdY^ 1\gQic dQ[U QVdUb Q ]UQ\ Q^T cgQ\\_g dXU `Y\\ gYdX Q Ve\\ W\Qcc _V gQdUb+ T_ ^_d SXUg

=_cd cUbY_ec* cUfUbU c[Y^ bQcX _b Q\\UbWYS bUQSdY_^ ?dXUb* SXQ^WUc Y^ R_Ti cXQ`U _b R_Ti VQd SXQ^WUc Y^ Y]]e^U cicdU] dY^W\Y^W _b `QY^ Y^ dXU XQ^Tc _b VUUd ^e]R^Ucc

400 mg (two or four tablets) three times daily

GXU^ dQ[Y^W BUcSbY`d_b T_ ^_d dQ[U FUbcUT 8Q\SY_^ HQ^Qh 4 8 5 $% 9^ZUSdY_^ 5bW_]Qb =YWbQ^Q\ GYWbQY^U 3QVUbW_d ?bQ` @b_`e\ cYT 8Yc]Q^Q\ CU\TQ^U bYVQ]`Y^ `XU^_RQbRYdQ\ 4Y\Q^dY^ DUWbUdb_\ CQY^d :_X^ºc g_bd =UfQS_b _b J_S_b DQ\[ d_ i_eb T_Sd_b RUV_bU dQ[ Y^W FYQWbQ <Y`Yd_b 2QiS_\ _b <UcS_\ 9V dQ[Y^W FYTUh _b Q^dQSYTc dQ[U Q^ X_eb RUV_bU _b Q^ X_eb QVdUb dQ[Y^W BUcSbY`d_b 4_cUc _V `b_dUQcU Y^XYRYd_bc 1WU^UbQcU 3bYhYfQ^ 9^fYbQcU 6_bd_fQcU ;Q\UdbQ >_bfYb Q^T FYbQSU`d ]Qi ^UUT d_ RU QTZecdUT DQ\[ gYdX i_eb T_Sd_b YV i_e XQfU \YfUb _b [YT^Ui TYcUQcU

=_cd cUbY_ec* cUfUbU c[Y^ bQcX QSS_]`Q^YUT Ri R\YcdUbc VUfUb Z_Y^d _b ]ecS\U `QY^ bUT^Ucc _b cgU\\Y^W _V dXU UiUc _b c_bUc Y^ dXU ]_edX ?dXUb* XUQTQSXU ^QecUQ TYQbbXUQ Q^T dYbUT^Ucc

600 mg (three capsules at once or one tablet), taken daily

4_ ^_d dQ[U 1dbY`\Q FQcS_b @b_`e\cYT FUbcUT ?bQ` 8Q\SY_^ _b UbW_d ]UTYSQdY_^c ceSX Qc GYWbQY^U Q^T 3QVUbW_d DXU V_\\_gY^W ]UTYSY^Uc ]Qi ^UUT d_ RU bU`\QSUT gYdX Q^_dXUb gXU^ i_e QbU dQ[Y^W CecdYfQ* 6_bd_fQcU 9^fYbQcU 2YQhY^ 3QbRQdb_\ DUWbUd_\ >_hQÂ\ C`_bQ^_h Q^T BUiQdQj YV dXYc Yc ^_d dXU Âbcd dY]U i_e XQfU RUU^ dbUQdUT V_b 89F DXU V_\\_gY^W TbeWc ]Qi bUaeYbU Q SXQ^WU Y^ dXU T_cU _V UYdXUb Cec dYfQ _b dXU _dXUb ]UTYSY^U* 3QbTYjU] DYQjQS 3_fUbQ 8C 9c_`dY^ CB <Y`Yd_b @bQfQSX_\ J_S_b 3bYhYfQ^ ;Q\UdbQ ]UdXQT_^U =iS_RedY^ BUiQdQj BYVQTY^ BYVQ]QdU BYVQdUb CU\jU^dbi FVU^T 7U^WbQV >U_bQ\ CQ^TY]]e^U @b_WbQV BQ`Q]e^U GU\\RedbY^ J_\_Vd Q^T JifQ^ 9V i_e QbU dQ[Y^W CecdYfQ Q^T BUiQdQj i_e cX_e\T Q\c_ RU dQ[Y^W >_bfYb DU\\ i_eb T_Sd_b YV i_e XQfU XQT XU`QdYdYc _b _dXUb \YfUb `b_R\U]c ]U^ dQ\ Y\\^Ucc _b cUYjebUc DQ[U CecdYfQ _^ Q^ U]`di cd_]QSX `bUVUbQR\i Qd RUTdY]U gYdX gQdUb

=_cd cUbY_ec* cUfUbU \YfUb `b_R\U]c bQcXUc Q^T c[Y^ bUQSdY_^c ?dXUb* SXQ^WUc Y^ dXU Y]]e^U cicdU] SXQ^WUc Y^ R_Ti VQd TYjjY^Ucc ^QecUQ XUQTQSXU Y^c_]^YQ dYbUT^Ucc

One 200-mg tablet daily for first 14 days, then one 200mg twice daily; also available in oral suspension

4_ ^_d dQ[U CQY^d :_X^ºc g_bd CecdYfQ 1dbY`\Q ;Q\UdbQ <UhYfQ BUiQdQj >Yj_bQ\ C`_bQ^_h BYVQTY^ BYVQ]QdU BYVQdUb _b RYbdX S_^ db_\ `Y\\c DU\\ T_Sd_b YV dQ[Y^W 2YQhY^ 4YÃeSQ^ 3bYhYfQ^ ]UdXQT_^U FYbQSU`d =iS_RedY^ 3_e]QTY^ :Q^d_fU^ _b 9^fYbQcU 4YcS_^dY^eU Y]]UTYQdU\i YV i_e TUfU\_` cYW^c _V XU`QdYdYc cUfUbU c[Y^ bUQSdY_^c _b bQcX gYdX cicdU]YS ci]`d_]c

=_cd cUbY_ec* cUfUbU `ciSXY QdbYS `b_R\U]c Y^S\eTY^W ceY SYTQ\ dX_eWXdc+ \YfUb TYc_bTUbc+ cUfUbU bQcX ?dXUb* TYjjY^Ucc ^QecUQ f_]YdY^W TYQbbXUQ bQcX c\UU` TYcdebRQ^SUc Tb_gcY^Ucc db_eR\U S_^SU^ dbQdY^W _b e^eceQ\ TbUQ]c

SIDE EFFECTS

J U LY/A U G U S T 2 0 1 3 HIV plus

25

=IG<CH;NCIH >LOAM B?FJ JL?P?HN L?JFC=;NCIH I@ BCP MEDICATION 4R[R_VP ;NZR =Q[Ub

STRIBILD RYcVaRT_NcV_ P\OVPV`aNa RZa_VPVaNOV[R aR[\S\cV_ QV`\]_\eVY SbZN_NaR 7Y\UQT CSYU^SUc

ATRIPLA RSNcV_R[g RZa_VPVaNOV[R N[Q aR[\S\cV_ QV`\]_\eVY SbZN_NaR 2bYcd_\ =iUbc CaeYRR 7Y\UQT CSYU^SUc

COMPLERA RZa_VPVaNOV[R _VY]VcV_V[R N[Q aR[\S\cV_ QV`\]_\eVY SbZN_NaR 7Y\UQT CSYU^SUc

TRADITIONAL DOSAGE

DRUG INTERACTIONS, PRECAUTIONS, & RECOMMENDATIONS

One tablet, once daily, with a meal (150 mg of elvitegravir, 150 mg of cobicistat, 200 mg of emtricitabine, and 300 mg of tenofovir disoproxil fumarate)

CdbYRY\T Yc ^_d Q``b_fUT V_b dbUQd]U^d _V `QdYU^dc gX_ XQfU XU`QdYdYc 2 Qc CdbYRY\T SQ^ UhQSUbRQdU dXU TYcUQcU Q^T SQecU ÃQbU e`c CdbYRY\T cX_e\T ^_d RU ecUT V_b `QdYU^dc gYdX Q^ UcdY]QdUT SbUQdY^Y^U S\UQbQ^SU RU\_g ' ]< `Ub ]Y^edU 4_ ^_d ecU gYdX _dXUb Q^dY 89F TbeWc S_^dQY^Y^W U]dbYSYdQRY^U _b dU^_V_fYb TYc_`b_hY\ Ve]QbQdU Y^S\eTY^W 1dbY`\Q 3_]`\UbQ 5]dbYfQ DbefQTQ _b FYbUQT+ T_ ^_d ecU gYdX TbeWc S_^dQY^Y^W \Q]YfeTY^U _b gYdX TbeWc _b bUWY]U^c S_^dQY^Y^W bYd_^QfYb ceSX Qc 3_]RYfYb 5`YfYb 5`YfYb 82F 5`jYS_] _b DbYjYfYb 4_ ^_d QT]Y^YcdUb Y^ S_]RY^QdY_^ gYdX 8U`cUbQ 4_ ^_d ecU gYdX cY\TU^QÂ\ gXU^ RbQ^TUT Qc BUfQdY_ dX_eWX cY\TU^QÂ\ gXU^ T_cUT Qc FYQWbQ ]Qi RU cQVU c_ S_^ce\d i_eb T_Sd_b 4_ ^_d ecU gYdX Q\Vej_cY^ bYVQ]`Y^ SYcQ`bYTU `Y]_jYTU _b dXU XUbRQ\ bU]UTi CQY^d :_X^ºc g_bd 4_ ^_d dQ[U CdbYRY\T gYdX UbW_d TUbYfQdYfUc ceSX Qc TYXiTb_UbW_dQ]Y^U UbW_dQ]Y^U _b ]UdXi\UbW_^_fY^U 8=7 3_1 BUTeSdQcU Y^XYRYd_bc ceSX Qc \_fQcdQdY^ Q^T cY]fQcdQdY^ _b gYdX cUTQdYfU Xi`^_dYSc

=_cd cUbY_ec* ReY\Te` _V \QSdYS QSYT Y^ dXU R\__T+ cUfUbU \YfUb _b [YT^Ui `b_R\U]c gXYSX S_e\T \UQT d_ `_dU^dYQ\\i VQdQ\ bU^Q\ VQY\ebU+ dXY^^Y^W R_^Uc Q^T SXQ^WUc Y^ dXU Y]]e^U cicdU] ?dXUb* ^QecUQ Q^T TYQbbXUQ

One tablet, once daily, on an empty stomach, preferably at bedtime (containing 600 mg of efavirenz, 200 mg of emtricitabine, and 300 mg of tenofovir disoproxil fumarate). If you are also taking Rifadin, add 200 mg of efavirenz

5VQfYbU^j Yc Q ^_^^eS\U_cYTU bUfUbcU dbQ^cSbY`dQcU Y^XYRY d_b >>BD9 dXU _dXUb S_]`_^U^dc QbU ^eS\U_cYTU bUfUbcU dbQ^cSbY`dQcU Y^XYRYd_bc >BD9c + dXU TYçUbU^d di`Uc _V TbeWc QddQS[ 89F Qd TYçUbU^d cdQWUc Y^ Ydc bU`\YSQdY_^ `b_SUcc 4_ ^_d dQ[U 1dbY`\Q gYdX Q^dY 89F TbeWc 3_]RYfYb 3_]`\UbQ 5]dbYfQ 5`YfYb _b 5`YfYb 82F 5`jYS_] DbYjYfYb DbefQTQ FYbUQT _b CdbYRY\T gXYSX XQfU dXU cQ]U _b cY]Y\Qb QSdYfU Y^WbUTYU^dc DQ[U gYdX CecdYfQ _^\i YV i_eb T_Sd_b bUS_] ]U^Tc 9V i_e QbU dQ[Y^W ;Q\UdbQ T_cQWU _V dXQd TbeW ]Qi ^UUT d_ RU QTZecdUT 4_ ^_d dQ[U gYdX FYSdbU\Yc FQcS_b @b_`e\cYT FUbcUT ?bQ` 8Q\SY_^ UbW_d ]UTYSQdY_^c ceSX Qc GYWbQY^U Q^T 3QVUbW_d FVU^T 8U`cUbQ _b dXU XUbRQ\ bU]UTi CQY^d :_X^ºc g_bd EcU gYdX SQedY_^ gYdX 6_bd_fQcU 9^fYbQcU FYTUh BUiQdQj 3bYhYfQ^ CU\jU^dbi 2YQhY^ >_hQÂ\ C`_bQ^_h SQ\SY e] SXQ^^U\ R\_S[Ubc ceSX Qc TY\dYQjU] Q^T fUbQ`Q]Y\ gXYSX XQfU fQbY_ec RbQ^T ^Q]Uc Y]]e^_ce``bUccQ^d TbeWc ceSX Qc SiS\_c`_bY^U dQSb_\Y]ec Q^T cYb_\Y]ec c_\T e^TUb fQbY_ec RbQ^T ^Q]Uc ]UdXQT_^U =iS_RedY^ BYVQTY^ BY]QSdQ^U <Y`Yd_b @bQfQSX_\ J_S_b J_\_Vd _b cUYjebU ]UTc ceSX Qc `XU^id_Y^ SQbRQ]QjU`Y^U Q^T `XU^_RQbRYdQ\ 9V i_e XQfU XU`QdYdYc 2 Q^T cd_` dQ[Y^W 1dbY`\Q i_e ]Qi Uh`UbYU^SU Q ÃQbU e` _V dXU TYcUQcU 4_ ^_d dQ[U YV i_e XQfU cUfUbU [YT^Ui Y]`QYb]U^d

=_cd cUbY_ec* ReY\Te` _V \QSdYS QSYT Y^ dXU R\__T cUfUbU \YfUb _b [YT^Ui `b_R\U]c cUbY_ec `ciSXY QdbYS `b_R\U]c dXY^^Y^W R_^Uc Q fYdQ]Y^ 4 ce``\U]U^d ]Qi RU Y^TYSQdUT V_b dXU \QddUb ?dXUb* TYjjY^Ucc XUQTQSXU Y^c_]^YQ Tb_gcY^Ucc db_eR\U S_^SU^dbQd Y^W e^eceQ\ TbUQ]c VQdYWeU e`cUd cd_]QSX ^QecUQ f_]Yd Y^W WQc TYQbbXUQ

One tablet, once daily, with a meal (200 mg of emtricitabine, 25 mg of rilpivirine, and 300 mg of tenofovir disoproxil fumarate)

BY\`YfYbY^U Yc Q^ >>BD9 dXU _dXUb S_]`_^U^dc >BD9c 3_] `\UbQ Yc _^\i V_b `QdYU^dc gX_ XQfU ^_d `bUfY_ec\i dQ[U^ Q^dY bUdb_fYbQ\ TbeWc Q^T XQfU Q fYbQ\ \_QT _V !

S_`YUc `Ub ]Y\\Y\YdUb _V R\__T _b \Ucc 4_ ^_d dQ[U gYdX ]UTYSY^Uc dXQd S_^dQY^ \Q]YfeTY^U 5`YfYb 5`YfYb 82F 5`jYS_] 3_]RYfYb Q^T DbYjYfYb _dXUb 89F Q^dYbUdb_fYbQ\ ]UTYSQdY_^c TbeWc d_ dbUQd cUYjebUc _b deRUbSe\_cYc `b_d_^ `e]` Y^XYRYd_bc ceSX Qc ;Q`YTUh _b 4UhY\Q^d 8Uc`UbQ CQY^d :_X^ºc g_bd _b ]_bU dXQ^ _^U T_cU _V TUhQ]UdXQc_^U EcU SQedY_^ gXU^ dQ[Y^W Q^dQSYTc Q^dYVe^WQ\ ]UTYSQdY_^c 8" bUSU`d_b Q^dQW_^Ycdc Q^dYRY_dYSc _b ]UdXQT_^U

=_cd cUbY_ec* ReY\Te` _V \QSdYS QSYT Y^ dXU R\__T cUfUbU \YfUb `b_R\U]c XU`QdYdYc 2 fYbec Y^VUS dY_^ ÃQbU e`c TU`bUccY_^ R_^U dXY^^Y^W Q^T SXQ^WUc Y^ dXU Y]]e^U cicdU] ?dXUb* Y^c_] ^YQ XUQTQSXU bQcXUc TYQb bXUQ ^QecUQ VQdYWeU TYjjY^Ucc TU`bUccY_^ QR^_b]Q\ TbUQ]c f_]YdY^W cd_]QSX _b _dXUb `QY^ Q^T c[Y^ TYcS_\_bQdY_^

SIDE EFFECTS

J U LY/A U G U S T 2 0 1 3 HIV plus

31

IJJILNOHCMNC= CH@?=NCIHM ;H> INB?L >LOAM MEDICATION TRADITIONAL DOSAGE

EGRIFTA

" ]W Y^ZUSdUT ceRSedQ^U_ec\i Zecd RU\_g dXU c[Y^ _^SU TQY\i

8U\`c bUTeSU 89F bU\QdUT UhSUcc RU\\i VQd Ri U^S_ebQWY^W dXU R_Ti d_ `b_TeSU ^QdebQ\ Wb_gdX X_b ]_^Uc dXQd bUTeSU VQd

4_ ^_d dQ[U YV i_e XQfU _b XQT YcceUc Y^f_\fY^W i_eb `YdeYdQbi W\Q^T YV i_e XQfU QSdYfU SQ^SUb _b YV i_e QbU `bUW^Q^d _b RbUQcd VUUTY^W

=_cd cUbY_ec* cUfUbU Q\\UbWYS bUQS dY_^ _b ÃeYT bUdU^dY_^ Y^ZUSdY_^ cYdU bUQSdY_^c _b Y^SbUQcU Y^ W\eS_cU Y^d_\UbQ^SU TYQRUdUc ?dXUb* @QY^ cgU\\Y^W ]ecS\U c_bU^Ucc dY^W\Y^W ^e]R^Ucc Q^T `bYS[Y^W ^QecUQ f_]YdY^W bQcX YdSXY^W

$ ]W dg_ _b V_eb dQR\Udc dXbUU dY]Uc TQY\i

DbUQdc Q^T XU\`c `bUfU^d bUSebbU^SU _V @^Ue]_SicdYc `^Ue]_^YQ Y^ 89F `_cYdYfU `QdYU^dc+ Q\c_ ecUT _^ _dXUb RQSdUbYQ\ Y^VUSdY_^c

DQ[U Qd dXU cQ]U dY]U UfUbi TQi Dbi ^_d d_ ]Ycc Q T_cU

=_cd cUbY_ec* c[Y^ bQcX Z_Y^d _b ]ecS\U QSXUc c_bU dXb_Qd _b VUfUb e^eceQ\ R\UUTY^W _b RbeYcY^W ?dXUb* TYjjY^Ucc ^QecUQ f_]YdY^W TYQbbXUQ \_cc _V Q``UdYdU VQdYWeU XUQTQSXU

?^U & ]W dQR\Ud UfUbi '" X_ebc _b " ]W _V _bQ\ c_\e dY_^ _^SU TQY\i

DbUQdc XU`QdYdYc 2

4_ ^_d dQ[U @UWQcic 9V ecY^W _bQ\ c_\edY_^ S\_cU R_dd\U Q^T S\UQ^ T_cY^W Se` Y]]UTYQdU\i QVdUb T_cY^W [UU` Se` Tbi RUdgUU^ ecUc Q^T T_ ^_d ecU V_b Q^idXY^W U\cU

=_cd cUbY_ec* ReY\Te` _V \QSdYS QSYT Y^ R_Ti cUfUbU \YfUb `b_R\U]c ]ecS\U `QY^ _b gUQ[^Ucc ^UbfU `b_R\U]c ÃQbU e` _V XU`QdYdYc 2 QVdUb TYcS_^ dY^eQdY_^ ?dXUb* TYQbbXUQ QRT_]Y ^Q\ `QY^ _b cgU\\Y^W S_eWX XUQTQSXU TYjjY^Ucc c_bU dXb_Qd VUfUb

Dg_ $% ]W dQR \Udc dgYSU TQY\i V_b "! TQic dXU^ dg_ dQR\Udc _^SU TQY\i

DbUQdc dXU UiU Y^VUS dY_^ Sid_]UWQ\_fY bec bUdY^YdYc

EcU gYdX SQedY_^ YV Q\c_ dQ[Y^W BUdb_fYb 2U^U]YT 3U\\3U`d =iV_bdYS _b FYTUh CY^SU FQ\ SidU SQ^ SQecU cUYjebUc T_ ^_d TbYfU e^dY\ i_e [^_g X_g dXU ]UTYSQdY_^ QçUSdc i_e

=_cd cUbY_ec* Q^U]YQ VUbdY\Ydi Y]`QYb]U^d VUdQ\ QR^_b]Q\YdYUc [YT ^Ui VQY\ebU ?dXUb* TYQbbXUQ f_]Yd Y^W VUfUb dbU]_bc Q^T cUYjebUc

! e^Ydc `Ub [Y\_WbQ] _V R_Ti gUYWXd dXbUU dY]Uc Q gUU[ WYfU^ Y^dbQfU^_ec\i

DbUQdc Q^U]YQ dXQd bUce\dc Qc Q cYTU UçUSd _V BUdb_fYb

4_ ^_d dQ[U YV i_e XQfU e^S_^ db_\\UT XYWX R\__T `bUccebU 9b_^ ce``\U]U^dc ]Qi RU ^UUT UT V_b `QdYU^dc gX_ e^TUbW_ R\__T dbQ^cVecY_^c DQ\[ d_ i_eb T_Sd_b YV i_e XQfU SQ^SUb

=_cd cUbY_ec* XYWX R\__T `bUccebU cUYjebUc TUfU\_`]U^d _V Q^dYR_T YUc QWQY^cd dXU TbeW cUfUbU Q\\UbWYS bUQSdY_^c ?dXUb* Z_Y^d ]ecS\U _b R_^U `QY^ VUfUb S_eWX bQcX ^QecUQ f_]YdY^W c_bU^Ucc _V ]_edX YdSXY^W XUQTQSXU `QY^ Qd Y^ZUSdY_^ cYdU

&"% ]W _^U dUQc`__^ _^SU TQY\i

DbUQdc Q``UdYdU \_cc cUfUbU ]Q\^edbYdY_^ _b e^Uh`\QY^UT cYW ^YÂSQ^d gUYWXd \_cc

=Qi TUSbUQcU UçUSdYfU^Ucc _V 3bYhYfQ^ 9V i_e XQfU Q XYcd_bi _V R\__T S\_dc SXUS[ gYdX i_eb T_Sd_b RUV_bU dQ[Y^W

=_cd cUbY_ec* 3ecXY^Wºc ci^Tb_]U TUfU\_`]U^d _b g_bcU^Y^W _V TYQRUdUc ?dXUb* TUSbUQcUT cUheQ\ TUcYbU _b `Ub V_b]Q^SU ÃQde\U^SU bQcX XYWX R\__T `bUccebU Y^c_]^YQ e`cUd cd_]QSX Y^SbUQcUT R\__T ceWQb RUdgUU^ `UbY _T R\UUTY^W

! ]W `Ub [Y\_ WbQ] _V R_Ti gUYWXd TQY\i e` d_ & ]W Y^ZUSdUT ceRSedQ^U_ec\i Qd RUTdY]U

DbUQdc gQcdY^W 89F bU\QdUT gUYWXd \_cc

4_ ^_d ecU YV i_e XQfU QSedU SbYdYSQ\ Y\\^Ucc V_\\_gY^W _`U^ XUQbd _b QRT_]Y^Q\ cebWUbi ]e\dY`\U QSSYTU^dQ\ dbQe]Q _b QSedU bUc`YbQd_bi VQY\ebU 4_ ^_d ecU YV i_e XQfU ^U_`\QcYQ

=_cd cUbY_ec* 7\eS_cU Y^d_\UbQ^SU gXYSX ]Qi bUaeYbU QTZecd]U^d _V TYQRUdUc ]UTYSQdY_^c V_b `QdYU^dc gYdX dXYc TYc_bTUb+ ]ecSe\_c[U\UdQ\ TYcS_]V_bd+ SQb`Q\ de^^U\ ci^Tb_]U+ cgU\\Y^W _V dXU XQ^Tc Q^T VUUd

(

DbUQdc cUfUbU ]Q\ ^edbYdY_^ Q``UdYdU \_cc _b cYW^YÂSQ^d gUYWXd \_cc

>_ cYW^YÂSQ^d Y^dUbQSdY_^c TYcS_fUbUT d_ TQdU 9V i_e XQfU Q XYcd_bi _V R\__T S\_dc SXUS[ gYdX i_eb T_Sd_b RUV_bU dQ[Y^W

=_cd cUbY_ec* 3ecXY^Wºc ci^ Tb_]U TYQRUdUc ?dXUb* TUSbUQcUT \YRYT_ V\Qde\U^SU XYWX R\__T `bUc cebU Y^c_]^YQ e`cUd cd_]QSX Y^SbUQcUT R\__T ceWQb RUdgUU^ `UbY_T R\UUTY^W

dUcQ]_bU\Y^ 5=4 CUb_^_

BACTRIM, SEPTRA, SULFATRIM ce\VQ]UdX_hQj_\U dbY]UdX_`bY] FQbY_ec cUU 89F@\ec]QW S_]

TYZEKA dU\RYfeTY^U 9TU^Yh >_fQbdYc

VALCYTE

fQ\WQ^SYS\_fYb 7U^U^dUSX

EPOGEN, PROCRIT U`_UdY^ Q\VQ 1]WU^ 5`_WU^ + :Q^ccU^ @b_SbYd

MEGACE ES

]UWUcdb_\ QSUdQdU CdbQdYfQ

SEROSTIM c_]Qdb_`Y^

5=4 CUb_^_

MEGACE ORAL SUSPENSION

]W _^SU TQY\i

]UWUcdb_\ QSUdQdU 2bYcd_\ =iUbc CaeYRR

32

DRUG INTERACTIONS, PRECAUTIONS, & RECOMMENDATIONS

4R[R_VP ;NZR =Q[Ub

HIV plus

J U LY/A U G U S T 2 0 1 3

WHAT IT DOES

SIDE EFFECTS

MEDICATION

TAXOL `QS\YdQhU\ 2bYcd_\ =iUbc CaeYRR ^Q]U RbQ^T + DUfQ @QbU^dUbQ\ =UTYSY^Uc WU^UbYS

PEGINTRON `UWY^dUbVUb_^ Q\VQ "R

DOSAGE

WHAT IT DOES

`UWY^dUbVUb_^ Q\VQ "Q

@b_fYTUc cUS_^T \Y^U dbUQd]U^d V_b ;Q`_cYºc cQbS_]Q

EcU SQedY_^ gXU^ dQ[Y^W gYdX FUbcUT 2ec`Qb FQ^cQb @\U^TY\ 1\d_S_b 1\d_`bUf =UfQS_b J_S_b BU\`Qh BUfQ dY_ FYQWbQ 8Q\SY_^ BUiQdQj 2YQhY^ 3bYhYfQ^ C`_bQ^_h 6U_bYc >Yj_bQ\ CUbj_^U FYbQSU`d >_bfYb Q^T cUfUbQ\ _dXUb TbeWc CUU 89F@\ec =QW S_] V_b _dXUbc

=_cd cUbY_ec* R_^U ]Qbb_g TYc_b TUbc ?dXUb* dYbUT^Ucc gUQ[^Ucc cX_bd^Ucc _V RbUQdX ^QecUQ f_]Yd Y^W TYQbbXUQ e^eceQ\ R\UUTY^W _b RbeYcY^W Z_Y^d `QY^ _b ^e]R^Ucc XQYb \_cc

! % ]YSb_WbQ]c `Ub [Y\_WbQ] _V R_Ti gUYWXd _^SU gUU[\i Ri ceRSedQ^U_ec Y^ZUSdY_^

DbUQdc SXb_^YS XU`Q dYdYc 3 Q\_^U _b Y^ S_]RY^QdY_^ gYdX _dXUb TbeWc

EcU gYdX SQedY_^ gYdX TbeWc ]UdQR_\YjUT Ri 3I@"3( ) _b 3I@"4& =_^Yd_b V_b d_hYSYdYUc gXU^ ecUT gYdX >BD9c 4_ ^_d dQ[U YV i_e XQfU Qed_Y]]e^U XU`QdYdYc _b SUbdQY^ _dXUb \YfUb `b_R\U]c

=_cd cUbY_ec* cUfUbU UiU R\__T \YfUb ^UbfU dXib_YT _b \e^W `b_R \U]c `Q^SbUQdYdYc S_\YdYc XYWX R\__T ceWQb _b TYQRUdUc Q\\UbWYS bUQSdY_^ ?dXUb* Ãe \Y[U ci]`d_]c dYbUT^Ucc Q``UdYdU `b_R\U]c c[Y^ bUQSdY_^c XQYb dXY^^Y^W

!( ]YSb_WbQ]c _^SU gUU[\i Ri ceRSedQ^U _ec Y^ZUSdY_^

DbUQdc SXb_^YS XU`Q dYdYc 3 _b 2 Q\_^U _b Y^ S_]RY^QdY_^ gYdX _dXUb TbeWc

4_ ^_d dQ[U YV i_e XQfU Qed_ Y]]e^U XU`QdYdYc _b \YfUb `b_R \U]c 4_ ^_d dQ[U gYdX 3_`UWec YV i_e QbU `bUW^Q^d YV i_e _b i_eb `Qbd^Ub `\Q^ d_ RUS_]U `bUW^Q^d _b YV i_e dQ[U FYTUh EcU gYdX SQedY_^ YV dQ[Y^W DijU[Q DXU_ "$ 5\Yh_`Xi\\Y^ E^Y`Xi\ DXU_\QYb ]UdXQT_^U 1jQcQ^ _b 9]ebQ^

=_cd cUbY_ec* cUfUbU UiU R\__T \YfUb ^UbfU dXib_YT _b \e^W `b_R\U]c `Q^ SbUQdYdYc S_\YdYc XYWX R\__T ceWQb _b TYQRUdUc Q\\UbWYS bUQSdY_^ ?dXUb* Ãe \Y[U ci]`d_]c dYbUT^Ucc Q^T gUQ[ ^Ucc cd_]QSX `b_R\U]c \_cc _V Q``U dYdU c[Y^ bUQSdY_^c XQYb dXY^^Y^W db_eR\U c\UU`Y^W

% _b ! ]W _^SU TQY\i Y^ dQR\Ud V_b] _b _bQ\ c_\edY_^ CX_e\T RU dQ[U^ gYdX _ed V__T _^ Q^ U]`di cd_]QSX Qd \UQcd dg_ X_ebc QVdUb Q ]UQ\ Q^T dg_ X_ebc RUV_bU dXU ^Uhd ]UQ\

DbUQdc SXb_^YS XU`Q dYdYc 2 =Qi Q\c_ XU\` Y^XYRYd 89F bU`\YSQ dY_^ Q\dX_eWX dXYc ecU XQc ^_d RUU^ cdeTYUT

@U_`\U gYdX 89F cX_e\T RU bUSUYfY^W Q^dYbUdb_fYbQ\ dbUQd ]U^d V_b dXQd Qc gU\\ Qc bUcYc dQ^SU d_ Q^dY 89F TbeWc ]Qi TUfU\_` _dXUbgYcU =Qi QçUSd S_^SU^dbQdY_^ _V TbeWc dXQd bUTeSU [YT^Ui Ve^SdY_^ _b fYSU fUbcQ DX_cU gYdX TUSbUQcUT [YT^Ui Ve^SdY_^ ]Qi ^UUT d_ bUTeSU T_cQWU

=_cd cUbY_ec* g_bcU^Y^W _V XU`QdYdYc 2 QVdUb TYcS_^dY^eQdY_^ _V dbUQd]U^d _dXUb \YfUb `b_R\U]c ReY\Te` _V \QSdYS QSYT Y^ dXU R\__T ?dXUb* XUQTQSXU VQdYWeU TYjjY^Ucc ^QecUQ

# ]W UfUbi V_eb gUU[c fYQ _bQ\ Y^XQ \QdY_^

8U\`c `bUfU^d @^Ue]_SicdYc `^Ue ]_^YQ Y^ `QdYU^dc gYdX Q XYcd_bi _V dXU TYcUQcU _b \_g D SU\\ S_e^dc

EcU gYdX SQedY_^ gYdX Q]Y^_ W\iS_cYTUc Q S\Qcc _V Q^dYRY_d YSc Q]`X_dUbYSY^ 2 Q^ Q^dY Ve^WQ\ TbeW ]Qb[UdUT e^TUb fQbY_ec RbQ^T ^Q]Uc @\QdY ^_\ 6_cSQfYb _b FQ^S_SY^ 9V RbUQcd VUUTY^W dQ[U _^\i YV T_Sd_b TUdUb]Y^Uc RU^UVYdc _edgUYWX bYc[c

=_cd cUbY_ec* QSedU `Q^SbUQdYdYc ?dXUb* ^YWXd cgUQdc Q^U]YQ Rb_^ SXYdYc ^_^c`USYÂS XUb`Uc XUb`Uc j_cdUb ^_^c`USYÂS Y^ÃeU^jQ _bQ\ 3Q^TYTQ `XQbi^WYdYc cY^ecYdYc XUQT QSXU SXUcd `QY^ S_eWX gXUUjY^W

# ]Y\\Y_^ Y^dUb^Q dY_^Q\ e^Ydc `Ub caeQbU ]UdUb _V R_Ti cebVQSU ceRSedQ^U_ec\i _b Y^dbQ]ecSe\Qb\i dXbUU dY]Uc Q gUU[ V_b ;Q`_ cYºc cQbS_]Q+ # ]Y\\Y_^ 9Ec dXbUU dY]Uc Q gUU[ V_b SXb_^YS XU`QdYdYc 3

DbUQdc 194C bU\QdUT ;Q`_cYºc cQbS_]Q Q^T XU`QdYdYc Y^VUS dY_^ Uc`USYQ\\i XU`QdYdYc 3

EcU SQedY_^ YV dQ[U^ gYdX BUd b_fYb dXU_`Xi\\Y^U _b DijU[Q 4_ ^_d dQ[U YV i_e XQfU Qed_Y] ]e^U XU`QdYdYc TUS_]`U^cQdUT \YfUb TYcUQcU dXQ\QccU]YQ ]QZ_b cYS[\U SU\\ Q^U]YQ _b `b_R\U]c gYdX SbUQdY^Y^U S\UQbQ^SU EcU gYdX SQedY_^ YV i_e XQfU XYcd_bi _V SQbTY_fQcSe\Qb _b SUbURb_ fQcSe\Qb TYcUQcUc

=_cd cUbY_ec* TU`bUccY_^ ceYSYTQ\ dX_eWXdc cUfUbU Ãe \Y[U ci]`d_]c ?dXUb* TYèSe\di c\UU`Y^W ^Ubf_ec ^Ucc ]ecS\U `QY^ _b ^e]R^Ucc R\__T Y^ ebY^U _b cd__\c `QY^Ve\ _b TYèSe\d ebY^QdY_^ SXUcd `QY^ VUfUb SXY\\c e^eceQ\ R\UUTY^W _b RbeYcY^W

# ]Y\\Y_^ 9Ec `Ub caeQbU ]UdUb _V R_Ti cebVQSU ceRSedQ^U _ec\i _b Y^dbQ]ec Se\Qb\i dXbUU dY]Uc Q gUU[

DbUQdc SXb_^YS XU`Q dYdYc 3

EcU SQedY_^ YV dQ[U^ gYdX BUdb_ fYb Q^T cY]Y\Qb Q^dY 89F TbeWc+ dXU_`Xi\\Y^U ]Qb[UdUT e^TUb fQbY_ec ^Q]Uc d_ dbUQd RbUQdX Y^W `b_R\U]c+ _b DijU[Q

=_cd cUbY_ec* TU`bUccY_^ ceYSYTQ\ RUXQfY_b `QY^ RbUQdXY^W Q^T fYcY_^ `b_R\U]c VUfUb R\UUTY^W _b RbeYcY^W ?dXUb* Ãe \Y[U ci]`d_]c c\UU` TYc debRQ^SUc XUQTQSXU dXib_YT `b_R \U]c VQdYWeU

8U\`c `bUfU^d Q^T dbUQd ]Y\T d_ ]_TUb QdU @^Ue]_SicdYc `^Ue]_^YQ Y^ `QdYU^dc gX_ SQ^^_d d_\UbQdU _dXUb TbeWc

9V Q\c_ dQ[Y^W bYVQ]`Y^ S_^cYTUb Q\dUb^QdYfUc Qc Yd ]Qi bUTeSU dXU Q]_e^d _V =U`b_^ Y^ dXU R_Ti

=_cd cUbY_ec* bQcX TYQbbXUQ ^QecUQ

7U^U^dUSX

BARACLUDE U^dUSQfYb 2bYcd_\ =iUbc CaeYRR

NEBUPENT `U^dQ]YTY^U YcUdXY_^QdU 1@@ @XQb]QSUedYSQ\c

INTRON A Y^dUbVUb_^ Q\VQ "R CSXUbY^W

ROFERON-A Y^dUbVUb_^ Q\VQ " B_SXU

MEPRON Qd_fQae_^U 7\Qh_C]YdX;\Y^U

SIDE EFFECTS

!#% ]W `Ub caeQbU ]UdUb _V R_Ti ceb VQSU Y^dbQfU^_ec\i _fUb dXbUU X_ebc UfUbi dXbUU gUU[c _b ! ]W `Ub caeQbU ]UdUb _V R_Ti ceb VQSU Y^dbQfU^_ec\i _fUb dXbUU X_ebc UfUbi dg_ gUU[c

=UbS[

PEGASYS

WHAT TO KNOW

6_b `bUfU^dY_^ ! % ]W _V _bQ\ c_\edY_^ _^SU TQY\i gYdX Q ]UQ\+ V_b dbUQd]U^d '% ]W _V c_\edY_^ dgYSU TQY\i gYdX ]UQ\c

J U LY/A U G U S T 2 0 1 3 HIV plus

33

MEDICATION

DOSAGE

WHAT IT DOES

WHAT TO KNOW

SIDE EFFECTS

% ]W `Ub [W _V R_Ti gUYWXd TQY\i V_b ) ]_^dXc V_b \QdU^d D2 _b dg_ gUU[c dXU^ !% ]W [W dgYSU gUU[\i V_b !( gUU[c V_b QSdYfU D2 Y^ S_]RY^QdY_^ gYdX BYVQTY^ BY]QSdQ^U `ibQjY^Q]YTU _b =iQ]Red_\

DbUQdc deRUbSe\_cYc

EcU gYdX SQedY_^ YV dQ[Y^W QSUd Q]Y^_`XU^ Q^dQSYTc DUWbUd_\ 1^dQRecU >Yj_bQ\ 4Y\Q^dY^ DXU_RYT DXU_ 4eb 4U`Q[U^U 4U`Q[_dU Q^T fYdQ]Y^c 1f_YT Q\S_X_\YS RUfUbQWUc DU\\ i_eb T_Sd_b YV i_e XQfU _b XQfU UfUb XQT \YfUb TYcUQcU _b Q XYcd_bi _V Q\S_X_\Yc] _b Y^ZUSdY_^ TbeW ecU

=_cd cUbY_ec* cUfUbU VQdQ\ \YfUb TQ]QWU UiU `QY^ ^e]R^Ucc _b dY^W\Y^W Y^ UhdbU]YdYUc bQcX VUfUb cg_\\U^ W\Q^Tc c_bU dXb_Qd R\UUTY^W _b RbeYcY^W cd_]QSX `QY^c ?dXUb* TYQbbXUQ fYcY_^ `b_R\U]c

DbUQdc Ve^WQ\ Y^VUS dY_^c ceSX Qc _bQ\ SQ^TYTYQcYc Q\c_ [^_g^ Qc dXbecX

4_ ^_d dQ[U YV dQ[Y^W 4 8 5 $% =YWbQ^Q\ 7Ub]Y^Q\ 8iTUbWY^U 5bW_dbQdU 2U\\UbWQ\ C 3QVUbW_d 5bW_]Qb GYWbQY^U =UdXUbWY^U CQ^cUbd 1\d_S_b 1\d_`bUf =UfQ S_b J_S_b _b 8Q\SY_^ EcU SQe dY_^ YV i_e XQfU XUQbd \e^W _b [YT^Ui TYcUQcU _b dQ[U `b_dUQcU Y^XYRYd_bc 4_ ^_d dQ[U SQ`ce\Uc YV i_e XQfU XUQbd VQY\ebU

=_cd cUbY_ec* \YfUb VQY\ebU ^Ue b_`QdXi XUQbY^W \_cc ?dXUb* ^QecUQ TYQbbXUQ f_]YdY^W VUfUb bUc`YbQd_bi TYc_bTUbc bQcX XUQTQSXU

:Q^ccU^

" ]W TQY\i Y^ _bQ\ c_\edY_^ V_b _^U d_ dg_ gUU[c V_b _bQ\ SQ^TYTY QcYc+ " ]W TQY\i Y^ SQ`ce\U V_b] V_b _dXUb Ve^WQ\ Y^VUSdY_^c ceSX Qc XYcd_`\Qc]_cYc Q^T R\Qcd_]iS_cYc

GAMIMUNE N, GAMUNEX, GAMMAGARD

# d_ & ]W `Ub [W _V R_Ti gUYWXd UfUbi dXbUU d_ V_eb gUU[c QT]Y^Yc dUbUT Y^dbQfU^_ec\i

8U\`c ÂWXd RQSdUbYQ\ Y^VUSdY_^c Y^ SXY\TbU^ gYdX 89F

=Qi Y^dUbVUbU gYdX Y]]e^U bUc`_^cU d_ \YfU fYbec fQSSY^Uc V_b ]UQc\Uc ]e]`c _b beRU\\Q

=_cd cUbY_ec* TU`bUccY_^ ceYSYTQ\ RUXQfY_b cUfUbU `QY^ TYVVYSe\di RbUQdXY^W fYcY_^ `b_R\U]c XYWX VUfUb R\UUTY^W _b RbeYcY^W ?dXUb* XUQTQSXU ^QecUQ TYQbbXUQ SXY\\c VQdYWeU

6_b 194C bU\QdUT ;Q`_cYºc cQbS_]Q " ]W `Ub caeQbU ]UdUb _V R_Ti cebVQSU UfUbi dXbUU gUU[c Ri Y^dbQfU^_ec Y^VecY_^

DbUQdc ;Q`_cYºc cQb S_]Q Y^ `QdYU^dc gX_ SQ^^_d d_\UbQdU _dXUb ]UTYSY^Uc _b gX_cU TYcUQcU Yc QTfQ^SUT

4_cU ]Qi ^UUT d_ RU QTZecdUT YV i_e XQfU \YfUb `b_R\U]c

=_cd cUbY_ec* S_^WUcdYfU XUQbd VQY\ ebU TUSbUQcU Y^ R\__T SU\\c ?dXUb* dY^W\Y^W _b Reb^Y^W cgU\\Y^W R\YcdUbc ]_edX c_bUc VUfUb ^UbfU TQ]QWU Q^T ]_bU cUU 89F@\ec=QW S_]

1]_e^d Q^T VbU aeU^Si fQbYUc Ri `QdYU^d+ TU\YfUbUT Ri ceRSedQ^U_ec Y^ZUSdY_^

8U\`c bUcd_bU _b S_b bUSd cYW^c _V VQSYQ\ VQd \_cc \Y`_Qdb_`Xi

9V i_e XQfU Q^ QSdYfU c[Y^ Y^VUSdY_^ _b Y^ÃQ]]QdY_^ Y^ _b ^UQb dXU dbUQd]U^d QbUQ T_ ^_d ecU e^dY\ dXYc S_^TYdY_^ Yc e^TUb S_^db_\ =Y^Y]YjU Uh`_cebU d_ ce^\YWXd _b ce^ \Q]`c

=_cd cUbY_ec* RbeYcY^W UTU]Q XU]Qd_]Q Y^ZUSdY_^ cYdU bUQSdY_^c

( d_ ! " ]W TQY\i TU`U^TY^W _^ `QdYU^dºc gUYWXd Q^T di`U _V fYbec dQ[U^ dgYSU TQY\i Y^ " ]W SQ`ce\Uc gYdX V__T

9^ S_]RY^QdY_^ gYdX @UWQcic dbUQdc SXb_^YS XU`QdYdYc 3 Y^VUSdY_^

4_ ^_d ecU YV i_e dQ[U FYTUh _b FYTUh 53 EcU SQedY_^ gXU^ dQ[ Y^W gYdX >BD9c \Y[U 3_]RYfYb 5`YfYb 5`jYS_] BUdb_fYb DbYj YfYb Qc TbeW Y^dUbQSdY_^c S_e\T \UQT d_ d_hYSYdi 4_ ^_d dQ[U YV i_e XQfU SUbdQY^ R\__T TYc_bTUbc ceSX Qc dXQ\QccU]YQ ]QZ_b _b cYS[ \U SU\\ Q^U]YQ _b SUbdQY^ di`Uc _V XU`QdYdYc 4_ ^_d dQ[U YV i_e QbU `bUW^Q^d _b YV i_e _b i_eb `Qbd^Ub `\Q^ d_ RUS_]U `bUW^Q^d

=_cd cUbY_ec* cUfUbU UiU R\__T \e^W _b \YfUb `b_R\U]c `Q^SbUQdYdYc TU`bUc cY_^ _b ceYSYTQ\ dX_eWXdc XYWX R\__T ceWQb _b TYQRUdUc VUdQ\ QR^_b]Q\YdYUc ?dXUb* Ãe \Y[U ci]`d_]c dYbUT^Ucc Q^T gUQ[^Ucc ^QecUQ Q^T f_]YdY^W \_cc _V Q``UdYdU c[Y^ bUQSdY_^c XQYb dXY^^Y^W db_eR\U c\UU`Y^W

FYdbQcUbd cebWY SQ\\i Y]`\Q^dUT Y^ dXU UiU S_^cYcdc _V Q $ % ]W `U\\Ud _V WQ^SYS\_fYb S_QdUT gYdX `_\i]Ubc 6_b 3id_fU^U 9F T_c QWUc fQbi Red cX_e\T ^_d UhSUUT & ]W `Ub [W _V R_Ti gUYWXd

DbUQdc dXU UiU Y^VUS dY_^ Sid_]UWQ\_ fYbec bUdY^YdYc Y^ dbQ^c`\Q^d bUSY`YU^dc Q^T `U_`\U gYdX gUQ[U^UT Y]]e^U cicdU]c ceSX Qc dX_cU gYdX 89F

4_ ^_d dQ[U gYdX R\__T TicSbQ cYQ SQecY^W ]UTYSQdY_^c R_^U ]Qbb_g TU`bUccQ^dc bQTYQdY_^ dXUbQ`i ^U`Xb_d_hYS ]UTYSQ dY_^c _b BUdb_fYb 4_cQWU ]Qi ^UUT QTZecd]U^d YV i_e XQfU [YT ^Ui `b_R\U]c _b dQ[U FYTUh _b FYTUh 53 EcU SQedY_^ YV i_e dQ[U Q^dY 89F ]UTYSQdY_^c S_^dQY^Y^W jYT_feTY^U _b TYTQ^_cY^U

=_cd cUbY_ec* R\__T TYc_bTUbc R\QS[ _b dQbbi cd__\c S_eWX c_bU dXb_Qd VUfUb _b SXY\\c `QY^ `QY^Ve\ ebY^QdY_^ cUUY^W ÃQcXUc _b c`Qb[c _V \YWXd Ã_Qd Y^W c`_dc _b Q `QbdYQ\ fUY\ QSb_cc fYcY_^ e^eceQ\ R\UUTY^W Q^T e^eceQ\ dYbUT ^Ucc _b gUQ[^Ucc ?dXUb* QRT_]Y^Q\ `QY^ SXQ^WUc Y^ RUXQfY_b TYQbbXUQ VUfUb XUQTQSXU Y^SbUQcUT cgUQdY^W \_cc _V Q``UdYdU f_]YdY^W gUYWXd \_cc

TUBIZID Yc_^YQjYT CU\\US[ 3XU]YSQ\c

SPORANOX YdbQS_^Qj_\U

Y]]e^U W\_Re\Y^ 2QiUb 2Y_\_WYSQ\ DQ\U SbYc 2Y_dXUbQ`UedYSc 2QhdUb 8UQ\dXSQbU

DOXIL T_h_beRYSY^ \Y`_c_]Q\ :Q^ccU^

SCULPTRA Y^ZUSdQR\U `_\i < \QSdYS QSYT 4Ub]Y[ <QR_bQd_bYUc

COPEGUS bYRYfQbY^ B_SXU

CYTOVENE-IV, VITRASERT WQ^SYS\_fYb B_SXU <QR_bQd_bYUc 3id_fU^U 9F 2QecSX Q^T <_]R FYdbQcUbd

34

HIV plus

J U LY/A U G U S T 2 0 1 3

MEDICATION

REBETOL bYRYfQbY^ CSXUbY^W =UbS[

MYCOBUTIN bYVQRedY^ @ÂjUb

RIFADIN, RIFADIN IV bYVQ]`Y^ CQ^_YÂ 1fU^dYc

AMBISOME, AMPHOTEC, ABELCET, AMPHOCIN,

DOSAGE

WHAT IT DOES

WHAT TO KNOW

SIDE EFFECTS

( ! $ ]W TQY\i RQcUT _^ `QdYU^dºc gUYWXd Ri SQ`ce\U _b _bQ\ c_\edY_^ dQ[U^ gYdX V__T

9^ S_]RY^QdY_^ gYdX 9^db_^ 1 _b @UW9^db_^ dbUQdc SXb_^YS XU`QdYdYc 3 Y^VUSdY_^

4_ ^_d ecU YV i_e dQ[U FYTUh _b FYTUh 53 4_ ^_dU dQ[U YV i_e XQfU Qed_Y]]e^U XU`Q dYdYc SUbdQY^ R\__T TYc_bTUbc _b cUfUbU [YT^Ui TYcUQcU 4_ ^_d dQ[U YV i_e QbU `bUW^Q^d _b YV i_e _b i_eb `Qbd^Ub `\Q^ d_ RUS_]U `bUW^Q^d EcU SQedY_^ gXU^ dQ[Y^W gYdX >BD9c ceSX Qc 3_]RYfYb 5`YfYb 5`jYS_] BUdb_fYb _b DbYjYfYb

=_cd cUbY_ec* cUfUbU UiU \e^W _b R\__T `b_R\U]c `Q^SbUQdYdYc cUfUbU TU`bUccY_^ _b ceYSYTQ\ dX_eWXdc TU^ dQ\ `b_R\U]c SQecUT Ri Tbi ]_edX ?dXUb* \Ucc cUbY_ec ]__T SXQ^WUc Ãe \Y[U ci]`d_]c XUQTQSXU VUfUb cdYç ^Ucc Q^_bUhYQ

# ]W Y^ SQ`ce\Uc _^SU TQY\i 9V `b_^U d_ ^QecUQ _b f_]YdY^W c`\Yd Y^d_ dg_ T_cUc TQY\i gYdX V__T

8U\`c `bUfU^d TYc cU]Y^QdUT =iS_ RQSdUbYe] QfYe] S_]`\Uh =13 TYcUQcU

4_ ^_d ecU gYdX BUcSbY`d_b _b >_bfYb =Qi bUTeSU UçUSdYfU ^Ucc _V C`_bQ^_h 2YQhY^ 6_b d_fQcU Q^T 9^fYbQcU Qc gU\\ Qc _bQ\ S_^dbQSU`dYfUc 3ed T_cU Y^ XQ\V YV Q\c_ dQ[Y^W 3bYhYfQ^ _b FYbQSU`d 4_ ^_d dQ[U YV i_e XQfU QSdYfU deRUbSe\_cYc

=_cd cUbY_ec* ^Uedb_`U^YQ ?dXUb* bQcX WQcdb_Y^dUcdY^Q\ TYc_bTUbc Ãe \Y[U ci]`d_]c

! ]W `Ub [W _V R_Ti gUYWXd _^SU TQY\i _bQ\\i Y^ SQ`ce\U V_b] BYVQTY^ _b Y^dbQfU ^_ec\i BYVQTY^ 9F 4QY\i T_cQWU cX_e\T ^_d UhSUUT & ]Y\\YWbQ]c ?bQ\ T_cQWU cX_e\T RU _^U X_eb RUV_bU _b dg_ X_ebc QVdUb Q ]UQ\ gYdX gQdUb

8U\`c `bUfU^d _b dbUQd Y^VUSdY_^c SQecUT Ri Q SUbdQY^ di`U _V RQSdUbYe] Y^S\eTY^W dXU _^U dXQd SQecUc deRUb Se\_cYc

4_ ^_d dQ[U YV dQ[Y^W BUiQdQj @bUjYcdQ <UhYfQ 6_bd_fQcU 9^fYbQcU _b 1`dYfec 4_cQWU _V Q^dYS_QWe\Q^d TbeWc cX_e\T RU QTZecdUT EcU gYdX SQedY_^ YV i_e XQfU TYQRUdUc CgYdSX d_ ^_^X_b]_^Q\ S_^dbQSU`dYfUc

=_cd cUbY_ec* 7Qcdb_Y^dUcdY^Q\ TYc dbUcc SXQ^WUc Y^ \YfUb Ve^SdY_^ XUQT QSXU Tb_gcY^Ucc TYjjY^Ucc ]U^cdbe Q\ YbbUWe\QbYdYUc ZQe^TYSU TQb[U^UT ebY^U ?dXUb* \_cc _V Q``UdYdU VUfUb Z_Y^d `QY^

>_ ]_bU dXQ^ ! % ]W `Ub [W _V R_Ti gUYWXd QT]Y^YcdUbUT Y^dbQfU ^_ec\i _^SU TQY\i

DbUQdc Ve^WQ\ Y^VUSdY_^c Y^S\eT Y^W Sbi`d_S_SSQ\ ]U^Y^WYdYc gXYSX QbU ]_bU S_]]_^ Y^ `U_`\U gYdX 89F

9^TYfYTeQ\c gX_ SQ^^_d ^_b]Q\ \i dQ[U dbQTYdY_^Q\ Q]`X_dUbYSY^ 2 RUSQecU Yd SQecUc TQ]QWU d_ dXUYb [YT^Uic ]Qi RU QR\U d_ dQ[U dXU V_b]e\QdY_^c Y^ 1]2Yc_]U 1RU\SUd _b 1]`X_dUS

=_cd cUbY_ec* Q\\UbWYS bUQSdY_^ [YT ^Ui `b_R\U]c bQcX YbbUWe\Qb XUQbd RUQd ]ecS\U SbQ]`c _b `QY^ gUQ[ ^Ucc R\UUTY^W XUQbY^W \_cc R\ebbUT fYcY_^ XU`QdYdYc ?dXUb* VUfUb cXQ[ Y^W SXY\\c gUYWXd \_cc ^QecUQ XUQT QSXU ZQe^TYSU

DXYc d_`YSQ\ WU\ cX_e\T Y^YdYQ\\i RU Q``\YUT dgYSU Q TQi d_ ;C \UcY_^c gYdX VbUaeU^Si Y^SbUQcUT d_ dXbUU _b V_eb dY]Uc Q TQi TU`U^TY^W _^ d_\Ub Q^SU _b bUTeSUT YV c[Y^ Yc YbbYdQdUT _b YV dXUbU Yc Q d_hYS bUQSdY_^ 1``\i U^_eWX d_ S_fUb dXU \UcY_^ dX_b_eWX\i Red Qf_YT WUddY^W _^ ^_b]Q\ c[Y^ cebb_e^TY^W dXU \UcY_^ Q^T Q\\_g dXU WU\ d_ Tbi RUV_bU S_fUbY^W dXU c[Y^ gYdX S\_dXY^W DbUQd]U^d SQ^ S_^dY^eU Qc \_^W Qc ^UUTUT

@b_fYTUc d_`YSQ\ dbUQd]U^d V_b ;C \UcY_^c

1f_YT ecY^W gYdX `b_TeSdc dXQd S_^dQY^ 455D Q S_]]_^ Y^WbU TYU^d _V Y^cUSd bU`U\\U^dc =Y^Y ]YjU c[Y^ºc Uh`_cebU d_ ce^

=_cd cUbY_ec* d_hYS c[Y^ bUQSdY_^c

% ]W Y^ dQR\Udc dgYSU TQY\i V_b cUfU^ TQic+ dQR\Udc S_]U Y^ !"% "% _b % ]W cdbU^WdXc

DbUQdc bUSebbU^d U`Yc_TUc _V _b_\Q RYQ\ XUb`Uc S_\T c_bUc _b WU^YdQ\ XUb`Uc

4_cQWU ]Qi ^UUT d_ RU bUTeSUT V_b `QdYU^dc gYdX [YT^Ui Y]`QYb ]U^d DXU TbeWc 2U^U]YT Q^T @b_RQ\Q^ ecUT d_ dbUQd W_ed ]Qi Y^SbUQcU dXU \UfU\ _V 6Q]fYb Y^ dXU `QdYU^dºc R_Ti c_ dXYc \UfU\ cX_e\T RU ]_^Yd_bUT

=_cd cUbY_ec* QSedU [YT^Ui VQY\ebU ?dXUb* XUQTQSXU ^QecUQ

Q]`X_dUbYSY^ 2 1cdU\\Qc 1\[_`XQb]Q CYW]Q DQe @ÂjUb

PANRETIN GEL Q\YdbUdY^_Y^ 5YcQY

FAMVIR VQ]SYS\_fYb >_fQbdYc

J U LY/A U G U S T 2 0 1 3 HIV plus

35

MEDICATION DOSAGE

WHAT IT DOES

WHAT TO KNOW

SIDE EFFECTS

DbUQdc Ve^WQ\ Y^VUS dY_^c ceSX Qc Uc_`X QWUQ\ SQ^TYTYQcYc

4_ ^_d ecU gYdX XYWX T_cU >_bfYb+ ecU gYdX SQedY_^ gYdX \_g T_cU >_bfYb 4_ ^_d ecU gYdX CQY^d :_X^ºc g_bd UbW_d Q\[Q\_YTc dUb VU^QTY^U QcdU]Yj_\U SYcQ`bYTU `Y]_jYTU aeY^YTY^U _b bYVQRedY^ EcU gYdX SQedY_^ Y^ `QdYU^dc gYdX XUQbd QbbXidX]YQc

=_cd cUbY_ec* cUfUbU \YfUb `b_R\U]c XUQbd QbbXidX]YQc fYceQ\ TYcdebRQ^S Uc ?dXUb* VUfUb ^QecUQ bQcX f_]Yd Y^W SXY\\c XUQTQSXU

DbUQdc Uc_`XQWUQ\ SQ^TYTYQcYc SQ^TY TU]YQ Q^T _dXUb SQ^TYTQ Y^VUSdY_^c

5çUSdc _^ g_]U^ gX_ QbU `bUW ^Q^d _b RbUQcd VUUTY^W XQfU ^_d RUU^ cdeTYUT c_ TYcSecc `_c cYRY\Ydi _V `bUW^Q^Si gYdX i_eb T_Sd_b

=_cd cUbY_ec* 1R^_b]Q\ \YfUb Ve^S dY_^ Q^Q`Xi\QSdYS cX_S[ ?dXUb* ^Qe cUQ TYQbbXUQ f_]YdY^W

DbUQdc QTfQ^SUT 89F bU\QdUT ;Q`_cYºc cQbS_]Q

4_ ^_d ecU Y^ `QdYU^dc gYdX \Ucc dXQ^ QTfQ^SUT ;C

=_cd cUbY_ec* ce``bUccY_^ _V dXU R_^U ]Qbb_gºc `b_TeSdY_^ _V R\__T SU\\c Q^T `\QdU\Udc+ `QdYU^dc cX_e\T XQfU bUWe\Qb R\__T S_e^dc ?dXUb* RQS[ `QY^ ÃecXY^W SXUcd dYWXd^Ucc

9^YdYQ\ T_cU _V 6_cSQfYb Q \Ya DbUQdc 3=F bUdY^YdYc eYT c_\edY_^ Yc Q^ Y^dbQfU^_ec Y^VecY_^ _V ) ]W `Ub [Y\_WbQ] _V gUYWXd UfUbi !" X_ebc _b & ]W [W UfUbi UYWXd X_ebc V_b dg_ d_ dXbUU gUU[c V_\\_gUT Ri Q ]QY^dU^Q^SU T_cU _V ) ]W [W d_ !" ]W [W TQY\i 4_cQWU cX_e\T RU Y^TYfYTeQ\ YjUT QSS_bTY^W d_ `QdYU^dcº [YT^Ui Ve^SdY_^ Red cX_e\T ^_d UhSUUT dXU bUS_]]U^TUT Q]_e^d _b VbUaeU^Si

=Qi RU ecUT Y^ S_]RY^QdY_^ gYdX WQ^SYS\_fYb TbeWc Y^ `QdYU^dc gX_ XQfU bU\Q`cUT QVdUb dbUQd]U^d gYdX UYdXUb TbeW Ri YdcU\V Red ^_ _dXUb TbeW cX_e\T RU TU\YfUbUT Y^ dXU cQ]U Y^VecY_^ EcU gYdX SQedY_^ gYdX Y^dbQfU^_ec `U^dQ ]QTY^U

=_cd cUbY_ec* Y]`QYb]U^d _V [YT^Ui Ve^SdY_^ U\USdb_\idU QR^_b]Q\YdYUc cUYjebUc Q^U]YQ ?dXUb* XUQTQSXU ^QecUQ f_]YdY^W TYQbbXUQ VUfUb

4U\YfUbUT Ri Y^dbQfU^_ec Y^Ve

DbUQdc 3=F bUdY^YdYc

DXU Q^dY W_ed TbeW `b_RU^USYT RbQ^T ^Q]U 2U^U]YT _b @b_RQ\Q^ cX_e\T RU dQ[U^ _bQ\ \i gYdX UQSX FYcdYTU dbUQd]U^d BUdb_fYb cX_e\T RU dU]`_bQb Y\i TYcS_^dY^eUT _b dXU T_cQWU XQ\fUT _^ dXU TQi _V UQSX FYcdYTU Y^VecY_^ 4_ ^_d ecU gYdX Q^i TbeWc dXQd XQfU dXU `_dU^dYQ\ d_ SQecU [YT^Ui d_hYSYdi 4_ ^_d dQ[U YV i_e XQfU XYWX SbUQdY^Y^U \UfU\c Qc ]UQcebUT Ri SbUQdY ^Y^U S\UQbQ^SU dUcd

=_cd cUbY_ec* [YT^Ui d_hYSYdi TUSbUQcUT Y^dUb_Se\Qb `bUccebU ?dXUb* ^QecUQ f_]YdY^W VUfUb

6YWXdc RQSdUbYQ\ Y^VUSdY_^c Uc`USYQ\\i =iS_RQSdU bYe] QfYe] S_]`\Uh =13

DXUbU XQfU RUU^ \YVU dXbUQdU^ Y^W Y^dUbQSdY_^c gYdX 3_\Sbic Q^T cUbY_ec Y^dUbQSdY_^c gYdX 1\dQS_b 1\d_`bUf =UfQS_b J_S_b <Y`Yd_b Q^T R\__T `bUc cebU TbeWc EcU SQedY_^ gXU^ dQ[Y^W gYdX FYQWbQ

=_cd cUbY_ec* QRT_]Y^Q\ `QY^ VUfUb ^QecUQ f_]YdY^W R\UUTY^W _b RbeYc Y^W TYQbbXUQ S_\YdYc \YfUb VQY\ebU XU` QdYdYc ?dXUb* ]Y\TUb TYQbbXUQ XUQT QSXU ^QecUQ Q^T f_]YdY^W SXQ^WU Y^ dQcdU

6_b Uc_`XQWUQ\ SQ^TYTYQcYc

VFEND " ]W Y^ dQR\Udc _b _bQ\

f_bYS_^Qj_\U @ÂjUb

ERAXIS Q^YTe\QVe^WY^ @ÂjUb

c_\edY_^ UfUbi !" X_ebc Qd \UQcd Q^ X_eb RUV_bU _b QVdUb Q ]UQ\ 6_b _dXUb Ve^WQ\ Y^VUS dY_^c dbUQd]U^d cdQbdc gYdX Q^ Y^dbQfU^_ec Y^VecY_^ _V & ]W `Ub [Y\_WbQ] _V gUYWXd UfUbi !" X_ebc V_b dXU Âbcd "$ X_ebc V_\\_gUT Ri Q ]QY^dU ^Q^SU T_cU _V UYdXUb $ ]W `Ub [Y\_WbQ] _V gUYWXd UfUbi !"

X_ebc _b " ]W Y^ dQR\Udc _b _bQ\ c_\edY_^ UfUbi !" X_ebc 4ebQdY_^ _V dbUQd]U^d fQbYUc QSS_bTY^W d_ dXU Y^VUSdY_^ 6_b Uc_`XQWUQ\ SQ^TYTYQcYc ! ]W Ri Y^ZUSdY_^ dXU Âbcd TQi V_\\_gUT Ri V_\\_gUT Ri % ]W TQY\i T_cU dXUbUQVdUb V_b Q ]Y^Y]e] _V !$ TQic+ V_b SQ^ TYTU]YQ Q^T _dXUb 3Q^TYTQ Y^VUSdY_^c " ]W Ri Y^ZUS dY_^ dXU Âbcd TQi V_\\_gUT Ri ! ]W TQY\i T_cU gYdX dXU ^e]RUb _V TQic TU`U^TY^W _^ dXU `QdYU^d 5bQhYc S_]Uc Qc Q `_gTUb dXQd Yc ]YhUT gYdX cdUbY\U gQdUb V_b Y^VecY_^

9^ZUSdUT Y^dbQfU^_ec\i Qd Q cdbU^WdX _V $ ]W `Ub caeQbU TQe^_beRYSY^ ]UdUb _V R_Ti cebVQSU QbUQ \Y`_c_]Q\ UfUbi dg_ gUU[c

DAUNOXOME

7Q\U^

FOSCAVIR V_cSQb^Ud c_TYe] 8_c`YbQ

VISTIDE cY_^ dXU Y^YdYQ\ T_cU TU`U^Tc SYT_V_fYb 7Y\UQT

BIAXIN S\QbYdXb_]iSY^ 1RR_dd <QR_bQd_bYUc

_^ dXU `QdYU^dºc gUYWXd WU^ TUb Q^T [YT^Ui Ve^SdY_^ gYdX dXU \QddUb ]UQcebUT Ri Q dUcd dXQd TUdUb]Y^Uc X_g gU\\ dXU [YT^Uic S\UQb SbUQdY^Y^U Vb_] dXU R\__T =QY^dU^Q^SU T_cU Yc % ]W `Ub [Y\_WbQ] _V R_Ti gUYWXd Ri Y^VecY_^ _^SU UfUbi dg_ gUU[c

% ]W " _b # dY]Uc TQY\i TU`U^TY^W _^ dXU Y^VUS dY_^ 1fQY\QR\U Y^ Y]]UTYQdU bU\UQcU dQR\Udc UhdU^TUT bU\UQcU dQR\Udc Q^T WbQ^e\Uc d_ RU ]YhUT gYdX gQdUb

3_^dY^eUT _^ `QWU $( 36

HIV plus

J U LY/A U G U S T 2 0 1 3

THE 2013 COMPLETE HIV TREATMENT GUIDE

CHP?MNCA;NCIH;F G?>C=;NCIHM The medications used to treat HIV and all its complications went through extensive investigations and clinical trials before being approved for general use. Doctors are now working on vaccines and cures for HIV, utilizing everything from bone marrow transplants to injections of disease-killing cells. But there are even more promising advances coming from medical, university, and pharmaceutical organizations. Some of these new medications, which are not yet approved for use outside clinical trials, may soon be coming to a pharmacy near you.

NAME & MAKER

WHAT IT DOES

BMS-806 #SJTUPM .ZFST 4RVJCC

1 ]YSb_RYSYTU Yc Q ceRcdQ^SU dXQd `b_dUSdc QWQY^cd ]YSb__bWQ^Yc]c RQSdUbYQ fYbecUc Ve^WY UYdXUb Ri TUcdb_iY^W dXU ]YSb_RUc _b `bUfU^dY^W dXU] Vb_] UcdQR\YcXY^W Q^ Y^VUSdY_^ 9^ 89F bUcUQbSX ]YSb_RYSYTU eceQ\\i bUVUbc d_ Q d_`YSQ\ WU\ ecUT QWQY^cd dXU fYbec 2=C ( & Yc Q^ 89F U^dbi Y^XYRYd_b dXQd XQc RUU^ cdeTYUT R_dX Y^ Q^ _bQ\ V_b] d_ dbUQd 89F Q^T Qc Q S_]`_^U^d _V Q fQWY^Q\ ]YSb_RYSYTU WU\ d_ bUTeSU 89F dbQ^c]YccY_^ 1 ]YSb_RYSYTU RQcUT _^ Q TUbYfQdYfU _V dXU TbeW SQ\\UT 4C # Yc Y^ TUfU\_`]U^d

TENOFOVIRUC781 (JMFBE 4DJFODFT

?^U V_b] _V dU^_V_fYb Yc ]Qb[UdUT Qc Q^ _bQ\ 89F ]UTYSQdY_^ e^TUb dXU RbQ^T ^Q]U FYbUQT Red Yd XQc Q\c_ RUU^ cdeTYUT Qc Q S_]`_^U^d _V Q ]YSb_RYSYTU WU\ V_b Q fQWY^Q\ ecU GXY\U c_]U WU\ dbYQ\c XQfU `b_TeSUT TYcQ``_Y^dY^W bUce\dc cSYU^dYcdc QbU cdeTiY^W gXUdXUb dU^_V_fYbยบc `UbV_b]Q^SU SQ^ RU Y]`b_fUT Ri S_]RY^Y^W Yd gYdX dXU ^_^^eS\U_cYTU bUfUbcU dbQ^cSbY`dQcU Y^XYRYd_b E3'(! Y^ Q fQWY^Q\ WU\ Q^T `_dU^dYQ\\i Q ร \]

ELVITEGRAVIR (JMFBE 4DJFODFT

1 di`U _V ]UTYSY^U dXQd R\_S[c Y^dUWbQcU Q `b_dUY^ dXQd 89F ^UUTc d_ Y^cUbd Ydc fYbQ\ WU^UdYS ]QdUbYQ\ Y^d_ dXU WU^UdYS ]QdUbYQ\ _V Q^ Y^VUSdUT SU\\ U\fYdUWbQfYb Yc dQ[U^ _bQ\\i d_ ร WXd 89F Y^ S_]RY^QdY_^ gYdX _dXUb Q^dYbUdb_fYbQ\ ]UTYSY^Uc 5\fYdUWbQfYb Yc Q S_]`_^U^d _V dXU CdbYRY\T S_]RY^QdY_^ `Y\\ 9^ 1`bY\ dXU 6__T Q^T 4beW 1T]Y^YcdbQdY_^ TUS\Y^UT d_ Q``b_fU Yd Qc Q cdQ^T Q\_^U TbeW Q^T Qc[UT 7Y\UQT V_b VebdXUb T_Se]U^dQdY_^ _^ Ydc cdeTi ]UdX_Tc DXU S_]`Q^i Yc g_b[Y^W d_ QTTbUcc dXU ]QddUb

COBICISTAT (GS-9350) (JMFBE 4DJFODFT

3_RYSYcdQd Yc Q `XQb]QS_ U^XQ^SUb _b ยทR__cdY^W QWU^dยธ dXQd bQYcUc dXU R\__T \UfU\c _V _dXUb TbeWc dXQd QbU Rb_[U^ T_g^ Ri dXU cQ]U `b_dUY^ 3_RYSYcdQd YdcU\V T_Uc ^_d XQfU Q^i Q^dYfYbQ\ QSdYfYdi <Y[U U\fYdUWbQfYb Yd Yc Q S_]`_^U^d _V CdbYRY\T 9d gQc Q\c_ bUZUSdUT Ri dXU 641 Qc Q cdQ^T Q\_^U TbeW V_b dXU cQ]U bUQc_^ Q^T 7Y\UQT Yc QTTbUccY^W dXU YcceU

572_TRII 7JJ7

DOLUTEGRAVIR 7JJ7

โ 744 LAP 7JJ7

TENOFOVIR ALAFENAMIDE (JMFBE 4DJFODFT

1 cY^W\U `Y\\ S_]`\UdU bUWY]U^ dXQd S_^dQY^c dXU Y^fUcdYWQdY_^Q\ Y^dUWbQcU Y^XYRYd_b T_\edUWbQfYb Q^T 5`jYS_] Q^ Q\bUQTi Q``b_fUT TbeW dXQd `bUfU^dc 89F Vb_] Q\dUbY^W dXU WU^UdYS ]QdUbYQ\ _V XUQ\dXi 34$ SU\\c 4_\edUWbQfYb Yc Q^ Y^dUWbQcU Y^XYRYd_b dXQd dQbWUdc 89F Y^dUWbQcU Q^ U^ji]U bUaeYbUT V_b dXU Y^dUWbQdY_^ _V fYbQ\ 4>1 Y^d_ dXU X_cd SU\\ WU^_]U Y^ Q^ Uรง_bd d_ `bUfU^d 89F Vb_] bU`\YSQdY^W

9V Q``b_fUT V_b ecU T_\edUWbQfYb cUU QR_fU g_e\T RU dXU cUS_^T Y^ Q ^Ug S\Qcc _V Y^dUWbQcU Y^XYRYd_bc dXQd g_b[ Ri R\_S[Y^W 89Fยบc QRY\Ydi d_ bU`\YSQdU 1``\YSQdY_^c gUbU ceR]YddUT d_ dXU 641 Q^T dXU 5eb_`UQ^ =UTYSY^Uc 1WU^Si \Qcd 4USU]RUb " !" gYdX Q^ 641 TUSYcY_^ Uh`USdUT Y^ 1eWecd

C 7C;!"&%'$$ _b cY]`\i ยบ'$$ <1@ Yc Q^ Y^dUWbQcU Y^XYRYd_b dXQd Yc S_^cYTUbUT FYYFยบc V_\\_g e` d_ T_\edUWbQfYb DXU TbeW Yc SebbU^d\i Y^ @XQcU 99 dbYQ\c

DU^_V_fYb TYc_`b_hY\ Ve]QbQdU Q ^eS\U_cYTU bUfUbcU dbQ^cSbY`dQcU Y^XYRYd_b Yc Q\bUQTi QfQY\QR\U Qc Q^ Q^dY 89F `Y\\ e^TUb dXU RbQ^T ^Q]U FYbUQT Q^T Qc Q S_]`_^U^d _V cUfUbQ\ S_]RY^QdY_^ TbeWc Y^S\eTY^W CdbYRY\T 7Y\UQT Yc SebbU^d\i S_^TeSdY^W S\Y^YSQ\ dbYQ\c _V Q fQbYQ^d dU^_V_fYb Q\QVU^Q]YTU _b D16 V_b]Ub\i 7C '#$ + D16 ]Qi RU QR\U d_ XQfU Q WbUQdUb Q^dYfYbQ\ UรงUSd dXQ^ FYbUQT Qd Q T_cU dXQd Yc ! dY]Uc \_gUb Q^T Yc RUddUb TYcdbYRedUT Y^d_ \i]`X_YT dYcceUc `_dU^dYQ\\i Y]`b_fY^W dXU d_\UbQRY\Ydi _V 89F dXUbQ`i 9^ Q @XQcU 99 cdeTi dXU D16 RQcUT cY^W\U dQR\Ud bUWY]U^ ce``bUccUT dXU fYbec Qc gU\\ Qc CdbYRY\T gXY\U RUY^W WU^d\Ub _^ [YT^Uic Q^T R_^Uc 1 @XQcU 999 cdeTi U^b_\\UT Y^ dXU c`bY^W

J U LY/A U G U S T 2 0 1 3 ย HIV plus

37

THE 2013 COMPLETE HIV TREATMENT GUIDE // INVESTIGATIONAL MEDICATIONS NAME & MAKER

AMD070 (FO[ZNF

IBALIZUMAB 5BJ.FE APRICITABINE "WFYB -UE

1 di`U _V ]UTYSY^U SQ\\UT Q 3H3B$ Y^XYRYd_b gXYSX g_b[c Ri R\_S[Y^W 89Fยบc U^dbi Y^d_ SU\\c 1=4 ' ]Qi g_b[ V_b `QdYU^dc gX_ XQfU bUcYcdQ^SU d_ _b SQ^^_d dQ[U _dXUb Q^dY 89F TbeWc 9^ _^U Xe]Q^ cdeTi bYd_^QfYb gQc V_e^T d_ XUYWXdU^ dXU ce``\i _V 1=4 ' Y^ dXU R_Ti 1=4 ' TUfU\_`]U^d Yc ^_g _^ X_\T RUSQecU _V \YfUb bU\QdUT UรงUSdc Y^ Q^Y]Q\ ceRZUSdc Red cSYU^dYcdc cdY\\ cUU `_dU^dYQ\ RU^Uร d RQcUT _^ dXU bYd_^QfYb cdeTi

1\c_ Q 3H3B$ Y^XYRYd_b YRQ\Yje]QR V_b]Ub\i [^_g^ Qc D=2 #%% Yc Y^ZUSdUT Y^dbQfU^_ec\i d_ dbUQd 89F FQbY_ec T_cUc RQcUT _^ R_Ti gUYWXd XQfU RUU^ cdeTYUT

1`bYSYdQRY^U Yc Q ^Ug ^eS\U_cYTU bUfUbcU dbQ^cSbY`dQcU Y^XYRYd_b dXQd ]Qi g_b[ V_b `U_`\U gYdX 89F cdbQY^c dXQd QbU bUcYcdQ^d d_ _dXUb >BD9c ?dXUb ^Q]Uc V_b Yd Y^S\eTU 1D3 1FH'%$ Q^T C@4'%$

ELVUCITABINE "DIJMMJPO 1IBSNBDFVUJDBMT

1^_dXUb >BD9 U\feSYdQRY^U _b 138 !"&$$# Yc cY]Y\Qb d_ dXU 641 Q``b_fUT Q^dY 89F TbeW \Q]YfeTY^U 5`YfYb 5\feSYdQRY^U ]Qi RU UรงUSdYfU Y^ dbUQdY^W Y^TYfYTeQ\c Y^VUSdUT gYdX 89F cdbQY^c bUcYcdQ^d d_ \Q]YfeTY^U Q^T ]Qi TU\Qi dXU U]UbWU^SU _V bUcYcdQ^SU Q^T `b_\_^W dXU UรงUSdYfU^Ucc _V dXUbQ`i

KP-1461 ,PSPOJT 1IBSNBDFVUJDBMT

;@ !$&! Yc Q^ _bQ\ V_b] _V ;@ !"!" Q S_]`_e^T cX_g^ d_ RU UรงUSdYfU Y^ SU\\ Se\debU QWQY^cd 89F 9d Yc Q\c_ UรงUSdYfU QWQY^cd fYbecUc gYdX ]edQdY_^c S_^VUbbY^W bUcYcdQ^SU d_ ]Q^i _V dXU TbeWc SebbU^d\i Q``b_fUT V_b 89F dbUQd]U^d 9d Yc RUY^W bUร ^UT V_b VebdXUb cdeTi

VIVAGEL 4UBSQIBSNB

PRO 140 $ZUP%ZO

AMPLIGEN )FNJTQIFSY #JPQIBSNB

38

WHAT IT DOES

FYfQ7U\ Yc Q fQWY^Q\ ]YSb_RYSYTU WU\ dXQd Yc RUY^W cdeTYUT V_b dXU `bUfU^dY_^ _V 89F Q^T _dXUb CD9c Y^S\eTY^W XUb`Uc cY]`\Uh fYbec " 9^ dUcdc Yd XQc RUU^ WYfU^ UYdXUb _^SU _b dgYSU TQY\i V_b e` d_ dg_ gUU[c 9dc QSdYfU Y^WbUTYU^d Yc C@<' !# Q^ 89F Y^XYRYd_b

@B? !$ Yc Q^ Q^dYR_Ti TUcYW^UT d_ R\_S[ 89F Vb_] U^dUbY^W Q SU\\ 9d QSS_]`\YcXUc dXYc Ri RY^TY^W d_ Q ]_\USe\U SQ\\UT 33B% Q ^_b]Q\ SU\\ `b_dUY^ dXQd 89F QddQSXUc d_ QVdUb S_^dQSd gYdX dXU `bY]Qbi bUSU`d_b V_b dXU fYbec @B? !$ Yc Q^ Q^dYR_Ti ^_d Q TbeW Q^T XQc ^_ Q``QbU^d YcceUc gYdX d_hYSYdi

1]`\YWU^ Yc Q^ B>1 TbeW `b_TeSd dXQd Yc QT]Y^YcdUbUT Y^dbQfU^_ec\i 9dยบc Y^ Xe]Q^ S\Y^YSQ\ TUfU\_`]U^d V_b fQbY_ec dXUbQ`UedYSQ\\i _bYU^dUT cdeTYUc Y^S\eTY^W dbUQd]U^d V_b 89F bU^Q\ SU\\ SQbSY^_]Q Q^T ]Q\YW^Q^d ]U\Q^_]Q

CARRAGUARD 1PQVMBUJPO $PVODJM '.$ #JP1PMZNFS

3QbbQWUU^Q^ Yc Q SXU]YSQ\ V_e^T Y^ SUbdQY^ di`Uc _V cUQgUUT gXYSX cSYU^dYcdc XQfU TYcS_fUbUT SQ^ `b_dUSd SU\\c Vb_] RUS_]Y^W Y^VUSdUT gYdX ]Q^i fYbecUc Y^S\eTY^W 89F Y^ \QR_bQd_bi U^fYb_^]U^dc 9d gQc dUcdUT Qc dXU ]YSb_RYSYTQ\ S_]`_^U^d _V dXU @_`e\QdY_^ 3_e^SY\ยบc fQWY^Q\ WU\ RbQ^T ^Q]U 3QbbQWeQbT d_ bUTeSU 89F dbQ^c]YccY_^ 9d TYT ^_d `b_fU UรงUSdYfU Y^ Q S\Y^YSQ\ dbYQ\ Q VUg iUQbc QW_ Red Yd TYT `b_fU cQVU Q^T 3QbbQWeQbT Yc Q S_]`_^U^d _V _dXUb WU\c RUY^W TUfU\_`UT DXU ceRcdQ^SU Yc Q\c_ [^_g^ Qc SQbbQWQU^ SQbbQWUU^Q^ We] SQbbQWUU^Y^ 9bYcX ]_cc UhdbQSd @3 %!% Q^T @3%!%

MUCOCEPT 0TFM *OD

=eS_3U`d Q dXYbT WU^UbQdY_^ U^WY^UUbUT `b_RY_dYS `b_TeSd Yc Y^ `bU S\Y^YSQ\ TUfU\_`]U^d Q^T ^UQbY^W Q^ 9^fUcdYWQdY_^Q\ >Ug 4beW ceR]YccY_^ Qc Q ^_fU\ ]YSb_RYSYTU V_b dXU `bUfU^dY_^ _V 89F Y^VUSdY_^ Y^ g_]U^

DEPAKENE "CCPUU -BCPSBUPSJFT

FQ\`b_YS QSYT gXYSX 1RR_dd ]Qb[Udc e^TUb dXU RbQ^T ^Q]U 4U`Q[U^U Yc di`YSQ\\i ecUT d_ dbUQd cUYjebUc Q^T _dXUb ^Ubf_ec cicdU] `b_R\U]c DXU QSYT ]Qi Q\c_ g_b[ QWQY^cd 89F Ri bU\UQcY^W dXU fYbec Vb_] bUcdY^W SU\\c c_ _dXUb Q^dY 89F ]UTYSY^Uc SQ^ QddQS[ Yd Q^T cdeTYUc XQfU RUU^ e^TUbdQ[U^ d_ TUdUb]Y^U Ydc UรงUSdYfU^Ucc Y^ dXYc Q``\YSQdY_^ 1\c_ [^_g^ Qc 4U`Q[_dU TYfQ\`b_Uh c_TYe] F@1 Q^T fQ\`b_QdU

HIV plus

ย J U LY/A U G U S T 2 0 1 3

YOUâ&#x20AC;&#x2122;VE COME A LONG WAY MANAGING YOUR HIV.

NOW, ON TO HIV-RELATED EXCESS ABDOMINAL FAT.

www.egrifta.com

Indication: EGRIFTA® (tesamorelin for injection) is a daily injectable prescription medicine to reduce the excess abdominal fat in HIV-infected patients with lipodystrophy.

Limitations of use: r 5IF JNQBDU BOE TBGFUZ PG EGRIFTA® on cardiovascular health has not been studied r EGRIFTA® is not indicated for weight-loss management r *U T OPU LOPXO XIFUIFS UBLJOH EGRIFTA® helps improve compliance with antiretroviral medications r EGRIFTA® is not recommended to be used in children Important Risk Information Do not use EGRIFTA® if you: r )BWF QJUVJUBSZ HMBOE UVNPS QJUVJUBSZ HMBOE TVSHFSZ PS PUIFS QSPCMFNT SFMBUFE to your pituitary gland r )BWF BDUJWF DBODFS FJUIFS OFXMZ EJBHOPTFE PS SFDVSSFOU PS BSF SFDFJWJOH treatment for cancer r "SF BMMFSHJD UP UFTBNPSFMJO PS BOZ PG UIF JOHSFEJFOUT JO EGRIFTA® JODMVEJOH mannitol or sterile water r "SF QSFHOBOU PS CFDPNF QSFHOBOU Before using EGRIFTA®, tell your healthcare provider if you: r )BWF PS IBWF IBE DBODFS

r )BWF EJBCFUFT r "SF CSFBTUGFFEJOH PS QMBO UP CSFBTUGFFE r )BWF LJEOFZ PS MJWFS QSPCMFNT

r )BWF BOZ PUIFS NFEJDBM DPOEJUJPO r 5BLF QSFTDSJQUJPO PS OPO QSFTDSJQUJPO NFEJDJOFT WJUBNJOT PS IFSCBM TVQQMFNFOUT EGRIFTA® may cause serious side effects, including: r 4FSJPVT BMMFSHJD SFBDUJPO 4UPQ VTJOH EGRIFTA® and get emergency help right away JG ZPV IBWF BOZ PG UIF GPMMPXJOH TZNQUPNT SBTI PWFS ZPVS CPEZ IJWFT TXFMMJOH PG ZPVS GBDF PS UISPBU TIPSUOFTT PG CSFBUI PS USPVCMF CSFBUIJOH GBTU IFBSUCFBU GFFMJOH of faintness or fainting r 4XFMMJOH áVJE SFUFOUJPO EGRIFTA® can cause swelling in some parts of your body. $BMM ZPVS IFBMUIDBSF QSPWJEFS JG ZPV IBWF BO JODSFBTF JO KPJOU QBJO PS QBJO PS numbness in your hands or wrist (carpal tunnel syndrome) r *ODSFBTF JO HMVDPTF CMPPE TVHBS JOUPMFSBODF BOE EJBCFUFT :PVS IFBMUIDBSF provider will measure your blood sugar periodically r *OKFDUJPO TJUF SFBDUJPOT TVDI BT SFEOFTT JUDIJOH QBJO JSSJUBUJPO CMFFEJOH SBTI BOE TXFMMJOH $IBOHF SPUBUF ZPVS JOKFDUJPO TJUF UP IFMQ MPXFS ZPVS SJTL GPS injection-site reactions The most common side effects of EGRIFTA® include: r KPJOU QBJO r OVNCOFTT BOE QSJDLJOH r QBJO JO MFHT BOE BSNT r OBVTFB r TXFMMJOH JO ZPVS MFHT r WPNJUJOH r NVTDMF TPSFOFTT r SBTI r UJOHMJOH r JUDIJOH EGRIFTA® XJMM /05 DVSF )*7 PS MPXFS ZPVS DIBODF PG QBTTJOH )*7 UP PUIFST You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Actual patient living with HIV since 2000

You can receive valuable information about ways to discuss this condition and EGRIFTA® with your doctor when you sign up at egrifta.com/info or call the AXIS Center2/13 at 877-714-AXIS (2947) 111122-102311

Please see Consumer Brief Summary of EGRIFTA® on following page.

Consumer Brief Summary for EGRIFTAÂŽ (tesamorelin for injection) EGRIFTAÂŽ (eh-GRIF-tuh) (tesamorelin for injection) for subcutaneous use Read the Patient Information that comes with EGRIFTAÂŽ CFGPSF ZPV TUBSU UP UBLF JU BOE FBDI UJNF ZPV HFU B SFĂ MM 5IFSF NBZ CF OFX JOGPSNBUJPO 5IJT MFBĂĄFU EPFT OPU UBLF UIF QMBDF PG UBMLJOH UP ZPVS IFBMUIDBSF QSPWJEFS BCPVU ZPVS NFEJDBM DPOEJUJPO PS your treatment.

What is EGRIFTAÂŽ? t EGRIFTAÂŽ is an injectable prescription medicine to reduce the excess in abdominal

fat in HIV-infected patients with lipodystrophy. EGRIFTAÂŽ contains a growth hormonereleasing factor (GRF) t 5IF JNQBDU BOE TBGFUZ PG EGRIFTAÂŽ on cardiovascular health has not been studied t EGRIFTAÂŽ is not indicated for weight-loss management t IU JT OPU LOPXO XIFUIFS UBLJOH EGRIFTAÂŽ helps improve compliance with antiretroviral medications t *U JT OPU LOPXO JG EGRIFTAÂŽ is safe and effective in children. EGRIFTAÂŽ is not recommended to be used in children Who should not use EGRIFTAÂŽ?

Do not use EGRIFTAÂŽ if you: t I BWF QJUVJUBSZ HMBOE UVNPS QJUVJUBSZ HMBOE TVSHFSZ PS PUIFS QSPCMFNT SFMBUFE UP ZPVS pituitary gland t have or have had a history of active cancer (either newly diagnosed or recurrent) t are allergic to tesamorelin or any of the ingredients in EGRIFTAÂŽ 4FF UIF FOE PG UIJT MFBĂĄFU GPS B DPNQMFUF MJTU PG JOHSFEJFOUT JO EGRIFTAÂŽ t BSF QSFHOBOU PS CFDPNF QSFHOBOU *G ZPV CFDPNF QSFHOBOU TUPQ VTJOH EGRIFTAÂŽ and UBML XJUI ZPVS IFBMUIDBSF QSPWJEFS 4FF i8IBU TIPVME * UFMM NZ IFBMUIDBSF QSPWJEFS before using EGRIFTAÂŽ?â&#x20AC;?

What should I tell my healthcare provider before using EGRIFTAÂŽ?

Before using EGRIFTAÂŽ UFMM ZPVS IFBMUIDBSF QSPWJEFS JG ZPV t have or have had cancer t have diabetes t BSF CSFBTUGFFEJOH PS QMBO UP CSFBTUGFFE *U JT OPU LOPXO JG EGRIFTAÂŽ passes into your CSFBTU NJML 5IF $FOUFST GPS %JTFBTF $POUSPM BOE 1SFWFOUJPO $%$ SFDPNNFOET UIBU )*7 JOGFDUFE NPUIFST OPU CSFBTUGFFE UP BWPJE UIF SJTL PG QBTTJOH )*7 JOGFDUJPO UP ZPVS CBCZ 5BML XJUI ZPVS IFBMUIDBSF QSPWJEFS BCPVU UIF CFTU XBZ UP GFFE ZPVS CBCZ JG ZPV BSF UBLJOH EGRIFTAÂŽ t IBWF LJEOFZ PS MJWFS QSPCMFNT t have any other medical condition 5FMM ZPVS IFBMUIDBSF QSPWJEFS BCPVU BMM UIF NFEJDJOFT ZPV UBLF JODMVEJOH QSFTDSJQUJPO BOE OPOQSFTDSJQUJPO NFEJDJOFT WJUBNJOT BOE IFSCBM TVQQMFNFOUT EGRIFTAÂŽ may affect UIF XBZ PUIFS NFEJDJOFT XPSL BOE PUIFS NFEJDJOFT NBZ BGGFDU IPX EGRIFTAÂŽ XPSLT ,OPX UIF NFEJDJOFT ZPV UBLF ,FFQ B MJTU XJUI ZPV UP TIPX ZPVS IFBMUIDBSF QSPWJEFS BOE pharmacist when you get a new medicine.

How should I use EGRIFTAÂŽ? t Read the detailed â&#x20AC;&#x153;Instructions for Useâ&#x20AC;? that comes with EGRIFTAÂŽ before you start using EGRIFTAÂŽ :PVS IFBMUIDBSF QSPWJEFS XJMM TIPX ZPV IPX UP JOKFDU EGRIFTAÂŽ t Use EGRIFTAÂŽ exactly as prescribed by your healthcare provider t Inject EGRIFTAÂŽ VOEFS UIF TLJO TVCDVUBOFPVTMZ PG ZPVS TUPNBDI BSFB BCEPNFO

t Change (rotate) the injection site on your stomach area (abdomen) with each dose.

Do not inject EGRIFTAÂŽ JOUP TDBS UJTTVF CSVJTFT PS ZPVS OBWFM t %P OPU TIBSF OFFEMFT PS TZSJOHFT XJUI PUIFS QFPQMF 4IBSJOH PG OFFEMFT DBO SFTVMU JO UIF USBOTNJTTJPO PG JOGFDUJPVT EJTFBTFT TVDI BT )*7 What are the possible side effects of EGRIFTAÂŽ?

EGRIFTAÂŽ may cause serious side effects including: t 4FSJPVT BMMFSHJD SFBDUJPO 4PNF QFPQMF UBLJOH EGRIFTAÂŽ may have an allergic reaction.

4UPQ VTJOH EGRIFTAÂŽ and get emergency help right away if you have any of the following symptoms: â&#x20AC;&#x201C; a rash over your body

â&#x20AC;&#x201C; hives â&#x20AC;&#x201C; swelling of your face or throat â&#x20AC;&#x201C; shortness of breath or trouble breathing â&#x20AC;&#x201C; fast heartbeat â&#x20AC;&#x201C; feeling of faintness or fainting t 4XFMMJOH ĂĄVJE SFUFOUJPO EGRIFTAÂŽ can cause swelling in some parts of your CPEZ $BMM ZPVS IFBMUIDBSF QSPWJEFS JG ZPV IBWF BO JODSFBTF JO KPJOU QBJO PS QBJO PS numbness in your hands or wrist (carpal tunnel syndrome) t *ODSFBTF JO HMVDPTF CMPPE TVHBS JOUPMFSBODF BOE EJBCFUFT :PVS IFBMUIDBSF QSPWJEFS

will measure your blood sugar periodically t *OKFDUJPO TJUF SFBDUJPOT $IBOHF SPUBUF ZPVS JOKFDUJPO TJUF UP IFMQ MPXFS ZPVS SJTL GPS

injection-site reactions. Call your healthcare provider for medical advice if you have the following symptoms around the area of the injection site: â&#x20AC;&#x201C; bleeding â&#x20AC;&#x201C; redness â&#x20AC;&#x201C; rash â&#x20AC;&#x201C; itching â&#x20AC;&#x201C; swelling â&#x20AC;&#x201C; pain â&#x20AC;&#x201C; irritation The most common side effects of EGRIFTAÂŽ include: â&#x20AC;&#x201C; joint pain â&#x20AC;&#x201C; nausea â&#x20AC;&#x201C; vomiting â&#x20AC;&#x201C; pain in legs and arms â&#x20AC;&#x201C; rash â&#x20AC;&#x201C; swelling in your legs â&#x20AC;&#x201C; itching â&#x20AC;&#x201C; muscle soreness m UJOHMJOH OVNCOFTT BOE QSJDLJOH 5FMM ZPVS IFBMUIDBSF QSPWJEFS JG ZPV IBWF BOZ TJEF FGGFDU UIBU CPUIFST ZPV PS UIBU EPFT not go away.

5IFTF BSF OPU BMM UIF QPTTJCMF TJEF FGGFDUT PG EGRIFTAÂŽ 'PS NPSF JOGPSNBUJPO BTL ZPVS healthcare provider or pharmacist. $BMM ZPVS IFBMUIDBSF QSPWJEFS GPS NFEJDBM BEWJDF BCPVU TJEF FGGFDUT 5P SFQPSU TJEF FGGFDUT DPOUBDU &.% 4FSPOP UPMM GSFF BU FYU :PV NBZ SFQPSU TJEF FGGFDUT UP UIF '%" BU '%" Keep EGRIFTAÂŽ and all medicines out of the reach of children.

General information about the safe and effective use of EGRIFTAÂŽ: .FEJDJOFT BSF TPNFUJNFT QSFTDSJCFE GPS QVSQPTFT PUIFS UIBO UIPTF MJTUFE JO B 1BUJFOU *OGPSNBUJPO MFBĂĄFU %P OPU VTF EGRIFTAÂŽ for a condition for which it was not prescribed.

Do not give EGRIFTAÂŽ UP PUIFS QFPQMF FWFO JG UIFZ IBWF UIF TBNF TZNQUPNT ZPV IBWF It may harm them.

Do not share your EGRIFTAÂŽ TZSJOHF XJUI BOPUIFS QFSTPO FWFO JG UIF OFFEMF JT DIBOHFE Do not share your EGRIFTAÂŽ needles with another person.

5IJT 1BUJFOU *OGPSNBUJPO MFBĂĄFU TVNNBSJ[FT UIF NPTU JNQPSUBOU JOGPSNBUJPO BCPVU EGRIFTAÂŽ *G ZPV XPVME MJLF NPSF JOGPSNBUJPO UBML XJUI ZPVS IFBMUIDBSF QSPWJEFS :PV DBO BTL ZPVS IFBMUIDBSF QSPWJEFS PS QIBSNBDJTU GPS JOGPSNBUJPO BCPVU EGRIFTAÂŽ that is written for healthcare professionals.

For more information about EGRIFTAÂŽ HP UP XXX EGRIFTA.com or contact the "9*4 $FOUFS UPMM GSFF BU What are the ingredients in EGRIFTAÂŽ?

Active ingredient: tesamorelin *OBDUJWF JOHSFEJFOUT NBOOJUPM BOE 4UFSJMF 8BUFS GPS *OKFDUJPO

EMD Serono, Inc. is a subsidiary of Merck KGaA, Darmstadt, Germany

ÂĽ &.% 4FSPOP *OD "MM SJHIUT SFTFSWFE &(3*'5" JT B SFHJTUFSFE USBEFNBSL PG 5IFSBUFDIOPMPHJFT *OD

THE 2013 COMPLETE HIV TREATMENT GUIDE

=IGJF?G?HN;LS ;H> ;FN?LH;NCP? G?>C=CH? The use of whatโ s called complementary and alternative medicine (CAM) is popular in the U.S., where yoga and massage have become mainstream activities. In fact, according to a study published in the journal AIDS Care, 60% of HIV-positive people have tried some form of CAM, most in addition to their antiretrovirals. While some CAMs have demonstrated bene๏ฌ ts, others are unproven and sometimes dangerous.

TREATMENT

WORTH IT?

ACUPUNCTURE

I5C

CHINESE BITTER MELON

=1I25

WHAT IT DOES

CdeTYUc XQfU cX_g^ Yd bUTeSUc ci]`d_]c _V 89F Q^T cYTU UรงUSdc _V ]UTYSQdY_^c Y^S\eTY^W VQdYWeU `QY^ XUQTQSXU V_bWUdVe\^Ucc Q^T ^QecUQ BUcUQbSXUbc V_e^T dg_ `b_dUY^c Y^ RYddUb ]U\_^ dXQd Y^XYRYd 89F Y^ \QR_bQd_bi dUcdc* =1@ # Q^T ]_]_bSXQbY^ 2ed ^_ _^U [^_gc V_b cebU YV dXUbUยบc Q^i S\Y^YSQ\ ecUVe\^Ucc

COLLOIDAL SILVER

>?

DXU 641 T_Uc^ยบd S_^cYTUb Yd d_ RU cQVU 1]_^W Ydc ]Q^i cYTU UรงUSdc Yc QbWibYQ Q^ YbbUfUbcYR\U R\eYcX TYcS_\_bQdY_^ _V dXU c[Y^

MANGANESE

>?

CSYU^dYcdc XQfU TYcS_fUbUT dXQd Y^SbUQcY^W ]Q^WQ^UcU Y^ SU\\c SQ^ TUSbUQcU 89Fยบc QRY\Ydi d_ bU`\YSQdU Red dXUbUยบc ^_ UfYTU^SU dXQd TYUdQbi ]Q^WQ^UcU XQc Q^i UรงUSd _^ 89F

MASSAGE

I5C

=QccQWU Yc Q S_]`\Y]U^dQbi ]UTYSY^U dXQd QSS_bTY^W d_ dXU =Qi_ 3\Y^YS bUTeSUc Q^hYUdi Q^T `QY^ \_gUbc R\__T `bUccebU bU\UQcUc U^T_b`XY^c Y]`b_fUc R\__T SYbSe\QdY_^ Q^T R__cdc Y]]e^Ydi

MULTIVITAMINS

I5C

?^U cdeTi V_e^T dXQd ]e\dYfYdQ]Y^c bUTeSUT 89F `_cYdYfU g_]U^ยบc bYc[ _V 194C Q^T TUQdX Ri #

PRAYER

=1I25

9V i_e QbU Q RU\YUfUb dXUbUยบc Q]`\U UfYTU^SU dXQd `bQiUb _รงUbc Q `_cYdYfU Y^dUb`Ubc_^Q\ S_`Y^W ]USXQ^Yc] Q^T ]Qi RU Qc RU^Uร SYQ\ Y^ XU\`Y^W i_e S_`U gYdX YV ^_d U\Y]Y^QdU ci]`d_]c

REFLEXOLOGY

=1I25

1 cdeTi Y^ DXQY\Q^T V_e^T dXQd V__d bUร Uh_\_Wi bUTeSUT `QY^ Q^T VQdYWeU Y^ X_c`YdQ\YjUT 194C `QdYU^dc

REIKI

>?

=Q^i `QbdYSY`Q^dc VUU\ RUddUb QVdUb dXYc U^UbWi dXUbQ`i Red dXUbUยบc ^_ cSYU^dYร S `b__V Yd g_b[c

SELENIUM

I5C

1 cdeTi Y^ dXU 1bSXYfUc _V 9^dUb^Q\ =UTYSY^U V_e^T dXQd cU\U^Ye] Y^SbUQcUT XUQ\dXi 34$ SU\\c Q^T bUTeSUT dXU Q]_e^d _V 89F Y^ dXU R\__T

SPIRULINA

I5C

DXU XUQ\dX RU^Uร dc _V c`Ybe\Y^Q Q\c_ [^_g^ Qc R\eU WbUU^ Q\WQU XQfU RUU^ d_edUT V_b iUQbc RUSQecU Yd ^QdebQ\\i Y^S\eTUc ^e]Ub_ec fYdQ]Y^c ?^U cdeTi Y^ dXU :_eb^Q\ _V 1SaeYbUT 9]]e^U 4Uร SYU^Si Ci^Tb_]Uc V_e^T dXQd dXU Q\WQU ce``\U]U^d Y^XYRYdUT 89F bU`\YSQdY_^ Y^ dXU R\__T 1 `Ub[* 9dยบc c_\T Y^ Q `_gTUb dXQd SQ^ UQcY\i RU QTTUT d_ c]__dXYUc

VITAMIN A

=1I25

DXU G8? bUS_]]U^Tc fYdQ]Y^ 1 UfUbi V_eb d_ cYh ]_^dXc V_b Q\\ i_e^W SXY\TbU^ Qd XYWX bYc[ _V TUร SYU^Si Red ^_ cdeTi Y^ dXU E C XQc cX_g^ Yd RU^Uร SYQ\ d_ 89F QTe\dc

YOGA

I5C

>e]Ub_ec cdeTYUc cX_g Yd XQc Q `_cYdYfU `XicY_\_WYSQ\ UรงUSd Q^T XU\`c Q\\UfYQdU ci]`d_]c _V 89F

ZINC

I5C

JY^S TUร SYU^Si _SSebc Y^ _fUb % _V 89F QTe\dc+ cdeTYUc cX_g dXQd jY^S TU\Qic Y]]e^_\_WYSQ\ VQY\ebU Q^T TUSbUQcUc TYQbbXUQ

never take these supplements without doctorโ s approval: sutherlandia, saint-johnโ s-wort, grapefruit, african potato, vitamin c, and garlic.

J U LY/A U G U S T 2 0 1 3 ย HIV plus

41

; MN;N?'<S'MN;N? AOC>? NI NB? ;C>M >LOA ;MMCMN;H=? JLIAL;G ";>;J# Don’t have deep pockets? The federally created, state-managed AIDS Drug Assistance Program (ADAP) can help people pay for their HIV medications.

The programs provide prescription medication to uninsured or underinsured people with HIV or AIDS. The requirements vary by state, but typically you have to be a resident, have HIV, and earn less than a certain amount per year, calculated as a percentage of the federal poverty level.

Below is a guide to ADAP income requirements, whether there is a waiting list to join, how many people are on it as of April (if available), and contact information. Each state’s Maximum Qualifying Income (MQI) to be in ADAP is shown as a percentage of the federal poverty level as well as the dollar amount for a one-person household (in the 48 contiguous states the federal poverty level for one person is $11,490; add $4,020 per family member).

ALABAMA GURcYdU* adph.org/aids @X_^U* (334) 206-5364 =A9* 250% or $28,725; GQYdY^W <Ycd* Yes, 27

IDAHO

ALASKA

ILLINOIS

GURcYdU* bit.ly/AKadap

(907) 263-2050 =A9* 300% or $43,050; GQYdY^W <Ycd* No

GURcYdU* bit.ly/illinoisADAP @X_^U* (217) 524-5983 =A9* 300% or $34,470; GQYdY^W <Ycd* No

ARIZONA

INDIANA

GURcYdU* bit.ly/AZadap @X_^U* (800) 334-1540 =A9* 300% or $34,470; GQYdY^W <Ycd* No

GURcYdU* bit.ly/indianaADAP @X_^U* (866) 588-4948 =A9* 300% or $34,470; GQYdY^W <Ycd* No

ARKANSAS GURcYdU* bit.ly/ARadap @X_^U* (501) 661-2408 =A9* 200% or $22,980; GQYdY^W <Ycd* Yes

IOWA

CALIFORNIA GURcYdU* bit.ly/CAadap @X_^U* (916) 449-5900 =A9* less than $50,000; GQYdY^W <Ycd* No

KANSAS

COLORADO GURcYdU* bit.ly/COadap @X_^U* (303) 692-2748 =A9* 400% or $45,960; GQYdY^W <Ycd* No

KENTUCKY GURcYdU* bit.ly/kentuckyADAP @X_^U* (866) 510-0005 =A9* 300% or $34,470; GQYdY^W <Ycd* No

CONNECTICUT GURcYdU* bit.ly/CTadap @X_^U* (800) 233-2503 =A9* 400% or $45,960; GQYdY^W <Ycd* No

LOUISIANA GURcYdU* hiv.dhh.louisiana.gov @X_^U* (504) 568-7474 =A9* 300% or $34,470; GQYdY^W <Ycd* Yes

DELAWARE GURcYdU* bit.ly/DEadap @X_^U* (302) 744-1050 =A9* 500% or $57,450; GQYdY^W <Ycd* No

MAINE

DISTRICT OF COLUMBIA GURcYdU* bit.ly/DCadap @X_^U* (202) 671-4900 =A9* 500% or $57,450; GQYdY^W <Ycd* No

MARYLAND GURcYdU* bit.ly/MDadap @X_^U* (800) 205-6308 =A9* 500% or $57,450; GQYdY^W <Ycd* No

FLORIDA

MASSACHUSETTS GURcYdU* bit.ly/MAadap @X_^U* (800) 228-2714 =A9* 500% or $57,450; GQYdY^W <Ycd* No

GURcYdU* floridaADAP.org @X_^U* (800) 352-2437 =A9* 400% or $45,960; GQYdY^W <Ycd* Yes, 22 GEORGIA

GURcYdU* bit.ly/georgiaADAP @X_^U* (404) 657-3100 =A9* 300% or $34,470; GQYdY^W <Ycd* No HAWAII

GURcYdU* bit.ly/hawaiiADAP @X_^U* (808) 733-9360 =A9* 400% or $52,920; GQYdY^W <Ycd* No

42

HIV plus

J U LY/A U G U S T 2 0 1 3

GURcYdU* safesex.idaho.gov @X_^U* (208) 334-6527 =A9* 200% or $22,980; GQYdY^W <Ycd* Yes, 14

GURcYdU* bit.ly/iowaADAP @X_^U* (515) 281-4775 =A9* 200% or $22,980; GQYdY^W <Ycd* No GURcYdU* bit.ly/kansasADAP @X_^U* (785) 368-8218 =A9* 300% or $34,470; GQYdY^W <Ycd* No

GURcYdU* bit.ly/MEadap @X_^U* (207) 287-3747 =A9* $55,850, add $3,960 per dependent; GQYdY^W <Ycd* No

MICHIGAN GURcYdU* michigan.gov/dap @X_^U* (888) 826-6565 =A9* 450% or $51,705; GQYdY^W <Ycd* No MINNESOTA GURcYdU* bit.ly/minnesotaADAP @X_^U* (800) 657-3761 =A9* 300% or $34,470; GQYdY^W <Ycd* No

THE 2013 COMPLETE HIV TREATMENT GUIDE MISSISSIPPI GURcYdU* bit.ly/mississippiADAP @X_^U* (601) 362-4356 =A9* 400% or $45,960; GQYdY^W <Ycd* No

PENNSYLVANIA

MISSOURI GURcYdU* bit.ly/missouriADAP @X_^U* (573) 751-6439 =A9* 300% or $34,470; GQYdY^W <Ycd* No

RHODE ISLAND GURcYdU* bit.ly/RIadap @X_^U* (401) 222-2320 =A9* 400% or $45,960; GQYdY^W <Ycd* No

MONTANA GURcYdU* bit.ly/montanaADAP @X_^U* (406) 444-4744 =A9* 330% or $37,917; GQYdY^W <Ycd* No

SOUTH CAROLINA GURcYdU* scdhec.gov/adap @X_^U* (803) 831-7806 =A9* 300% or $34,470; GQYdY^W <Ycd* No

NEBRASKA GURcYdU* bit.ly/NEadap @X_^U* (402) 559-4673 =A9* 200% or $22,980; GQYdY^W <Ycd* No

SOUTH DAKOTA GURcYdU* bit.ly/SDadap @X_^U* (605) 773-3737 =A9* 300% or $34,470; GQYdY^W <Ycd* No

NEVADA

TENNESSEE GURcYdU* bit.ly/TNadap @X_^U* (615) 532-2392 =A9* 300% or $34,470; GQYdY^W <Ycd* No

GURcYdU* bit.ly/nevadaADAP @X_^U* (775) 684-3499 =A9* 400% or $45,960; GQYdY^W <Ycd* No

GURcYdU* bit.ly/PennADAP @X_^U* (800) 922-9384 =A9* 337% or $38,721; GQYdY^W <Ycd* No

NEW HAMPSHIRE GURcYdU* bit.ly/NHadap @X_^U* (603) 271-4502 =A9* 500% or $57,450; GQYdY^W <Ycd* No

TEXAS

NEW JERSEY GURcYdU* bit.ly/newjerseyADAP @X_^U* (877) 613-4533 =A9* 500% or $57,450; GQYdY^W <Ycd* No

UTAH

NEW MEXICO GURcYdU* bit.ly/newmexicoADAP @X_^U* (505) 827-2433 =A9* 400% or $45,960; GQYdY^W <Ycd* No

VERMONT

NEW YORK GURcYdU* bit.ly/newyorkADAP @X_^U* (800) 542-2437 =A9* 435% or $49,981; GQYdY^W <Ycd* No

VIRGINIA

NORTH CAROLINA GURcYdU* bit.ly/NCadap @X_^U* (877) 466-2232 =A9* 300% or $34,470; GQYdY^W <Ycd* No

WASHINGTON GURcYdU* bit.ly/WAadap @X_^U* (360) 236-3426 =A9* 300% or $34,470; GQYdY^W <Ycd* No

NORTH DAKOTA GURcYdU* ndhealth.gov/HIV @X_^U* (701) 328-1059 =A9* 300% or $34,470; GQYdY^W <Ycd* No

WEST VIRGINIA GURcYdU* bit.ly/WestVAADAP @X_^U* (304) 232-6822 =A9* 400% or $45,960; GQYdY^W <Ycd* No

OHIO

GURcYdU* bit.ly/OHadap @X_^U* (866) 777-4775 =A9* 300% or $34,470; GQYdY^W <Ycd* No

WISCONSIN GURcYdU* bit.ly/WIadap @X_^U* (800) 991-5532 =A9* 300% or $34,470; GQYdY^W <Ycd* No

OKLAHOMA GURcYdU* bit.ly/OKADAP @X_^U* (405) 271-4636 =A9* 200% or $22,980; GQYdY^W <Ycd* No

WYOMING GURcYdU* bit.ly/WYadap @X_^U* (307) 777-5856 =A9* $38,300-$45,500, based on county; GQYdY^W <Ycd* No

GURcYdU* bit.ly/texasADAP @X_^U* (800) 255-1090 =A9* 200% or $22,980; GQYdY^W <Ycd* No GURcYdU* bit.ly/utahADAP @X_^U* (801) 538-6197 =A9* 250% or $28,725; GQYdY^W <Ycd* No GURcYdU* bit.ly/vermontADAP @X_^U* (802) 951-4005 =A9* 500% or $57,540; GQYdY^W <Ycd* No GURcYdU* bit.ly/virginiaADAP @X_^U* (866) 392-1309 =A9* 400% or $45,960; GQYdY^W <Ycd* No

OREGON

GURcYdU* bit.ly/oregonADAP @X_^U* (800) 805-2313 =A9* 200% or $22,980; GQYdY^W <Ycd* No

.1.= NY`\ P\cR_` =bR_a\ ?VP\ 4bNZ aUR CV_TV[ 6`YN[Q` N[Q =NPVยบP 6`YN[Q AR__Va\_VR` CV`Va Uaa]' OVa Yf .1.=SNPa` S\_ Z\_R V[S\_ZNaV\[

J U LY/A U G U S T 2 0 1 3 ย HIV plus

43

A H C N H ?

G O >I= L ?

G ; L =

?

H >O;

The famed HIV-positive photographer has shot celebrities, dignitaries, and everyday people. Now heâ&#x20AC;&#x2122;s back with a family history project and a new campaign to change how we deal with the chronic condition

By Diane Anderson-Minshall

E

ong before he died, 4eQ^U 3bQ]UbÂşc VQdXUb dQ`UT Q ^_dU d_ dXU gQ\\ gXYSX bUQT ¡Ae_^T ^_^ Ucd Y^ \YRb_ ^_^ Ucd Y^ ]_^T_¸ ¡GXQd Yc ^_d T_Se]U^dUT T_Uc ^_d UhYcd¸ :_U : 3bQ]Ub gQc Q dbQY\R\QjUb Q R\QS[ @X 4 Y^ dXU_bUdYSQ\ QSS_e^dY^W gX_ cUbfUT Qc Q^ Qcc_SYQdU TUQ^ Qd 8_gQbT E^YfUbcYdi 8U Q\c_ TYUT _V 194C S_]`\YSQdY_^c Y^ !)(& Q cX_S[ d_ 3bQ]UbÂşc U^dYbU VQ]Y\i ¡=_cd _V dXU Y]QWUc Qb_e^T dXU e^^Q]UT TYcUQcUÂśYd gQc \QdUb SQ\\UT dXU WQi `\QWeUÂśgUbU _V gXYdU WQi ]U^ ¸ dXU i_e^WUb 3bQ]Ub bUSQ\\c ¡?eb VQdXUb TYT ^_d Ă&#x201A;d dXU cdUbU_di`U _V dXU `U_`\UÂŻcX_g^ Y^ dXU ]UTYQ 9^YdYQ\\i gU d_\T `U_`\U dXQd XU TYUT _V SQ^SUb RUSQecU _V dXU cXQ]U Q^T WeY\d >_g dXU g_b\T [^_gc dXQd R\QS[ Q^T Rb_g^ `U_`\U gUbU Qc TYc`b_`_bdY_^QdU\i QçUSdUT Q^T Y^VUSdUT Ri dXU 194C fYbec Vb_] dXU UQb\YUcd TQicÂśY^ dXU EC1 Q^T W\_RQ\\iÂśZecd Qc gU S_^dY^eU d_ RU d_TQi 8_gUfUb dXU ]UTYQ SX_cU d_ V_Sec _^ dXU gXYdU WQi S_]]e^Ydi ¸ 3bQ]Ub ^_g % gQc QçUSdUT R_dX Ri dXU TUQdX _V XYc VQdXUbÂśQ ]Q^ XU cdY\\ SQ\\c XYc RUcd VbYU^TÂśQ^T Ri dXQd dY^i ^_dU dQ`UT d_ dXU gQ\\ gYdX Q `XbQcU dXQd XQc cXQ`UT XYc \YVU SQbUUb Q^T QSdYfYc] 1VdUb cdY^dc Qc Q^ UhUSedYfU Qd HUb_h Q^T Q ]Qb[UdY^W Webe 3bQ]Ub RUSQ]U Q g_b\T bU^_g^UT `X_d_WbQ`XUb gX_cU g_b[ XQc Q``UQbUT Y^ `eR\Y SQdY_^c Qc TYfUbcU Qc CVOR AUR ;Rd F\_X AVZR` Q^T 5N_]R_Âł` /NgNN_ 8UÂşc `X_d_WbQ`XUT SU\URbYdYUc U\TUb cdQdUc]U^ Q^T UfU^ dbYRQ\ S_] ]e^YdYUc Y^ 1VbYSQ 2ed YdÂşc dXU Ă&#x201A;WXd QWQY^cd 89F Q^T 194C dXQd 3bQ] Ub XQc T_Se]U^dUT RUcd WYfY^W f_YSU d_ 89F `_cYdYfU `U_`\U Qb_e^T dXU W\_RU Y^S\eTY^W $ 194C QçUSdUT SXY\TbU^ Y^ >Q[ebe ;U^iQ gX_ \QdUb ^Q]UT Q cSX__\ dXU 4eQ^U 3bQ]Ub 1SQTU]i V_b XY] 5hQSd\i ! iUQbc QVdUb XYc VQdXUbÂşc TUQdX 3bQ]Ub dXU^ #$ V_e^T _ed XU d__ gQc 89F `_cYdYfU 8U d_\T XYc V_b]Ub `Qbd^Ub Q^T XYc cYc dUbc Red XU gQYdUT Q iUQb d_ dU\\ XYc ]_dXUb 2UUTYU 2bQj_c 3bQ]Ub Q S_^fUbcQdY_^ dXQdÂşc T_Se]U^dUT Y^ dXU cX_bd Ă&#x201A;\] ARYY :R directed by Veronica Deliz, Q `Qbd _V dXU 89F Cd_bi @b_ZUSd ¡9d gQc S\UQb dXU _^\i gQi gUÂşbU W_Y^W d_ cd_` dXYc TYcUQcU Yc d_ dQ\[ QR_ed Yd Q^T dXU _^\i gQi 9 gQc W_Y^W d_ RU QR\U d_ Ve\\i Y^dUbQSd gYdX ]i VQ]Y\i gQc d_ RU X_^Ucd ¸ XU cQic ¡c_ dXQd dXUi S_e\T S_^dY^eU d_ ce``_bd Q^T \_fU ]U Qc dXUi Q\gQic XQT T_^U ¸ 2bQj_c 3bQ]Ub cQic cXU gYcXUc XUb c_^ XQT cXQbUT XYc cdQdec gYdX XUb UQb\YUb c_ cXU S_e\T ce``_bd XY] ¡2i ^_d cXQbY^W KXUM ]YccUT _ed ¸ cXU cQic 3bQ]Ub cQic XU gQc S_^SUb^UT QR_ed XYc ]_dXUbÂşc bUQSdY_^* ¡CXU \_cd XUb V_b]Ub XecRQ^T d_ 194C 9 gQc VUQbVe\ dXQd cXU g_e\T RU Previous page, clockwise from top left: Cramerâ&#x20AC;&#x2122;s photographs of Marjorie Hill, CEO of Gay Menâ&#x20AC;&#x2122;s Health Crisis; Congresswoman Maxine Waters; the AIDS Quilt; CSI: New York star Hill Harper; actors Samuel L. Jackson and Rockmond Dunbar.

Right: Cramer, photographed by Stephen Churchill Downes, is the celebrity grand marshal of San Franciscoâ&#x20AC;&#x2122;s LGBT Pride celebration this year.

J U LY/A U G U S T 2 0 1 3 Â&#x17E; HIV plus

45

QVbQYT _V \_cY^W ]U c_ 9 gQc dbi Y^W d_ `b_dUSd XUb DXU dbedX gQc dXQd 9 gQc TU^iY^W ]icU\V Q ]_dXUbºc \_fU =i QTfYSU d_ _dXUbc gX_ XQfU 89F _b _dXUb `_dU^dYQ\ SXQ\\U^WUc Y^ \YVU KYcM d_ cXQbU gYdX dX_cU Y^ i_eb VQ] Y\i¶RY_\_WYSQ\ Q^T _dXUbgYcU¶ gX_ i_e SQ^ RU QedXU^dYS fe\ ^UbQR\U Q^T cXQbU i_eb dbedX >_ _^U ^UUTc d_ RU Q\_^U Q^T dXUbU QbU Q ]e\dYdeTU _V gQic d_ WUd dXU ce``_bd dXQd Yc ^UUTUT I_e QbU ^_d Q\_^U ¸ 9V XU c_e^Tc \Y[U dXU 89F `_cYdYfU fUbcY_^ _V >Y[Uºc :ecd 4_ 9d SQ]`QYW^ Ydºc RUSQecU 3bQ]Ub Yc Q ]Y^Yµ`eR\YS cUbfYSU SQ]`QYW^ e^d_ XY]cU\V 8U `bUc U^dc Qd S_^VUbU^SUc \Y[U 2_\TUb DXQ^ ?ed Q SXQ^WU QWU^d V_b dXU <72D R\QS[ S_]]e^Ydi cXQbUc XYc g_b[ Qd UfU^dc QY]UT Qd R\QS[ WQi Q^T RY ]U^ 43 2\QS[ @bYTU 8_ecd_^ C`\QcX XQc cUbfUT _^ dXU R_QbTc _V TYbUSd_bc V_b ]Q^i WQi Q^T 89F Wb_e`c >Q]Uc @b_ZUSd 194C =U]_bYQ\ AeY\d dXU 6bQ]U\Y^U Â\] VUcdYfQ\ Y^ CQ^ 6bQ^SYcS_ S_V_e^TUT CQ^ 6bQ^SYcS_ºc Âbcd <72D S_]]e ^Ydi SU^dUb S_SXQYbUT dXU =Y\ \U^^Ye] =QbSX _^ GQcXY^Wd_^ V_b 5aeQ\Ydi Q^T f_\e^dUUbc gYdX dXU 2\QS[ 194C 9^cdYdedU 9V Q\\ dXQd TYT^ºd [UU` XY] Reci U^_eWX 3bQ]Ub XQc Q\c_ RUU^ Y^f_\fUT Y^ cUfUbQ\ 89F SQ]`QYW^c c_]UdY]Uc RUXY^T dXU SQ]UbQ c_]UdY]Uc Y^ Vb_^d 3bQ]Ub g_b[UT gYdX dXU 7bUQdUb DXQ^ 194C SQ]`QYW^ Q^T XU cX_d dXU ]_cd bUSU^d QTc V_b dXU 343ºc DUcdY^W =Q[Uc Ec Cdb_^WUb SQ]`QYW^ 8Yc SebbU^d SQ]`QYW^ gYdX =UbS[ SQ\\UT 9 4UcYW^ @b_ZUSd94UcYW^ S_] Y^ S_\\QR_bQdY_^ gYdX @b_ZUSd Be^gQi cdQb =_^T_ 7eUbbQ U^S_ebQWUc 89FUbc d_ g_b[ gYdX dXUYb T_Sd_bc _^ Q dQY\_bUT dbUQd ]U^d bUWY]U^ 9 4UcYW^ XU cQic Yc QR_ed U]`_gUbY^W `U_`\U \YfY^W gYdX 89F d_ Q``b_QSX dXUYb dbUQd ]U^d ·dXb_eWX dXUYb _g^ \U^c 9 4UcYW^ U^S_ebQWUc KÂ^TY^WM SbUQdYfU _ed\Udc V_b TYcSeccY^W 89F Q^T V_b ]U Yd Yc dXb_eWX ]i `X_d_WbQ`Xi ¸ 3bQ]Ub Uh`\QY^c ·DXU SQ]`QYW^ `b_fYTUc Y^dUb

46

HIV plus

J U LY/A U G U S T 2 0 1 3

QSdYfU TYWYdQ\ d__\c dXQd XU\` `b_]_dU QSdYfU S_^fUbcQdY_^c Y^S\eTY^W dXU =i 8UQ\dX =Qd dUbc TYWYdQ\ Q`` Q^T =i @_cY dYfU 1WU^TQ ]_RY\U Q`` DXUcU Q``c XU\` i_e [UU` dbQS[ _V i_eb ci]`d_]c Q^T ]__T Q^T bU]Y^T i_e gXU^ Yd Yc dY]U d_ dQ[U i_eb ]UTYSQdY_^c DXUbU Yc Q\c_ Q S_^fUbcQdY_^ SXUS[\Ycd gXYSX XU\`c WeYTU i_eb S_^fUb cQdY_^ _^ Y]`_bdQ^d d_`YSc \Y[U fYbQ\ \_QT 34$ SU\\ S_e^d cYTU UçUSdc Q^T _dXUb XUQ\dX S_^ SUb^c ceSX Qc SX_\UcdUb_\ ¸ 7UddY^W _dXUb 89F `_cYdYfU 1VbYSQ^ 1]UbYSQ^c d_ cdQi XUQ\dXi gXY\U Q\c_ bUTeSY^W cdYW]Q Yc Q XUQTi dQc[ Red 3bQ ]Ub X_`Uc XYc QSdYfYc] XU\`c ·9 WbUg e` Y^ Q VQ]Y\i dXQd gQc Y^Y dYQ\\i VbYWXdU^UT Q^T QcXQ]UT _V 89F cY]`\i RUSQecU dXUbU gQc ^_d Q \_d _V Y^V_b]QdY_^ QR_ed dXU fYbec Y^ dXU º( c ¸ XU cQic ·9^ dXU !)) c gXU^ 9 V_e^T _ed 9 gQc 89F `_cYdYfU dXU 1VbY SQ^ 1]UbYSQ^ S_]]e^Ydi cdY\\ gQc^ºd dQ\[Y^W ]eSX QR_ed dXU TYcUQcU D_TQi dXU R\QS[ S_] ]e^Ydi S_^dY^eUc d_ RU TYc`b_ `_bdY_^QdU\i QçUSdUT Ri 89F Q^T dXUbU Yc Q WbUQd TUQ\ ]_bU S_^fUbcQdY_^ ]_RY\YjQdY_^ Q^T UTeSQdY_^ CY^SU 9 [^_g Âbcd XQ^T dXU Y]`QSd 89F XQc Y^ dXYc `_`e\QdY_^ 9 gQ^d d_ U^S_ebQWU _dXUbc d_ RU _`U^ Q^T X_^Ucd ^_d

_^\i gYdX dXUYb \_fUT _^Uc Q^T cUheQ\ `Qbd^Ubc Red Q\c_ gXU^ TYcSeccY^W X_g d_ RUcd ]Q^QWU dXUYb `Ubc_^Q\ dbUQd]U^d `\Q^ gYdX dXUYb T_Sd_bc ¸ 3bQ]Ub Q\c_ S_]]U^Tc dXU ]Q^i 89F ]Y^YcdbYUc dXQd UhYcd \Y[U dXU 2Q\] Y^ 7Y\UQT gXYSX V_SecUc _^ _edbUQSX gYdX VQYdX RQcUT Y^cdYdedY_^c Q^T dXU c`YbY deQ\ S_]]e^Ydi 8U RU\YUfUc cdYW]Q Yc SXQ^WY^W ^_g dXQd `U_`\U gYdX 89F QbU \YfY^W \_^ WUb ·9 RU\YUfU dXU ]_bU UTeSQdUT `U_`\U QbU dXU \Ucc VUQbVe\ dXUi RUS_]U ¸ XU Y^cYcdc ·DXUbU XQfU Q\c_ RUU^ c_]U ^_dQR\U `U_`\U gX_ XQfU S_]U _ed QR_ed dXUYb cdQdec Y^ dXU `eR\YS UiU¯Q^T Ri Xe]Q^YjY^W dXU TYcUQcU Q^T cUU Y^W UfUbiTQi `U_`\U gX_ Yd SQ^ XQ``U^ d_ \UQT XUQ\dXi `b_TeS dYfU \YfUc dXU^ ]Q[Uc Yd \Ucc cSQbi Q^T ]_bU U]`_gUbY^W ¸ 2ed gXQd _V dXU SbYdYSYc] dXQd `_`e\Qb Se\debU \Y[U dXU Â\]c _V Di\Ub @Ubbi cdY\\ `bUcU^dc 89F Qc Q `e^YcX]U^d/ ·Di\Ub @Ubbi Yc Q^ Y^SbUTYR\i Y^dU\\YWU^d SbUQdYfU Q^T Y^c`YbY^W ]Q^ SbUTYdUT gYdX ]Q^i Q]QjY^W `b_ZUSdc dXQd UTe SQdU U^dUbdQY^ Q^T U^\YWXdU^ `U_`\U ¸ 3bQ]Ub cQic ·GXY\U 9 ]Qi ^_d e^TUbcdQ^T _b ^USUccQb Y\i QWbUU¯gYdX UQSX QbdYcdºc `bU cU^dQdY_^ 9 Q\c_ T_ ^_d `b_S\QY] d_ [^_g XYc Y^dU^dY_^c 1^T T_^ºd dXY^[ gU cX_e\T aeYS[\i

S_]U d_ S_^S\ecY_^c QR_ed gXQd Q^ QbdYcd Yc QddU]`dY^W d_ S_^fUi 9 T_^ºd RU\YUfU dXQd ]i VQdXUbºc TUQdX d_ 194C bU\QdUT S_]`\YSQ dY_^c _b ]i _g^ cUb_S_^fUbcY_^ RUS_]Y^W 89F `_cYdYfU gQc _b QbU `e^YcX]U^d 9 T_ [^_g dXQd ]Q^i g_]U^ Q^T ]U^¶R_dX XUdUb_cUheQ\ _b X_]_cUheQ\¶ gX_ XQfU cUh _edcYTU _V Q dbe\i S_]]YddUT ]_^_WQ]_ec bU\Q dY_^cXY` XQfU S_^dbQSdUT 89F Q^T _dXUb CD4c 9d Yc Q cY]`\U VQSd _V \YVU GXQd gU T_ Yc \UQb^ Vb_] dXU Uh`UbYU^SU Q^T `b_dUSd _ebcU\fUc Q^T _dXUbc Qc gU \YfU UQSX TQi <YVU Yc _VdU^ Q cUbYUc _V SX_YSUc Q^T S_^cUaeU^SUc ¸ 1^T gXY\U dXU cY\fUb cSbUU^ XQc iUd d_ cX_g UfUbiTQi `U_`\U gYdX 89F Y^ _bTY^Qbi SYbSe] cdQ^SUc 3bQ]Ub Yc aeYS[ d_ `_Y^d _ed dXQd dXYc Yc^ºd Q R\QS[ YcceU ·GU cUU dXUcU ]UccQWUc Y^ ]Q^i S_]]e^YdYUc ^_d _^\i dXU 1VbYSQ^ 1]UbYSQ^ ¸ XU ^_dUc ·6_bde^QdU\i gU XQfU `b_TeS Ubc gbYdUbc TYbUSd_bc Y^ 8_\ \ig__T R_dX R\QS[ Q^T gXYdU \Y[U @QdbY[ 9Q^ @_\[ KAUR @XV[[f ;\NU³` ._PM Q^T : bW 6_S[U\U KdXU 89F Cd_bi @b_ZUSd >bRR_ 2fRM dXQd T_ cX_g 89F `_cYdYfU g_]U^ Q^T ]U^ Y^ QedXU^dYS Q^T Xe]Q^U gQic ¸ 6_b XYc `Qbd 3bQ]Ub Yc Reci S_^dY^eY^W d_ TYfUbcYVi XYc SbU QdYfU U^TUQf_bc 9^ QTTYdY_^ d_

From left: Cramer with model Helena Christensen; Cramerโ s greatgrandparents Alonzo Cramer and Martha Collins and their two children circa 1890; Edsel M. Cramer, a noted artist who took many of the images in Cramerโ s upcoming book, was also commissioned by luminaries like President George H.W. Bush.

XYc QSdYfYc] Q^T `X_d_WbQ`Xi XUยบc Q\c_ TYbUSdUT ]ecYS fYTU_c V_b 7bQ]]i gY^^Y^W QbdYcdc ceSX Qc CQbQX 4QcX _V <QRU\\U VQ]U Q^T CYb 1bY 7_\T Q^T XUยบ\\ Q``UQb _^ A_baU /R A\YQ dXU ^Ug DF cUbYUc T_Se]U^dY^W dXU \YfUc _V aeUUb R\QS[ fYcY_^Qb YUc 8Uยบc S_\\QR_bQdY^W gYdX \Yd UbQdebU `b_VUcc_b >YWU\ 4U :eQ^ 8Qdd_^ Q VU\\_g Qd dXU G 5 2 4e 2_Yc 9^cdYdedU V_b 1VbYSQ^ Q^T 1VbYSQ^ 1]UbYSQ^ BUcUQbSX Qd 8QbfQbT E^YfUbcYdi _^ Q `X_ d_ dUhd R__[ AUR 6Z]\_aN[PR \S /RV[T 5bZN[ dXQd U]`XQcYjUc dXU ci^SXb_^YSYdi _V RUY^W Xe]Q^ Q^T RUY^W R\QS[ 2ed XYc `QccY_^ `b_ZUSd Yc UfU^ S\_cUb d_ X_]U* Q S_\\US dY_^ _V XYcd_bYS Y]QWUc _V 1VbY SQ^ 1]UbYSQ^c TQdY^W RQS[ d_ dXU !( c Y^S\eTY^W ]Q^i _V XYc VQ]Y\i ]U]RUbc C_]U _V dXU `X_d_WbQ`Xc QbU Q\bUQTi QbSXYfUT Qd CQ^ 6bQ^SYcS_ยบc 1VbY SQ^ 1]UbYSQ^ 1bd Q^T 3e\debU 3_]`\Uh gXYSX X_ecUc dXU \QbW Ucd Y^cdYdedY_^Q\ S_\\USdY_^ _V XYc g_b[ Red dXYc R__[ gY\\ RU UfU^ ]_bU Uh`Q^cYfU ยท6Q]Y\i Q^T XYcd_bi QbU _V ed]_cd Y]`_bdQ^SU d_ ]U ยธ 3bQ]Ub cQic DXU S_\\USdY_^c _V Y]QWUc `X_d_WbQ`Xc Q^T `QY^dY^Wc QbU `bY]QbY\i Vb_] dXU 3bQ]Ub 2bQj_c 6UQbc S\Q^ TQdY^W RQS[ d_ dXU UQb\i !( c

โ It was clear the only way weโ re going to stop this disease is to talk about it, and the only way I was going to be able to fully interact with my family was to be open and honest so that they could continue to support and love me as they always had done.โ dXQd dXU QbdYcd VUU\c S_]`U\\UT d_ cXQbU gYdX dXU g_b\T ยท6_b KR\QS[M `U_`\U d_ cUU _ebcU\fUc QSSebQdU\i bUร USdUT Q^T ยนT_Se ]U^dUTยบ Yc SbeSYQ\ Y^ ReY\TY^W cU\V g_bdX Q^T UcdUU] S_^dY^e Y^W Q \UWQSi =eSX _V 1VbYSQ^ 1]UbYSQ^ KXYcd_biM XQc RUU^ \_cd @Qbd _V dXU ]YTT\U `Qc cQWU Q^T c\QfUbi gQc Y^dU^d _^ cU`QbQdY^W Q^T TUcdb_iY^W Se\debU Q^T VQ]Y\i DXUbUV_bU T_Se]U^dUT gbYddU^ Q^T fYceQ\ XYcd_bi Yc bQbU 9 Y^dU^T _^ S_^ dY^eY^W ]i `Qbd d_ `U\d dXQd Q^T `bUcUbfU Yd V_b `bUcU^d Q^T VedebU WU^UbQdY_^c ยธ @bUcUbfY^W XYcd_bi be^c Y^ 3bQ]Ubยบc VQ]Y\i 1 S_ecY^ =Qbi < :QS[c_^ 6UQbc XQc T_^U UhdU^cYfU WU^UQ\_Wi bUcUQbSX _^

dXU VQ]Y\i Q^T XYc U\TUcd e^S\U 5TcU\ = 3bQ]Ub d__[ ]Q^i _V dXU `X_d_c Q^T SbUQdUT _bYWY^Q\ `_bdbQYd `QY^dY^Wc DXU Y]QWUc QbU Q bU]Y^TUb _V dXU TYfUbcYdi _V Zecd _^U WYQ^d VQ]Y\i 6_b UhQ]`\U 3bQ]Ub Uh`\QY^c dXQd XYc \Qcd ^Q]U ยทS_]Uc Vb_] ]i WbUQd WbQ^TVQdXUb gX_ gQc dXU c_^ _V Q 7Ub]Q^ :UgYcX Y]]Y WbQ^d 9d Yc XQbT d_ RU\YUfU 9 S_]U Vb_] ceSX Q TYfUbcU Q^SUcdbi Red 9 XQfU `X_d_c _V XY] Q^T _dXUb VQ]Y\i ]U]RUbc Vb_] dXU !( c d_ cX_g Yd 6_bde^QdU\i 9 XQfU ^_d _^\i Y]QWUc _V bU\QdYfUc gX_ gUbU R_b^ Y^d_ c\QfUbi Red Q\c_ T_Se]U^dc Y^S\eTY^W S_`YUc _V TUUTc _V cQ\U dXQd SXb_^YS\U ]i Q^SUcd_bcยบ Z_eb^Ui ยธ DXYc XYcd_bi Zecd \Y[U dXU

Y]QWUc _V `U_`\U gYdX 89F Q^T Q\\YUc Y^ dXU cdbeWW\U QWQY^cd 194C QbU `Qbd _V 3bQ]Ubยบc cU\V Y]`_cUT bUc`_^cYRY\Ydi ยท9 XQfU RUU^ V_bde^QdU U^_eWX d_ dQ[U `X_d_c _V `b_]Y^U^d \UQTUbc Q^T UfUbiTQi XUb_Uc Y^ dXU ร WXd QWQY^cd 89F 9 RU\YUfU Y]QWUc \Y[U dXUcU SQ^ ]Q[U Q^ Y]`QSd Q^T cX_g Y^TYfYTeQ\c Y^ `_gUbVe\ cYdeQdY_^c QTf_SQdY^W SXQ^WU U^S_ebQWY^W _dXUbc d_ dQ[U `_cYdYfU QSdY_^c DXb_eWX ]i QSdYfYc] g_b[ 9 X_`U d_ XQfU Q^ Y]`QSd _^ _dXUbc \YfY^W gYdX 89F Q^T cUbfU Qc Q b_\U ]_TU\ d_ _dXUbc gX_ ]Qi RU W_Y^W dXb_eWX Q cY]Y\Qb cYdeQdY_^ ยฏ 9^ dXU cQ]U gQi dXQd 9 QTf_SQdU V_b ]i _g^ XUQ\dX 9 X_`U d_ RU QR\U d_ XU\` U]`_gUb `U_`\U \YfY^W gYdX 89F ยธ DX_eWX XU dXY^[c Ydยบc Q\gQic ยทY]`_bdQ^d d_ \__[ Qd dXY^Wc Vb_] Q^ _`dY]YcdYS `Ubc`US dYfU Q^T deb^ \U]_^c Y^d_ \U] _^QTU ยธ 3bQ]Ub SQ^ Y]QWY^U YV Q^dYbUdb_fYbQ\c XQT RUU^ QfQY\ QR\U # iUQbc QW_ XU ]YWXd cdY\\ XQfU XYc ยทRUcd VbYU^T ยธ XYc VQdXUb Ri XYc cYTU d_TQi ยท=i TQT XY] cU\V gQc Q^ UTeSQd_b Q^T S_] ]e^Ydi QSdYfYcd Q^T 9 Q] S_^ ร TU^d YV XU gUbU XUbU gU g_e\T RU bQYcY^W QgQbU^Ucc d_WUdXUb d_ XU\` U]`_gUb `U_`\U \YfY^W gYdX 89F ยธ 3bQ]Ub cQic 8Uยบc cebU\i SQbbYUT _ed XYc TQTยบc ]YccY_^ d_ T_Se]U^d dXU g_b\T gXY\U Qd dXU cQ]U dY]U RUS_]Y^W Q V_bSU _V SXQ^WU ยท9 T_^ยบd gQ^d Q^i_^U d_ RUS_]U 89F `_cYdYfU ยธ 3bQ ]Ub cQic ยท8_gUfUb V_b dX_cU \YfY^W gYdX dXU fYbec 9 U^S_eb QWU ec d_ RU fYSd_bc D_ UTeSQdU U]`_gUb Q^T e`\YVdยฏY^ _bTUb d_ `bUfU^d dXU c`bUQT _V dXU 194C fYbec Q^T e\dY]QdU\i RbY^W Q^ U^T d_ 194C ยธ 6_b ]_bU Y^V_ _^ 3bQ]Ubยบc g_b[ fYcYd 4eQ^U3bQ]Ub S_] _b DgYd dUb 04eQ^U3bQ]Ub 1\\ `X_d_c _^ dXYc `QWU S_ebdUci 4eQ^U 3bQ]Ub

J U LY/A U G U S T 2 0 1 3 ย HIV plus

47

MEDICATION

ETOPOPHOS Ud_`_cYTU 2bYcd_\ =iUbc CaeYRR

ZOVIRAX QSiS\_fYb 7\Qh_C]YdX;\Y^U

HEPSERA QTUV_fYb TY`Yf_hY\

DOSAGE

WHAT IT DOES

WHAT TO KNOW

SIDE EFFECTS

4_cQWUc fQbi V_b c]Q\\ SU\\ \e^W SQ^ SUb Q^T dUcdYSe\Qb SQ^SUb ecUT Y^ S_] RY^QdY_^ gYdX _dXUb SXU]_dXUbQ`UedYS QWU^dc

DbUQdc fQbY_ec di`Uc _V SQ^SUb+ RUY^W dUcd UT V_b dbUQd]U^d _V ^_^ 8_TW[Y^ºc \i] `X_]Q Q^T ;Q`_cYºc cQbS_]Q

8YWX T_cU SiS\_c`_bY^U Q^T TbeWc ceSX Qc \UfQ]Yc_\U XiTb_ SX\_b SQ^ SQecU Y^dUbQSdY_^c EcU _V Q \YfU fYbec fQSSY^U S_e\T RU S_]`\YSQdUT Ri gUQ[U^UT Y]]e^U ]USXQ^Yc]c 4_ ^_d TU\YfUb Ri R_\ec Y^dbQfU^_ec Y^ZUSdY_^

=_cd cUbY_ec* cUfUbU Q\\UbWYS bUQSdY_^ Q\_`USYQ XQYb \_cc SXY\\c _b VUfUb ^Qe cUQ S_^cdY`QdY_^ QRT_]Y^Q\ `QY^ ?dXUb* bQcX e^eceQ\ dYbUT^Ucc

4_cQWU fQbYUc TU`U^TY^W _^ di`U _V Y^VUSdY_^+ QfQY\QR\U Y^ SQ`ce\Uc dQR\Udc _bQ\ cec`U^cY_^ d_`YSQ\ SbUQ] Q^T Qc Y^dbQ fU^_ec Y^ZUSdQR\U

DbUQdc Q^T S_^db_\c XUb`Uc fYbQ\ Y^VUS dY_^c \Y[U cXY^W\Uc WU^YdQ\ gQbdc Q^T SXYS[U^ `_h

EcU gYdX SQedY_^ gYdX BUdb_fYb Q^dYVe^WQ\ QWU^dc 2U^U]YT Y^dUbVUb_^ Y^dbQdXUSQ\ ]UdX_ dbUhQdU Q^T TbeWc dXQd SQ^ SQecU [YT^Ui d_hYSYdi 4bY^[ `\U^di _V ÃeYTc gXY\U dQ[Y^W dXU TbeW

=_cd cUbY_ec* CUfUbU Q\\UbWYS bUQS dY_^ R\__T Q^T \YfUb TYc_bTUbc XU`Q dYdYc `UbY`XUbQ\ UTU]Q R\__T S\_d dY^W \UQTY^W d_ cgU\\Y^W _V dXU \UWc _b Qb]c WQcdb_Y^dUcdY^Q\ e`cUd ^QecUQ Q\_`USYQ XQYb \_cc ZQe^TYSU cUYjebUc S_^VecY_^ XQ\\eSY^QdY_^ ?dXUb* XUQT QSXU fYceQ\ Y]`QYb]U^d dbU]_bc bQcX _b cdY^WY^W c[Y^ gYdX d_`YSQ\ _Y^d]U^d

?^U ! ]W dQR\Ud TQY\i

DbUQdc SXb_^YS XU`Q dYdYc 2 Y^VUSdY_^

4_ ^_d dQ[U gYdX FYbUQT 1dbY`\Q DbefQTQ 3_]`\UbQ _b CdbYRY\T EcU SQedY_^ gXU^ dQ[Y^W gYdX TbeWc dXQd QçUSd [YT^Ui Ve^SdY_^ _b QbU U\Y]Y ^QdUT Ri dXU [YT^Uic _b gYdX _dXUb >BD9c

=_cd cUbY_ec* g_bcU^Y^W _V XU`QdY dYc 2 [YT^Ui ]Q\Ve^SdY_^ ReY\Te` _V \QSdYS QSYT Y^ dXU R\__T ?dXUb* gUQ[ ^Ucc XUQTQSXU QRT_]Y^Q\ `QY^ ^Qe cUQ TYQbbXUQ Y^TYWUcdY_^ WQc

FQbYUc Red eceQ\\i cdQbdc gYdX _^U " % ]W SQ`ce\U dQ[U^ dgYSU TQY\i RUV_bU \e^SX Q^T TY^^Ub 1\c_ QfQY\ QR\U Y^ % ]W _b ! ]W SQ`ce\Uc DQ[U dXU SQ`ce\Uc gX_\U+ T_ ^_d SbecX _b SXUg

8U\`c cdY]e\QdU dXU Q``UdYdU _V 89F `QdYU^dc

3Q^ Y^dUbQSd TQ^WUb_ec\i gYdX Q\S_X_\ FQ\Ye] <YRbYe] CUS _^Q\ HQ^Qh _b >U]RedQ\ 4_ ^_d c]_[U ]QbYZeQ^Q Qc dXYc SQ^ SQecU Q^ _fUbT_cU 3Q^ RUS_]U XQRYd V_b]Y^W

=_cd cUbY_ec* Q]^UcYQ S_^VecY_^ TU\ecY_^c ]__T SXQ^WUc VUU\Y^Wc _V e^bUQ\Ydi XQ\\eSY^QdY_^c TU`bUc cY_^ ^Ubf_ec^Ucc Q^hYUdi Q^T bQ`YT XUQbdRUQd ?dXUb* S\e]cY^Ucc _b e^cdUQTY^Ucc TYjjY^Ucc Tb_gcY^Ucc Ue`X_bYQ db_eR\U dXY^[Y^W ^QecUQ f_]YdY^W

6_b dbUQd]U^d _V ]iS_RQSdUbYe] QfYe] S_]`\Uh _^U & ]W dQR\Ud TQY\i gYdX !% ]W _V =iQ]Red_\+ V_b `bU fU^dY_^ dg_ & ]W dQR\Udc _^SU gUU[\i gXYSX ]Qi RU S_] RY^UT gYdX =iS_RedY^

DbUQdc Q^T XU\`c `bU fU^d ]iS_RQSdUbYe] QfYe] S_]`\Uh

GXU^ dXYc TbeW Yc ecUT gYdX FYbQSU`d gXYSX SQ^ Y^SbUQcU S_^SU^dbQdY_^c _V JYdXb_]Qh dXU `QdYU^d cX_e\T RU ]_^Yd_bUT S\_cU\i V_b [^_g^ cYTU UçUSdc _V JYdXb_]Qh ceSX Qc \YfUb U^ji]U QR^_b]Q\YdYUc Q^T XUQbY^W Y]`QYb]U^d

=_cd cUbY_ec* YbbUWe\Qb XUQbd QSdYf Ydi Y^ bQbU SQcUc VQdQ\+ \YfUb U^ji]U QR^_b]Q\YdYUc Q^T _dXUb \YfUb `b_R \U]c cUfUbU TYQbbXUQ XUQbY^W Y]`QYb ]U^d ?dXUb* ^QecUQ f_]YdY^W ]Y\T d_ ]_TUbQdU TYQbbXUQ QRT_]Y^Q\ `QY^

FQbYUc+ dXU TbeW Yc QfQY\QR\U Y^ cY^W\U ecU fYQ\c gYdX # ! _b ! # ]Y\\Y\YdUbc _V SQ\SYe] XiTb_hi\Q` dYdU cec`U^TUT Y^ Q gQdUb RQcUT WU\ 9d Yc Y^ZUSdUT Y^d_ dXU c[Y^ Q^T bUce\dc SQ^ \Qcd e` d_ Q iUQb

DbUQdc VQSYQ\ VQd \_cc \Y`_Qdb_`Xi Q^T cdY]e\QdUc dXU R_Tiºc S_\\QWU^ `b_TeSdY_^ d_ S_]RQd 89F bU\Qd UT VQSYQ\ gQcdY^W

EcUbc _V R\__T dXY^^Ubc _b Qc`Y bY^ ]Qi XQfU R\UUTY^W _b RbeYc Y^W Qd dXU Y^ZUSdY_^ cYdU 6_b "$ X_ebc QVdUb dbUQd]U^d Qf_YT cYW ^YÂSQ^d ]_fU]U^d ]QccQWU ce^ Uh`_cebU _b ]Q[Ue` ecU

9bbYdQdY_^ bUT^Ucc cgU\\Y^W YdSXY^W Reb^Y^W _b dU^TUb^Ucc Qd dXU Y^ZUS dY_^ cYdU ]Qi _SSeb Red di`YSQ\\i bUc_\fU cX_bd\i QVdUb dbUQd]U^d

?^U !"% ]W TU\QiUT bU\UQcU dQR\Ud dgYSU TQY\i gYdX _b gYdX_ed V__T DQR\Udc cX_e\T RU cgQ\\_gUT gX_\U Q^T ^_d SbecXUT _b SXUgUT

BU\YUfUc TYQbbXUQ dXQd Yc Q cYTU UçUSd _V Q^dY bUdb_fYbQ\ TbeWc

@QdYU^dc cX_e\T RU dUcdUT d_ ]Q[U cebU dXU TYQbbXUQ Yc ^_d SQecUT Ri Q^ Y^VUSdY_^ _b WQc db_Y^dUcdY^Q\ TYcUQcU

=_cd cUbY_ec* e``Ub bUc`YbQd_bi dbQSd Y^VUSdY_^ Rb_^SXYdYc S_eWX ÃQde \U^SU Q^T Y^SbUQcUT \UfU\c _V dXU \YfUb U^ji]U RY\YbeRY^

4_cUc fQbi RQcUT _^ dQbWUdUT Y^VUSdY_^ 1fQY\QR\U Qc dQR\Udc Q `_gTUb d_ RU ]YhUT gYdX gQdUb Q^T dQ[U^ _bQ\\i _b Q^ Y^ZUSdY_^ V_b]e\Q

DbUQdc ]Q^i di`Uc _V Ve^WQ\ Y^VUSdY_^c Y^S\eTY^W 194C bU\QdUT 3Q^TYTQ _bQ\ Uc_`XQWUQ\ ebY^Qbi _b fQWY^Q\ iUQcd Y^VUSdY_^c

4_ ^_d dQ[U gYdX AeY^QW\edU AeY^YTUh 8Yc]Q^Q\ @b_`e\cYT ?bQ` _b UbidXb_]iSY^ EcU gYdX SQedY_^ gYdX Q^dYTYQRUdYS QWU^dc Q^dYS_^fe\cQ^dc R\__T `bUccebU ]UTYSQdY_^c Y]]e^_ce``bUc cYfU TbeWc `b_dUQcU Y^XYRYd_bc R\__T dXY^^Ubc Q^T fYdQ]Y^ 1 ^edbYdY_^Q\ ce``\U]U^dc

=_cd cUbY_ec* \YfUb `b_R\U]c `_dU^ dYQ\\i cUfUbU Q\\UbWYS bUQSdY_^ ?dXUb* bQcX ^QecUQ XUQTQSXU f_]YdY^W TYQbbXUQ

7Y\UQT

MARINOL Tb_^QRY^_\\ 1RR_dd <QR_bQd_bYUc

ZITHROMAX QjYdXb_]iSY^ @ÂjUb JYdXb_]Qh + fQbY_ec _dXUbc WU^UbYS

RADIESSE SQ\SYe] XiTb_hi\Q`QdYdU =Ubj 1UcdXUdYSc

FULYZAQ Sb_VU\]Ub CQ\Yh

DIFLUCAN ÃeS_^Qj_\U @ÂjUb

48

HIV plus

J U LY/A U G U S T 2 0 1 3

HIV/AIDS is not the same epidemic it was 30 years ago. But it’s far from over. Here in the U.S., someone is infected with HIV every 9 1/2 minutes.1

HIV ends with

US

Ending HIV is not magic.

All of us have the basic tools to end the epidemic:

Break the silence - Talk to family, friends, church, your community and coworkers.

Be a role model - Get tested regularly as part of your overall health and well-being and encourage others to follow your lead.

If you’re HIV-, take steps to stay negative.

If you’re HIV+, protect yourself and others - Talk to your doctor about how early and effective treatment may help protect your immune system and vital organs.

Get involved - With all of us fighting stigma and discrimination, we will turn the tide.

1) Every 9 1/2 Minutes, Someone In The United States Is Infected with HIV. (2009). Accessed January 12, 2012 from http://communitydispatch.com/CDC_Health_Advisory _Notices__amp__Announcements_48/HIV_in_US1032 6.shtml

To view and share the video, Go to NMAC.org.

To find an HIV test site, visit hivtest.org.

For treatment information go to treathivnow.com.

Gilead Sciences, Inc. All rights reserved. UN11989 2/12.